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Abstract 
The environment is increasingly recognised as a key player in the emergence 
and mobilisation of antibiotic resistance, which negatively impacts human health, 
healthcare systems, and farming practices worldwide. Recent work has 
demonstrated concentrations of antibiotics in the natural environment may select 
for resistance in situ, but a scarcity of meaningful data has prevented rigorous 
environmental risk assessment of antibiotics. Without such data, mitigation 
strategies, such as improved antibiotic stewardship or environmental discharge 
limits, cannot be effectively designed or implemented.  
This thesis designed and developed two methods for determining effect 
concentrations of antibiotics in complex microbial communities, thereby 
generating a significant amount of data to address this knowledge gap. Minimal 
selective concentrations (MSCs) were determined in long term selection 
experiments for four classes of antibiotic at concentrations as low as 0.4 µg/L, 
which is below many measured environmental concentrations. Lowest observed 
effect concentrations were determined using a short term, growth based assay 
which were highly predictive of MSCs. A novel finding was significant selection 
for cefotaxime resistance occurred at a wide range of antibiotic concentrations, 
from 125 µg/L - 64 mg/L, which has important clinical implications. Determination 
of MSC in single species assays was also shown to be a poor predictor of MSC 
in a complex microbial community. 
Co-selection for antimicrobial resistance was demonstrated in selection 
experiments and through improved understanding of class 1 integron evolution, 
assessing selective effects on resistance gene acquisition using a novel PCR 
method and next-generation sequencing. In the final study, a novel resistance 
determinant (UDP-galactose 4-epimerase) conferring cross-resistance to 
biocides and antibiotics was discovered, providing a target for further study. 
These findings indicate selection and co-selection for antimicrobial 
resistance is likely to occur in the environment, and provides the means to rapidly 
generate further data to aid in the development of appropriate mitigation 
strategies.  
 
 
 
3 
 
Table of Contents  
Abstract ........................................................................................................................................ 2 
List of tables ................................................................................................................................ 9 
List of figures ............................................................................................................................. 12 
Author’s declaration ................................................................................................................. 21 
Acknowledgements .................................................................................................................. 22 
Definitions .................................................................................................................................. 23 
Abbreviations ............................................................................................................................. 28 
Chapter one: Literature review ............................................................................................... 29 
1.1. Background ................................................................................................................... 29 
1.2. Environmental resistome ............................................................................................. 30 
1.3. Selection for resistance ............................................................................................... 31 
1.4. Costs of resistance ....................................................................................................... 33 
1.5. Antibiotic uses and discharge to the environment ................................................... 35 
1.6. What is driving environmental prevalence of AMR – discharge of antibiotics or 
resistant bacteria? .................................................................................................................... 38 
1.7. Mobilisation of resistance genes ................................................................................ 41 
1.8. Issues with current research methods aiming to study resistance in the 
environment ............................................................................................................................... 45 
1.9. Problems for risk assessment of antibiotics using current methods ..................... 48 
1.10. New microbiological methods to inform risk assessment ................................... 51 
1.11. Thesis overview ........................................................................................................ 53 
1.11.1. Co-authored papers ............................................................................................. 54 
Chapter two: Selection and co-selection for antibiotic resistance in a complex 
community, at low antibiotic concentrations ......................................................................... 56 
2.1. Introduction .................................................................................................................... 56 
2.1.2. MSC determination ................................................................................................ 56 
2.1.3. The environmental aspect .................................................................................... 58 
2.1.4. Indirect selection .................................................................................................... 60 
4 
 
2.2. This study ....................................................................................................................... 61 
2.2.1. Primary aims of this study .................................................................................... 63 
2.2.2. Secondary aims of this study ............................................................................... 63 
2.3. Author contribution ....................................................................................................... 63 
2.4. Materials and Methods ................................................................................................. 64 
2.4.1. Sample collection, storage and preparation ...................................................... 64 
2.4.2. Strains ..................................................................................................................... 64 
2.4.3. Minimum Inhibitory Concentration (MIC) determination .................................. 64 
2.4.4. Antibiotics ............................................................................................................... 65 
2.4.5. Pilot experiments ................................................................................................... 65 
2.4.5.1. Experimental evolution experiment ..................................................................... 65 
2.4.5.2. Cefotaxime 24 hour degradation ......................................................................... 65 
2.4.6. Supernatant experiment ........................................................................................... 66 
2.4.7. Cefotaxime 24 hour degradation experiment ........................................................ 66 
2.4.8. Waste water (complex community) microcosm experiment ............................... 67 
2.4.9. Single species microcosm experiment ................................................................... 67 
2.4.10. Chemical extraction ................................................................................................ 68 
2.4.11. Chemical analysis ................................................................................................... 68 
2.4.12. QPCR ........................................................................................................................ 68 
2.4.13. Minimal Selective Concentration (MSC) determination ..................................... 71 
2.4.14. Plating for phenotypic resistance .......................................................................... 71 
2.4.15. Metagenome analyses ........................................................................................... 72 
2.4.16. Statistics ................................................................................................................... 73 
2.5. Results ............................................................................................................................ 73 
2.5.1. BlaCTX-M genes are selected for at low cefotaxime concentrations in a complex 
community ............................................................................................................................. 73 
2.5.2. The increase in blaCTX-M genes is not due to an enrichment for 
Enterobacteriaceae .............................................................................................................. 78 
5 
 
2.5.3. BlaCTX-M prevalence does not reach 1 even at extremely high cefotaxime 
concentrations ....................................................................................................................... 79 
2.5.4. Phenotypic clinical resistance in Enterobacteriaceae agrees with LOEC ........ 81 
2.5.5. Co-selection for different gene classes occurred ................................................. 84 
2.5.6. Single species assays are not representative of complex communities ........... 88 
2.5.7. Cefotaxime is readily degraded, mostly via biodegradation ............................... 91 
2.5.8. Relatively small amounts of ESBLs can protect susceptible bacteria to very 
high antibiotic concentrations ............................................................................................. 95 
2.6. Discussion ...................................................................................................................... 96 
2.7. Conclusions ............................................................................................................. 104 
2.7.1. The clinical implications .......................................................................................... 104 
2.7.2. The environmental implications ............................................................................. 105 
2.7.3. Final comments ....................................................................................................... 106 
Chapter three: Development of a simple assay to detect effect concentrations of 
antimicrobials .......................................................................................................................... 107 
3.1. Introduction .................................................................................................................. 107 
3.1.1. Development of a novel assay .............................................................................. 107 
3.1.2. Effect concentrations of micropollutants (antimicrobials) .................................. 109 
3.1.3. Clarithromycin (CLA) ............................................................................................... 109 
3.1.4. Ciprofloxacin (CIP) .................................................................................................. 110 
3.1.5. Trimethoprim (TRMP) ............................................................................................. 111 
3.1.6. Cefotaxime (TAX) .................................................................................................... 112 
3.1.7. Primary aims of the study ....................................................................................... 114 
3.2. Materials and Methods ............................................................................................... 114 
3.2.1. Sample collection, storage and preparation ........................................................ 114 
3.2.2. Antibiotics ................................................................................................................. 115 
3.2.3. Growth rate experiments ........................................................................................ 115 
3.2.4. Pilot effluent experiment ......................................................................................... 115 
3.2.5. Pilot low temperature and low nutrient experiment ............................................ 116 
6 
 
3.2.6. Long term waste water (complex community) microcosm experiments ......... 116 
3.2.7. QPCR ........................................................................................................................ 117 
3.2.8. Minimal Selective Concentration (MSC) determination ..................................... 119 
3.2.9. Statistics .................................................................................................................... 119 
3.2.10. Author Contributions ............................................................................................. 120 
3.3. Results .......................................................................................................................... 120 
3.3.1. Growth based experimental results ...................................................................... 120 
3.3.2. Long term selection experiment results ............................................................... 126 
3.3.2.1. Cefotaxime (TAX) ................................................................................................. 126 
3.3.2.2. Clarithromycin (CLA) ........................................................................................... 127 
3.3.2.3. Ciprofloxacin (CIP) ............................................................................................... 129 
3.3.2.4. Trimethoprim (TRMP) .......................................................................................... 131 
3.3.3. Statistical comparison of methods ........................................................................ 134 
3.3.4. Utility of the growth based assay with different bacterial communities ........... 137 
3.3.5. Pilot test at lower temperature and lower nutrient levels ................................... 139 
3.4. Discussion .................................................................................................................... 140 
3.4.1. Targeted genes ........................................................................................................ 140 
3.4.2. MSCs and PNECRs ................................................................................................. 141 
3.4.3. Assessing the risk of resistance selection in situ ............................................... 142 
3.4.4. Growth based assays for rapid data generation ................................................. 144 
3.5. Conclusions ................................................................................................................. 146 
Chapter four: Using PCR and next-generation sequencing to study class 1 integron 
array diversity under selective pressure ............................................................................. 147 
4.1. Introduction .............................................................................................................. 147 
4.1.2. Class 1 integrons ................................................................................................ 148 
4.1.3. Previous methods studying integron gene cassette diversity ...................... 148 
4.2. This study ................................................................................................................. 150 
4.2.1. A novel PCR approach: FUN-PCR .................................................................. 150 
4.2.2. Use of PacBio NGS ............................................................................................ 153 
7 
 
4.2.3. Studying the effects of different selective pressures ..................................... 153 
4.2.4. Author contributions ........................................................................................... 154 
4.3. Materials and Methods .......................................................................................... 154 
4.3.1. Evolution experiment .......................................................................................... 154 
4.3.2. DNA extraction .................................................................................................... 155 
4.3.3. Primer design and PCR conditions .................................................................. 155 
4.3.4. Quality control and PacBio sequencing .......................................................... 157 
4.4.4. Sequence analysis pipeline .............................................................................. 157 
4.4.5. Sequence data analyses ................................................................................... 160 
4.5. Results ..................................................................................................................... 160 
4.5.1. PCR optimisation and final primer selection ................................................... 160 
4.5.2. PacBio sequencing QC ...................................................................................... 162 
4.5.3. IntI1 detection ...................................................................................................... 163 
4.5.4. Antibiotic resistance gene detection with ARG-ANNOT and CARD ........... 164 
4.5.5. Qac gene detection ............................................................................................ 167 
4.6. Discussion ............................................................................................................... 167 
4.6.1. FUN-PCR – fit for purpose? .............................................................................. 167 
4.6.2. Sequence analysis pipeline .............................................................................. 169 
4.6.3. Selective effects of antimicrobial treatment .................................................... 169 
4.7. Conclusions ............................................................................................................. 170 
Chapter five: Investigating co-selection for antibiotic and quaternary ammonium 
compound resistance in the environment – a functional metagenomics study ............ 171 
5.1. Introduction ...................................................................................................................... 171 
5.1.2. Quaternary ammonium compounds (QACs) and resistance genes .................... 172 
5.1.3. This study ..................................................................................................................... 174 
5.1.3.1. Choice of antibiotics for investigating co-selection ............................................. 175 
5.1.3.2. Primary aims of the study ....................................................................................... 176 
5.1.3.3. Secondary aim of the study .................................................................................... 176 
5.1.4. Author contributions .................................................................................................... 176 
8 
 
5.2. Materials and methods ................................................................................................... 177 
5.2.1 Sampling sites and metagenomics library construction ......................................... 177 
5.2.2. Culturing and identifying unique inserts ................................................................... 177 
5.2.3. Gene knock out and sequencing .............................................................................. 177 
5.2.4. Phylogenetic analysis ................................................................................................. 179 
5.2.5. Cloning UDP-galactose-4-epimerase -like ORFs and expression ....................... 179 
5.2.6. MIC/Co-selection testing ............................................................................................ 181 
5.2.7. Statistics ........................................................................................................................ 182 
5.3. Results .............................................................................................................................. 182 
5.3.1. QAC exposed libraries had higher QAC, TRMP and AMP resistance ................ 182 
5.3.2. Full insert sequencing discovered many co-resistance and cross-resistance 
genes ........................................................................................................................................ 183 
5.3.3. Transposon mutagenesis revealed QAC resistance was mediated by a diverse 
set of previously uncharacterised genes ............................................................................ 185 
5.4. Discussion ........................................................................................................................ 189 
5.5. Conclusions ..................................................................................................................... 192 
Chapter six: Thesis discussion ............................................................................................. 194 
6.1. Environmental implications ................................................................................... 194 
6.2. Towards improved ERA ......................................................................................... 196 
6.3. Clinical implications ................................................................................................ 198 
6.4. Concluding remarks ............................................................................................... 200 
Appendix .................................................................................................................................. 201 
References .............................................................................................................................. 208 
 
 
 
 
 
 
9 
 
List of tables 
Table 1. Sequences and length of the different primers, probes and gBlocks used 
in this study, with original references or the accession number used where 
applicable. 
Table 2. The expected (nominal) cefotaxime concentration, actual measured 
cefotaxime concentration immediately sampled and following 24 hours incubation 
in the complex community assay. Averages of 2 biological replicates (chosen at 
random) and 2 chemical replicates. The two cefotaxime stock concentrations 
were also quantified. 
Table 3. The compounds used in this study, with a selection of available PNECs 
and all available MSCs, with corresponding references. Concentrations with a * 
are toxicity data, i.e. with a safety factor added (normally 10 for chronic and 1000 
for acute (Straub, 2013)).  
Table 4. Sequences and length of the different primers, probes and gBlocks used 
in this study, with original references or the accession number used where 
applicable. 
Table 5. Rho (rs Spearman's rank) values (in bold) and p values (italicised) to test 
for a dose response relationship between complex community growth and 
antimicrobial concentration, at different time points during different growth 
phases. 
Table 6. The growth based effect concentration, experimentally derived using 
average growth data (n=6) at 6 hours growth. Determined using Dunn's test 
(significance = p < 0.05).  
Table 7. Summary of the statistical tests performed for each antimicrobial and 
the endpoints determined. For Spearman's Rank column, values in bold are the 
rs value, italics is the corresponding p value. ‘KW’ = Kruskal Wallis test, * = with 
ANOVA.  
Table 8. The estimated MSCs and experimentally derived LOECs in µg/L, 
derived in this study. TAX = cefotaxime, CLA = clarithromycin, CIP = 
ciprofloxacin, TRMP = trimethoprim. Also shown is the fold difference between 
the two values (LOEC/MSC, rounded to 1 decimal place). Experimentally derived 
10 
 
MSCs marked with a * were determined by Dunn’s test; all others were fit to 
GLMs. Significance = p < 0.05.  
Table 9. The rs (bold) and p (italicised) values for Spearman's rank correlations 
performed at different time points during growth rate assays of influent and 
effluent complex communities under TAX exposure. 
Table 10. Table showing the MSCs and PNECRs determined in this study 
alongside previously estimated PNECRs. MECs shown are the highest reported 
MECs for a particular environmental compartment in the Umweltbundesamt 
database (2016); or by Gomez et al. (2007) (indicated by ‘*’). RQs are derived by 
MEC/MSC or PNECR: red, yellow and green RQ’s represent unacceptably high, 
medium and low risk respectively. 
Table 11. Full list of primers used in this study, their sequence, gene/primer 
target, approximate product size in kb, and reference. 
Table 12. Table showing the numbers of reads at each stage of intI1 filtering. 
Table 13. Average percentage (n=6 for blaTEM, mphA and aad, n=3 for catB, strB 
and aph) of intI1 filtered reads with different resistance gene hits.  
Table 14. Numbers of BKC or CTAB resistant colonies from each of the three 
metagenomics libraries from the initial screen, and corrected for per Gb of library, 
rounded to the nearest whole number. The library coverages are 0.63, 1.59 and 
1.53 Gb for RB, SC and GL, respectively. 
Table 15. E test MIC results for cloned UDP-like ORFs. TRMP = Trimethoprim, 
SMX = Sulfamethoxazole, TRMP / SMX = Trimethoprim / Sulfamethoxazole 
combination strip. ' '^ represents increase in MIC, '-' represents no difference in 
MIC, '˅' = decrease in MIC (all compared to empty vector control pET101).  
Table 16. Table showing primer sequences used for amplifying UDP-galactose-
4-epimerase-like ORFs to be cloned into the pET101 vector. 
Table 17. Co-resistance experiment. CTAB resistant clones and a random 
selection of unscreened clones from RB and SC libraries were replica plated onto 
ampicillin (‘AMP’) and trimethoprim (‘TRMP’) at different concentrations. Average 
percent resistance (n = 200). Increased resistance at 1.5x MIC compared to at 
11 
 
MIC could be explained by stress-induced expression of resistance determinants 
or spontaneous mutation in the host. 
Table 18. All the ORFs identified by primer walking all unique BKC resistant 
inserts.  Shown is the name of the predicted protein, the % identity to the entry in 
the GenBank database, and the accession number for this highest hit. For some 
ORFs, multiple predicted proteins are shown with coverage in brackets. ORFs of 
particular interest (antimicrobial resistance genes or genes that logically could 
have roles in conferring resistance) are marked by ‘***’.  
Table 19. Predicted ORFs' function and amino acid identity, and the numbers of 
knock outs containing this ORF. 
Table 20. Table showing sequence similarity between UDP-galactose-4-
epimerases identified in this study and in the study by Kazimierczak et al. (2009) 
(‘Clone 9’ and ‘Clone 15’). M = Megablast, n = blastn. The first number is the 
sequence identity, the second number following the / is the percentage coverage. 
Alignment was performed with NCBI blastn for alignment of two sequences.  
 
 
 
 
 
 
 
 
 
 
 
12 
 
List of figures  
Figure 1. Based on the figure on page 28 from the report by the CDC (2013). 
Resistance to a drug soon arises after development and use in the clinic. 
Figure 2. Taken from Furuya & Lowy (2006). The three main mechanisms of 
horizontal gene transfer ('a, b' and 'c'). 
Figure 3. Schematic showing the traditional selective (antibiotic concentration 
>MIC of the susceptible strain) and sub-inhibitory selective (antibiotic 
concentration <MIC susceptible strain) windows. The MSC is defined as the 
lowest antibiotic concentration where the growth rate of the susceptible strain is 
reduced, to be the same as the growth rate of the resistant strain. 
Figure 4. Theoretical selection coefficient graph, the black dotted line is the x-
axis which crosses the y axis at 0 (i.e. a selection coefficient of 0, meaning any 
trait with a selection coefficient of exactly 0 is perfectly neutral in terms of fitness). 
A = The cost of resistance is decreasing, but the resistance determinant is not 
yet conferring a fitness advantage (selection coefficients are still < 0, i.e. gene 
prevalence is decreasing over time). B = Where the line of best fit crosses the x 
axis is the MSC – this is also where the first selection coefficient is > 0, meaning 
at this point, the resistance determinant is conferring at slight fitness advantage 
at that antibiotic concentration. C = at even higher antibiotic concentrations, the 
resistance determinant is now conferring a significant fitness advantage 
(selection coefficient much > 0, i.e. gene prevalence is increasing over time). 
Figure 5. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M gene 
prevalence at the beginning and end of the lower cefotaxime concentration 
complex community experiment, shown with standard error bars. Prevalence 
calculated by dividing blaCTX-M gene copy number by 16S copy number for each 
biological replicate. There is a significant increase in blaCTX-M gene prevalence 
from 125 µg/L, and all treatments above (p < 0.05, Dunn’s test ‘*’). 
Figure 6. Average (biological replicate n=5, qPCR replicate n=2) selection 
coefficients based on the qPCR blaCTX-M prevalence data at day 0 and day 8 
shown with standard error bars and polynomial (order 2) line of best fit. The MSC 
is where the line crosses the x-axis - at 0.4 µg/L. 
13 
 
Figure 7. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M gene 
copy number at day 0 and day 8 in the lower cefotaxime concentration complex 
community experiment. The 125 µg/L treatment and all treatments above were 
significantly different to the no antibiotic control (p < 0.05, Dunn’s test ‘*’). 
Figure 8. Average (biological replicate n=5, qPCR replicate n=2) copy number 
for group 1 and group 9 blaCTX-M genes following 8 days cefotaxime exposure. 
Shown with standard error bars, on a logged y axis. The 125 µg/L treatment and 
all treatments above were significantly different to the no antibiotic control (p < 
0.05, Dunn’s test ‘*’). 
Figure 9. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M 
prevalence at day 0, 1, 4 and 8 of the lower cefotaxime concentration complex 
community experiment. 
Figure 10. Average (biological replicate n=5, qPCR replicate n=2) numbers of E. 
coli and enterics in the complex community following 8 days cefotaxime 
exposure, using SYBR green qPCR. Shown with standard error bars. 
Figure 11. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M gene 
prevalence in the complex community before and after exposure to the higher 
cefotaxime concentrations. Shown with standard error bars. BlaCTX-M gene 
prevalence calculated by dividing the blaCTX-M gene copy number by 16S copy 
number for each biological replicate.  
Figure 12. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M gene 
copy number for group 1 and group 9 blaCTX-M genes. Shown with standard error 
bars. 
Figure 13. The average (biological replicate n=5 combined, plating replicate n=2) 
colony forming units (cfu) per ml of presumptive E. coli, other enterics and other 
Gram negatives quantified on Chromocult Coliform Enhanced Selectivity agar 
supplemented with the clinical breakpoint concentration of cefotaxime (2000 
µg/L, (EUCAST, 2014)), at the end of the lower cefotaxime concentration, 
complex community experiment. Shown with standard error bars. 
Figure 14. Average (biological replicate n=5 combined, plating replicate n=3) 
colony forming units (cfu) per ml of presumptive E. coli, other enterics and other 
14 
 
Gram negatives quantified on Chromocult Coliform Enhanced Selectivity agar 
supplemented with the clinical breakpoint concentration of cefotaxime (2 mg/L, 
(EUCAST, 2014)), at the end of the higher cefotaxime concentration, complex 
community experiment. Shown with standard error bars. 
Figure 15. Percentage of coliforms at the end of the higher cefotaxime 
concentration, complex community experiment that were clinically resistant (MIC 
> 2 mg/L) to cefotaxime. Percentage calculated by taking the average numbers 
of resistant bacteria (Figure 14) and dividing by the average total coliform count, 
multiplied by 100. 
Figure 16. Average (biological replicate n=3) resistance gene class abundance, 
normalised by 16S copy number. 
Figure 17. Average (biological replicate n=3) β-lactam resistance gene subtype 
abundance, normalised by 16S copy number. Only detected resistance gene 
subtypes are shown. Resistance gene key for encoded enzymes: ACT = AmpC 
type β-lactamase, CAZ = ceftazidimase, CFE-1 = AmpC type β-lactamase, CGB-
1 = Ambler Class B β-lactamase, CMY = Ambler Class C β-lactamase, CTX-M = 
ESBL, CfxA = Divergent Ambler Class A β-lactamase, DHA = AmpC type β-
lactamase, FOX = AmpC type β-lactamase, KLUY = chromosomally-encoded β-
lactamase, LEN = chromosomally-encoded β-lactamase, MIR = AmpC type β-
lactamase, MOX = AmpC type β-lactamase, OXA = Ambler Class D β-lactamase, 
PBP = penicillin binding protein, PDC = AmpC type β-lactamase, SHV = Ambler 
Class A β-lactamase or ESBL, TEM = Ambler Class A β-lactamase or ESBL, 
Toho-1 = Ambler Class A mutant β-lactamase, AmpC = Ambler Class C β-
lactamase, blaZ = Staphylococcus aureus β-lactamase, CcrA = Ambler Class B 
metallo-β-lactamase, FmtC = membrane-associated protein, MecA = penicillin 
binding protein, PenA = Ambler Class A secreted β-lactamase. 
Figure 18. The change in average ESBL abundance over different 
concentrations (normalised by 16S copy number), for each of the cefotaxime 
(‘TAX’) concentrations, in µg/L. On average, blaTEM genes were most prevalent 
in the 2000 µg/L treatment, though the increase from 0 to 2000 µg/L was largest 
for the blaCTX-M genes. 
15 
 
Figure 19. Average (biological replicate n=3, qPCR replicate n=2) blaCTX-M gene 
prevalence at the beginning and end of the lower cefotaxime concentration single 
species experiment, shown with standard error bars. Prevalence calculated by 
dividing blaCTX-M gene copy by 16S copy number. There are no significant 
differences between treatments. 
Figure 20. Average (biological replicate n=3, qPCR replicate n=2) blaCTX-M gene 
prevalence at the beginning and end of the higher cefotaxime concentration 
single species experiment, shown with standard error bars. Prevalence 
calculated by dividing blaCTX-M gene copy by 16S copy number. There were 
significant differences between 8 mg/L and all concentrations above compared 
to the not antibiotic control (p < 0.05, Dunn’s test). 
Figure 21. Average (biological replicate n=3, qPCR replicate n=2) blaCTX-M gene 
copy number at day 0 and day 8 in the higher cefotaxime concentration single 
species experiment. The 8 mg/L treatment and all treatments above were 
significantly different to the no antibiotic control (p < 0.05, Dunn’s test). 
Figure 22. Average (biological replicate n=5, qPCR replicate n=2) selection 
coefficients based on day 0 and day 8 blaCTX-M prevalence data in the low and 
high cefotaxime concentration single species selection experiment, using both 
data points for the no antibiotic control and 2 mg/L treatments. All selection 
coefficients are positive, so no MSC was determined.  
Figure 23. Single biological replicate, duplicate chemical replicate of cefotaxime 
degradation over 24 hours, sampling at 0, 4, 8 and 24 hours, in the presence (AB) 
and absence (A) of the complex community. 
Figure 24. Single biological replicate, duplicate chemical replicate chemical 
quantification of cefotaxime (‘Measured cefotaxime concentration µg/L) every 3 
hours for 24 hours at different concentrations (µg/L) in the presence of the 
complex community (A). (B) The growth (optical density measured at 600 nm) 
from the same sampling time points, single replicate only. 
Figure 25. BlaCTX-M gene copy number at different time points (6, 9 and 12 hours) 
during the cefotaxime 24 hour degradation experiment. Single biological replicate 
only, qPCR replicate n=2. 
16 
 
Figure 26. 16S gene copy number at different time points during the cefotaxime 
24 hour degradation experiment. Single biological replicate only, qPCR replicate 
n=2. 
Figure 27. BlaCTX-M gene prevalence (blaCTX-M gene copy number/16S copy 
number) at different time points during the cefotaxime 24 hour degradation 
experiment. Single biological replicate only, qPCR replicate n=2. 
Figure 28. Average (n=4) growth of susceptible J53 at different cefotaxime 
concentrations, without (A) and with (B) ESBL-containing supernatant (i.e. 
supernatant from susceptible J53 and resistant J53, respectively) at different 
cefotaxime concentrations. “Jsp0AB” or “Nsp 0AB” represents the no antibiotic 
control bearing the ESBL free (J53) and ESBL-containing (NCTC 13451) 
supernatant respectively. Shown with standard deviation bars. 
Figure 29. The three mechanisms of co-selection. 1. Cross-resistance - when a 
single gene confers resistance to multiple compounds, e.g. a multi-drug efflux 
pump. 2. Co-resistance - selection for one or more genes which are genetically 
linked (e.g. on a plasmid). Only one gene need be under positive selection for the 
plasmid and therefore all genes to be selected for. 3. Protective co-selection – 
this occurs when resistant bacteria (pink) produce a degradative (blue) enzyme 
(A), which binds to the (red triangle) antibiotic (B). Following antibiotic 
degradation (C), the antibiotic (red circle) is inactive (D), allowing both susceptible 
bacteria and susceptible bacteria carrying different resistant mechanisms (green) 
to grow (E). 
Figure 30. Average (n=7) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/L) of 
cefotaxime, over 6 hours. Shown with standard deviation bars. 
Figure 31. Average (n=7) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/L) of 
cefotaxime, over 24 hours. Shown with standard deviation bars. 
Figure 32. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/ml) of 
azithromycin, over 24 hours. Shown with standard deviation bars. 
17 
 
Figure 33. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/ml) of 
clarithromycin, over 24 hours. Shown with standard deviation bars. 
Figure 34. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/ml) of 
erythromycin, over 24 hours. Shown with standard deviation bars. 
Figure 35. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/ml) of 
ciprofloxacin, over 24 hours. Shown with standard deviation bars. 
Figure 36. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/ml) of 
trimethoprim, over 24 hours. Shown with standard deviation bars. 
Figure 37. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/ml) of 
benzalkonium-chloride, over 24 hours. Shown with standard deviation bars. 
Figure 38. Average (n = 8) p values and rho (rs) values from Spearman's rank 
correlation analysis of growth (optical density) against increasing antibiotic 
concentration, at four different time points. Shown with standard deviation bars. 
Figure 39. The qPCR data (technical replicate, n=2) for the long term experiment 
evolution experiment for clarithromycin. Shown is average (n=5, except day 7 250 
µg/L n=4) ermF prevalence (ermF gene copy number divided by 16S copy 
number) at day 0 and day 7. Shown with standard error bars. 
Figure 40. Average (biological replicate n=5 except day 7 250 µg/L n=4, qPCR 
replicate n=2) selection coefficients based on the qPCR ermF gene prevalence 
data at day 0 and day 7, shown with standard error bars and polynomial (order 
2) line of best fit. The MSC is where the line crosses the x-axis – at 65 µg/L. 
Figure 41. The qPCR data (technical replicate, n=2) for the long term evolution 
experiment for ciprofloxacin. Shown is average (n=5) qnrS prevalence (qnrS 
gene copy number divided by 16S copy number) at day 0 and day 7. Shown with 
standard error bars. 
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Figure 42. The qPCR data (technical replicate, n=2) for the long term evolution 
experiment for ciprofloxacin. Shown is average (n=5) intI1 prevalence (intI1 gene 
copy number divided by 16S copy number) at day 0 and day 7. Shown with 
standard error bars.  
Figure 43. Average (biological replicate n=5, qPCR replicate n=2) selection 
coefficients based on the qPCR intI1 gene prevalence data at day 0 and day 7, 
shown with standard error bars and polynomial (order 4) line of best fit. The MSC 
is where the line crosses the x-axis - at 10.5 µg/L. 
Figure 44. The qPCR data (technical replicate, n=2) for the long term experiment 
evolution experiment for trimethoprim. Shown is average (n=5, except 4,000 µg/L 
which was n=3) intI1 prevalence (intI1 gene copy number divided by 16S copy 
number) at day 0 and day 7. Shown with standard error bars. 
Figure 45. Average (biological replicate n=5, qPCR replicate n=2) selection 
coefficients based on the qPCR intI1 gene prevalence data at day 0 and day 7, 
shown with standard error bars and linear line of best fit. The MSC is where the 
line crosses the x axis, here at 24 µg/L.  
Figure 46. Bland-Altman plot with 95 % confidence intervals (shown in brown 
and blue), using the log transformed MSC and statistical LOEC for the long term 
data. The 95 % confidence intervals (brown, dashed lines) around the mean 
differences (red dashed line) must encompass 0 on the y axis (i.e. complete 
equality between measurements) in order for the bias between measurements to 
be acceptable.  
Figure 47. Bland-Altman plot with 95 % confidence intervals (shown in brown 
and blue), using the log transformed MSC and the growth LOEC data. The 95 % 
confidence intervals (brown, dashed lines) around the mean differences (red 
dashed line) must encompass 0 on the y axis (i.e. complete equality between 
measurements) in order for the bias between measurements to be acceptable. 
Figure 48. Bland-Altman plot with 95 % confidence intervals (shown in brown 
and blue), using the log transformed LOECs from the long term and growth 
experiments. The 95 % confidence intervals (brown, dashed lines) around the 
mean differences (red dashed line) must encompass 0 on the y axis (i.e. complete 
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equality between measurements) in order for the bias between measurements to 
be acceptable. 
Figure 49. Average (n=6) growth (optical density measured at 600 nm) of the 
influent community in the presence of different concentrations (µg/L) of 
cefotaxime, over 24 hours. Shown with standard deviation bars. 
Figure 50. Average (n=6) growth (optical density measured at 600 nm) of the 
effluent community in the presence of different concentrations (µg/L) of TAX, over 
24 hours. Shown with standard deviation bars. 
Figure 51. Growth of influent and effluent complex communities at low 
temperature (20°C) in broth (A) and M9 buffer (B), over time. Single replicate 
only. 
Figure 52. Figure 2 taken from Wang et al. (2011). “A general (theoretical) 
scheme for FPNI-PCR (PCR based method for genomic walking or tagged 
flanking sequence cloning).”  
Figure 53. PCR 2 amplification products using 7 bp cutter primers FP1-BbvC1-1 
and FP2-Bsu361-1 in combination for the evolution experiment replicates (0 = no 
treatment, T = trimethoprim, C = Ciprofloxacin, B = BKC). A 1 % agarose gel 
stained with ethidium bromide run at 120 V for 40 minutes, with GeneRuler 1 kb 
Plus DNA Ladder (ThermoScientific). 5 μl sample with 1 μl DNA loading dye 
(ThermoScientific). 
Figure 54. Barcode PCR amplification products using the 7 bp restriction site 
primers FP1-BbvC1-1 and FP2-Bsu361-1 in combination, for the evolution 
experiment replicates (O = no treatment, T = trimethoprim, C = Ciprofloxacin, B 
= BKC). A 1 % agarose gel stained with ethidium bromide run at 120 V for 40 
minutes, with GeneRuler 1 kb Plus DNA Ladder (ThermoScientific). 5 μl sample 
with 1 μl DNA loading dye (ThermoScientific). 
Figure 55. The average read length (left charts) for numbers of reads of insert 
and read quality (right charts) for SMRT cells 1 (top) and 2 (bottom). 
Figure 56. Average (n=3, except ‘Raw’ n=1) percent of total reads bearing hits 
for intI1 within the first 75 bp of the read, with a minimum of 80 % coverage and 
identity. Shown with standard error bars. 
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Figure 57. Average (n=6 for blaTEM, mphA and aad, n=3 for strB, aph and catB) 
percent of intI1 filtered reads containing different resistance genes hits of a 
minimum of 75 bp and 80 % identity, using both the ARG-ANNOT and CARD 
databases. Shown with standard deviation bars. 
Figure 58. Average (n=6 for blaTEM, mphA and aad, n=3 for strB, aph and catB) 
percent of intI1 filtered reads containing different resistance genes hits of a 
minimum of 75 bp and 80 % identity, using both the ARG-ANNOT and CARD 
databases. Average percentages are normalised within each resistance gene 
type (for each column, the minimum is subtracted from each value and then 
divided by maximum value). 
Figure 59. Percentage of the entire sewage cake (‘SC’) and reed bed (‘RB’) 
libraries resistant to CTAB, or with reduced susceptibility to Ampicillin, and 
Trimethoprim compared to the empty vector control (MIC 32 mg/L, 4 mg/L and 
1.5 mg/L respectively). 
Figure 60. Maximum likelihood tree of the UDP-galactose-4-epimerases 
identified in this study, with a reference strain from GenBank (Accession NC 
004663.1). Bootstrap values based on 500 bootstrap replicates. Sequences 
beginning with R are from the RB library, and with S from the SC library. 
Figure 61. A reduction in the average inhibition zone indicates decreased 
susceptibility compared to the empty vector control. Values are calculated by 
averaging (n=3) the inhibition zone sizes, and subtracting the control zone size 
from the zone size of the inserts (S# = from the SC library; R# = from the RB 
library). TRMP = Trimethoprim, IMP = Imipenem, COL = Colistin, TAX = 
Cefotaxime, AMP = Ampicillin, SMX = Sulfamethoxazole. * indicates significant 
difference in size compared to control (p < 0.05, ANOVA and Tukey post-hoc test. 
Red * = p < 0.1). 
Figure 62. Values are calculated by averaging (n=3) the inhibition zone sizes, 
and subtracting the control zone size from the zone size of the inserts. COL = 
Colistin, DOX = Doxycycline, MIN = Minocycline, TAX = cefotaxime, SMX = 
sulfamethoxazole, TRMP = trimethoprim, IMP = imipenem. Average difference = 
average size of inhibition zone (mm) for ‘UDP-like’ ORF (11, 161 or 78) – average 
size of inhibition zone (mm) for the empty vector control. Biological replicates n=3. 
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Significance according to ANOVA and Tukey test, p value < 0.05 = *. (Unable to 
screen on AMP as used for vector maintenance).  
Figure 63. Pilot experiment for determining the dilution of untreated waste water 
to use for the complex community experiments. Average (n=2) growth of blaCTX-
M bearing E. coli in cefotaxime (µg/L) over 24 hours, shown with standard 
deviation. 
Figure 64. Pilot experiment for determining the dilution of untreated waste water 
to use for the complex community experiments. Average (n=2) growth of 
untreated waste water inoculated at a 10x dilution in cefotaxime (µg/L) over 24 
hours, shown with standard deviation. 
Figure 65. Pilot experiment for determining the dilution of untreated waste water 
to use for the complex community experiments. Average (n=2) growth of 
untreated waste water inoculated at a 100x dilution in cefotaxime (µg/L) over 24 
hours, shown with standard deviation. 
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Definitions 
Term Definition 
A priori Knowledge of a fact based on theoretical deduction rather 
than experimental evidence. 
Antibiotic  A chemical compound used to treat bacterial infections in 
humans or animals by killing the bacterium or preventing 
its growth. 
Antibiotic 
resistance 
Ability of a bacterium to survive antibiotic therapy due to 
presence of mutations/mobile genetic elements 
containing resistance genes which prevent cell death or 
growth inhibition. 
Antimicrobial A chemical compound used to kill micro-organisms 
(including bacteria, fungi, protozoa and viruses) or inhibit 
their growth. Includes antibiotics and biocides. 
Antimicrobial 
resistance 
Ability of a micro-organism to survive exposure to an 
antimicrobial due to presence of mutations / mobile 
genetic elements containing resistance genes which 
prevent cell death or growth inhibition. 
Array Referring to gene cassettes – several adjacent gene 
cassettes in an integron form an array. 
Bacteria A large group of prokaryotic organisms. 
Bactericidal An antibiotic which kills bacteria. 
Bacteriostatic An antibiotic which prevents bacterial cell growth. 
Beta-lactam (β-
lactam) 
A class of antibiotics which prevents cellular division and 
growth through binding penicillin binding proteins, thereby 
preventing cell wall synthesis. 
Beta-lactamase 
(β-lactamase) 
An enzyme capable of degrading members of the β-
lactam antibiotic class. 
Biocide An antimicrobial not used in chemotherapy but as a 
disinfectant or detergent. 
Biofilm Extracellular matrix comprising of excreted proteins and 
DNA excreted by sessile bacteria to allow attachment to 
surfaces or particles, prevent desiccation, reduce 
susceptibility to antimicrobials etc. 
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Cephalosporin An antibiotic belonging to the beta-lactam class of 
antibiotics. There are five generations of cephalosporins 
(e.g. cefotaxime is a third generation cephalosporin). 
Commensal A non-pathogenic bacterial species which co-exists with 
other commensals, pathogens and opportunistic 
pathogens in a bacterial community. 
Competent Bacterial cells which are able to take up and integrate 
DNA. 
Conjugation A mechanism of horizontal gene transfer whereby a donor 
bacterial cell forms a pilus to connect to the recipient cell, 
through which DNA is exchanged (commonly plasmids). 
Co-resistance When a bacterium is resistant to two or more antimicrobial 
compounds due to co-localisation of two or more 
resistance genes (most commonly on mobile genetic 
elements such as plasmids or integrons). 
Co-selection The process whereby resistance to one or more 
antimicrobial compounds is selected, due to either co-
resistance or cross-resistance. 
Cross-resistance When a bacterium is resistant to two or more antimicrobial 
compounds due to presence of a single resistance 
mechanism which confers resistance to more than one 
compound (e.g. a multidrug efflux pump). 
De novo Completely new or novel. 
Dose-response 
relationship  
Where a variable (e.g. resistance) increases with 
treatment dose (e.g. antibiotic concentration). 
Environment The natural environment (including soils, lakes, rivers, 
sediments, and the sea). 
Environmental 
resistome 
The reservoir of resistance genes in all bacteria in the 
natural environment. 
Extended 
spectrum beta-
lactamase (ESBL) 
A type of beta-lactamase which has extended spectrum 
of activity i.e. can degrade 2nd and 3rd generation beta-
lactams, as opposed to β-lactamases which degrade only 
1st generation β-lactams. 
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Fitness advantage The benefit conferred by a given trait on an organism’s 
ability to survive, grow and / or reproduce. 
Fitness cost The disadvantage conferred by a given trait on an 
organism’s ability to survive, grow and / or reproduce. 
Gene cassette A short, extracellular, circular piece of DNA containing 
one or more genes (often resistance genes) and the attC 
site to allow integration into integrons.  
Gram positive 
bacteria 
Classification term for bacteria which only have plasma 
membrane, periplasmic space and thick peptidoglycan 
layer in their cell wall.  
Gram negative 
bacteria 
Classification term for bacteria which have plasma 
membrane, a thin layer of peptidoglycan sandwiched 
between two layers of perisplasmic space, and an outer 
membrane (lipopolysaccharide layer) as constituents of 
their cell wall. 
Horizontal Gene 
Transfer (HGT) 
The movement or resistance genes and/or mobile genetic 
elements between bacteria of the same or even distantly 
related species by conjugation, transduction or 
transformation. 
In situ In place. 
In vitro In a laboratory setting; not within a living organism. 
In vivo In real life. 
Indirect selection When susceptible bacteria are able to grow following 
antibiotic administration due to presence of resistant 
bacteria which degrade the antibiotic, allowing susceptible 
bacteria to grow once the antibiotic concentration reaches 
a low enough concentration. 
Integrase An enzyme encoded for by the integrase (‘int’) gene on 
integrons which facilitates site specific recombination 
between the attI site in integrons and the attC site on gene 
cassettes. 
Integron A genetic structure comprising of an integrase gene, an 
attI site, and usually one or more gene cassettes.  
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Isogenic Refers to two or more bacteria which have completely 
identical genomes and accessory genomes. 
Minimum inhibitory 
concentration 
(MIC) 
The lowest concentration of an antimicrobial which kills / 
prevents growth of a bacterium. 
Minimal selective 
concentration 
(MSC) 
The lowest concentration of an antimicrobial at which 
positive selection for resistance occurs. 
Microbiome All of the bacteria living on or in another living thing (e.g. 
human / animal / plant microbiome). 
Mobile genetic 
element (MGE) 
A piece of DNA which can be transferred horizontally, e.g. 
plasmids, integrons. 
Mobilisation When a mobile genetic element moves from one bacterial 
cell to another, or gains the ability to be mobilised (e.g. by 
being relocated to a plasmid by a transposase). 
Mutation Used to describe changes in both DNA and amino acid 
sequence, which may be either advantageous or 
disadvantageous in terms of fitness. 
Opportunistic 
pathogen 
A bacterium which does not normally cause disease in a 
healthy host, but can infect immunocompromised hosts. 
Pathogen A bacterium which infects and causes disease in the host. 
Plasmid An extracellular, circular piece of DNA; which is also a 
mobile genetic element. 
Polymerase chain 
reaction 
A molecular technique used to amplify target DNA of 
interest exponentially.  
Point mutation A mutation occurring in one single DNA base. 
Proto-resistome All the genes in the environment which have the ability to 
form part of the resistome, either through a point mutation 
or mobilisation from the chromosome to a mobile genetic 
element. 
Real-time PCR 
(qPCR) 
Real-time or quantitative PCR is used to exponentially 
amplify target DNA in real time, quantitatively. This allows 
quantification of the numbers of target genes in the 
original DNA sample. 
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Resistome The reservoir of resistance genes in a given environment. 
Transduction A mechanism of horizontal gene transfer, whereby 
bacteriophage capture bacterial DNA during the infection 
cycle and then release this DNA into a new bacterial cell 
upon infection.  
Transformation  A mechanism of horizontal gene transfer. Competent 
bacterial cells can absorb DNA from the environment 
released by other bacteria e.g. during biofilm formation or 
cell lysis following death. 
Transposase An enzyme which can excise itself and surrounding genes 
and reintegrate itself into a new location. 
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Abbreviations 
Abbreviation Definition 
3GC(s) Third generation cephalosporin(s) (e.g. cefotaxime) 
AVMA American Veterinary Medical Association 
βLI(s) β-lactamase Inhibitor(s) (e.g. avibactam) 
bp Base Pairs (of DNA) 
cfu Colony Forming Units 
CDC Centre for Disease Control and Prevention 
ECDC European Centre for Disease Control and Prevention 
ESBL Extended-spectrum β-lactamase 
EU European Union 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
DNA Deoxyribonucleic Acid 
HGT Horizontal Gene Transfer 
kb Kilo Base Pairs (of DNA) 
LOEC Lowest Observed Effect Concentration 
MEC Measure Environmental Concentration 
MGE Mobile Genetic Element 
MIC Minimum Inhibitory Concentration 
MSC Minimal Selective Concentration 
OECD Organisation for Economic Co-operation and Development 
PEC Predicted Environmental Concentration 
PCR Polymerase Chain Reaction 
PICT Pollution-induced Community Tolerance Assay 
PNEC Predicted No Effect Concentration 
PNECR Predicted No Effect Concentration for Resistance selection 
QAC(s) Quaternary Ammonium Compound(s) 
qPCR Real-time Polymerase Chain Reaction 
ROS Reactive Oxygen Species 
RQ Risk Quotient 
UBA UmweltBundesamt (German Environment Agency) 
WHO World Health Organisation 
WWTP(s) Waste Water Treatment Plant(s) 
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Chapter one: Literature review 
 
1.1. Background 
Antibiotic resistance is ancient, as it has been detected in pristine environments 
which predate the Anthropocene (D'Costa et al., 2011, Allen et al., 2009, Hall and 
Barlow, 2004). However, since the first clinical use of antibiotics in the 1940’s 
(Zaffiri et al., 2012), the rate that resistance is emerging has steadily increased 
(Morrissey et al., 2013). The ‘golden age’ of antibiotic discovery has ended, with 
few antibiotics developed for clinical use over the last few decades (CDC, 2013). 
With some isolated cases of pan-resistance already being documented (Chen et 
al., 2017), we are on the path towards a ‘post-antibiotic’ era where routine 
infections cannot be effectively treated and as a result, other modern medical 
practices (routine surgery, organ transplants, cancer treatment) will be 
compromised (Livermore, 2009, Laxminarayan et al., 2013).  
Estimated figures for global mortality rates and financial losses paint a 
bleak picture, with 10 million estimated annual deaths and a $100.2 trillion dollar 
reduction in global GDP by 2050 if resistance continues to emerge at its current 
rate (O'Neill, 2014). Research to determine the causes of increased resistance 
and treatment failure is of critical importance, so novel mitigation strategies can 
be designed and implemented to enhance current antimicrobial stewardship. 
Until recently, research has focused on selection for resistance in the 
clinic; despite the fact that environmental, antibiotic resistant bacteria may act as 
a reservoir of resistance mechanisms acquirable by pathogens (Wellington et al., 
2013). Antibiotics are also present in the environment, albeit at much lower 
concentrations (Kummerer, 2009a) than at point of use and it is currently 
unknown whether these environmental concentrations of antibiotics can select 
for de novo resistance (or maintain and increase transfer of pre-existing 
resistance determinants, or alter their expression), in situ.  
Below is a brief overview of antibiotic resistance. The different pathways 
of how antibiotics and antibiotic resistance genes / bacteria enter the environment 
are described, as well as how these resistance genes can be mobilised within 
bacterial populations. The concept that environmental concentrations of 
antibiotics can select for antibiotic resistance is introduced. Finally, methods to 
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research this area are evaluated and ideas for how the area can progress are 
discussed. 
 
1.2. Environmental resistome 
The environmental resistome is all environmental genes which can contribute to 
or confer antibiotic resistance. It has long been recognised as a potential reservoir 
for pathogenic bacteria to acquire novel resistance (Wright, 2010), for example 
by mobilisation of a previously non-mobile resistance gene situated on the 
chromosome. Soil archaea may also contribute to the resistome, but there is little 
work in this area (Chee-Sanford et al., 2009). 
Resistance is ancient and widespread (even in pristine areas). For 
example, a metagenomic study conducted on soil taken from a remote, pristine, 
Alaskan site discovered ancient β-lactamase genes and a previously unobserved 
bi-functional β-lactamase (Allen et al., 2009). Phylogenetic analysis of β-
lactamases revealed they evolved over 2 billion years ago (Hall and Barlow, 
2004). D'Costa et al. (2011) also found resistance genes in ancient permafrost 
via metagenomic analysis, and suggest selection for these pre-existing 
resistance determinants may be a cause for the rapid emergence of resistance 
we observe today, rather than selection of completely novel resistance genes. 
Maintenance of these genes in absence of an antibiotic selective pressure is 
possible (see 1.2. Selection for resistance).  
In fact, both ancient and modern, naturally-occurring antibiotics may have 
a variety of ecological functions in bacterial communities, aside from growth 
inhibition of nearby competitors. Antibiotics may act as signalling molecules at 
sub-inhibitory concentrations (Aminov (2009), and can also be used as a carbon 
source (Wright, 2007, D'Costa et al., 2006). Aminov (2009) suggests the spread 
of resistance in the modern era is a result of positive selection for genes 
performing these roles, which by chance, also confer resistance as a secondary 
function. Therefore anthropogenic pollution of the environment may simply 
increase selection for pre-existing resistance determinants, but further work is 
required before this can be confirmed. 
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1.3. Selection for resistance 
The Minimum Inhibitory Concentration (MIC) is the measured antibiotic 
concentration at which bacterial growth is inhibited. The ecological cut-off value 
(ECOFF) is the upper limit MIC of the wild-type bacteria in the population, and is 
used to describe emergence of ‘ecological’ resistance (Turnidge et al., 2006, 
Olivares et al., 2013). This differs to clinical definitions of resistance based on the 
likelihood of therapy failure; and as such, ecologically resistant bacteria may be 
considered susceptible in terms of clinical break points (Olivares et al., 2013). 
From here on, ‘resistance’ is used in terms of both the ecological and clinical 
perspective, though clinical resistance will be specified by comparison to 
published clinical breakpoint antibiotic concentrations (EUCAST, 2014). 
Resistance can be either intrinsic or acquired. Intrinsic resistance is innate 
and conferred by several mechanisms including absence or modification of the 
drug target, production of enzymes which inactivate the compound, reduced drug 
uptake due to decreased permeability or increased number of efflux pumps; or 
even sequestration of the antibiotic inside the bacterial cell (Olivares et al., 2013, 
Rodriguez-Rojas et al., 2013, Taylor et al., 2011). Intrinsic resistance does not 
arise as a consequence of horizontal gene transfer (‘HGT’ (Olivares et al., 2013)). 
Conversely, acquired resistance arises through horizontal acquisition of whole 
genes; acquisition of mutation(s) in housekeeping genes; or mutations in 
inessential duplicated genes. This pool of genes with the potential to become 
antibiotic resistance genes has been termed the ‘hidden resistome’ (Baquero et 
al., 2008).  
Acquired resistance is often associated with a fitness cost. For example, 
a mutation which alters the antibiotic target may impair the original function of 
that target; resistance genes which code for antibiotic-degrading enzymes will 
also increase the metabolic burden on the bacterium (Enne et al., 2005). This is 
why the adaptive mutation mechanism (whereby gene copy numbers are 
increased, so each can acquire different mutations to generate slightly different 
resistance mechanisms) concludes with elimination of extra gene copies 
(Blazquez et al., 2012), to reduce the burden of superfluous metabolic processes. 
Additionally, metabolic costs as a result of resistance can be offset through 
reorganisation of metabolic pathways (Handel et al., 2013) or through 
compensatory mutations (Enne et al., 2005, Baquero, 2001, Durao et al., 2015). 
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In rare cases, resistance genes can even confer a fitness advantage as with 
qnrA3 (a quinolone resistance gene), which when present on a small plasmid 
carried by Escherichia coli resulted in greater bacterial growth than the same 
strain bearing the same plasmid, but without qnrA3 (Michon et al., 2011). Some 
resistance determinants can also have neutral fitness, meaning resistance (once 
emerged) can be difficult to eradicate (Enne et al., 2005). 
The lowest concentration at which selection can occur is known as the 
Minimal Selective Concentration (‘MSC’ (Andersson and Hughes, 2012)). The 
fact resistance can be maintained in the presence of very low antibiotic 
concentrations suggests the resistance determinant could confer a low fitness 
cost, and worryingly, is therefore more likely to become fixed in the population, 
particularly in the absence of antibiotic selection (Andersson and Hughes, 2012). 
It is also important to note that sub-MIC selection has clinical implications, as 
antibiotics have varying diffusion rates, resulting in different antibiotic 
concentrations in different body compartments. This may also allow selection for 
resistant bacteria in vivo at sub-therapeutic concentrations (Pena-Miller et al., 
2013). 
Antibiotics are hormetic compounds (meaning low doses can sometimes 
result in increases in bacterial growth, as shown previously with low level 
tetracycline treatment resulting in increased colony forming units (Migliore et al., 
2013)). Therefore, they can have dose-dependent effects on bacteria (though 
these are not well described) and many of these can lead to resistance 
acquisition. For example, sub-inhibitory concentrations of β-lactams induce 
release of DNA by Staphylococcus aureus, which promotes biofilm formation and 
cell aggregation, thereby potentially increasing its own resistance levels and 
those of other community members indirectly (Kaplan, 2011). Sub-MIC 
concentrations of antibiotics can also upregulate expression of toxins in E. coli 
and S. aureus, increase rates of HGT and increase mutagenesis by generation 
of reactive oxygen species (‘ROS’ (Gutierrez et al., 2013)). ROS can stall the 
replication fork or inhibit DNA gyrase leading to many transcriptional changes 
(Lopez et al., 2007), the foremost of these being transcription of a specialised 
DNA polymerase which can bypass DNA lesions with reduced fidelity (Blazquez 
et al., 2012). This synchronized reaction that can lead to mutation (and potentially 
acquired resistance) is known as the ‘SOS’ response, which is induced by a 
multitude of different stresses, including some antibiotics (Baquero et al., 2013). 
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Antibiotic induced hormesis has also been shown to increase tolerance to heat 
shock and ROS (Mathieu et al., 2016) and so can increase general fitness. 
Antibiotics can also increase levels of HGT. Tetracycline has been shown 
to increase transcription of the rteC gene which controls excision of genes and 
mobile genetic elements (Moon et al., 2005). Kim et al. (2014a) monitored 
transfer of the Inc resistance plasmid from E. coli to P. aeruginosa or sewage 
sludge recipients, and found an increasing dose-response relationship for 
transfer rates. However, there have also been cases where antibiotics have been 
found to decrease the rate of HGT (Riedl et al., 2000), or have no effect on 
transfer rates (Cottell et al., 2012).  
The mechanisms are varied and complex, but there is enough supporting 
evidence to suggest that sub-MIC concentrations of antibiotics may not only 
select for pre-existing resistant clones, but also promote the generation of novel 
resistance mechanisms and the movement of these within bacterial populations. 
 
1.4. Costs of resistance 
Resistance to an antibiotic often arises soon after it is introduced as a therapeutic 
agent (Figure 1 (CDC, 2013)) which has significant clinical, social and economic 
repercussions. Infections caused by antibiotic resistant bacteria can increase 
mortality rates and cost of hospital care due to prolonged hospital stay (Neidell et 
al., 2012), requirement for multiple courses of treatment, and in extreme cases 
the need for patients to be isolated. It has been conservatively estimated that 
greater than 2 million cases of antibiotic resistant bacterial infections occur in the 
USA each year, with around 23,000 of these directly causing death. Around 
26,000 of these infections are caused by extended-spectrum β-lactamase 
producing Enterobacteriaceae, which cost an extra estimated $40,000 per case 
(CDC, 2013).  
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Figure 1. Based on the figure on page 28 from the report by the CDC (2013). 
Resistance to a drug soon arises after development and use in the clinic.  
 
In Europe, a report by the European Centre for Disease Control and 
Prevention (ECDC) and the European Medicines Agency (EMA) found 25,000 
deaths are caused by multi-drug resistant bacteria annually, with 2.5 million extra 
hospital days required for treatment of drug-resistant bacterial infections, 
amounting to estimated costs of resistance of €1.5 billion per year (ECDC/EMEA, 
2009). Subsequently, the European Union (EU) funded the BURDEN project 
(‘Burden of Resistance and Disease in European Nations’) which found that 
mortality rates in patients infected with resistant bacteria were significantly higher 
than in patients infected with susceptible bacteria (Lambert et al., 2011). 
Specifically, for third generation cephalosporin-resistant E. coli blood stream 
infections, 30 day mortality rate was 2.5x higher and hospital stay was on average 
5 days longer in patients infected with resistant E.coli compared to those infected 
with susceptible E. coli (de Kraker et al., 2011).  
In 2014, a Review on Antimicrobial Resistance was commissioned by 
British Prime Minister David Cameron to propose concrete solutions to the global 
threat of antimicrobial resistance, which if left unaddressed, could be 
‘catastrophic’ according to England’s Chief Medical Officer Dame Sally Davies 
(McKenna, 2013). Chaired by economist Jim O’Neill, the committee produced 
several publications until its final report in May 2016 which estimated that should 
resistance continue to emerge at its current rate, by 2050 there will be a human 
casualty resulting from an antibiotic resistant infection every three seconds 
(O'Neill, 2015). Other doomsday scenarios predict that infections caused by 
resistant bacteria will be the leading cause of death worldwide with over 50 million 
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cases annually, and that this will cost the global economy in excess of $100 trillion 
(USD (O'Neill, 2014)). 
Despite the obvious need for new antibiotics, very few are being 
developed; in fact, only 4 new classes have been introduced in the last 40 years 
(Cooper and Shlaes, 2011). One contributing factor is diminishing returns for 
pharmaceutical companies. With around a $70 million outlay to reach just the 
Phase III clinical trial on a drug which is prescribed usually only in short courses 
and to which resistance may quickly arise (Cooper and Shlaes, 2011), it’s 
unsurprising companies prioritise investment elsewhere. Even most antibiotics 
currently in development are not novel, but rather the chemical groups 
surrounding the active core of the molecule are slightly altered (Baquero et al., 
2009). This is more economical than developing a completely new compound 
and is argued to provide short term solutions; but resistance can quickly arise 
again (Altman, 2013), and it is therefore an inadequate long-term solution. New 
antibiotics are occasionally discovered, such as Teixobactin in 2015 (Ling et al., 
2015), but the time and costs involved in reaching market makes investment high 
risk (O'Neill, 2014). In the final Review on Antimicrobial Resistance report, one of 
the ten final recommendations was to introduce funding incentives for 
development of new antibiotics (O'Neill, 2015) for these reasons.  
 
1.5. Antibiotic uses and discharge to the environment 
Antibiotics are not only used extensively as therapeutics and prophylactics in the 
clinic; they are also used in the community, farming, aquaculture and even 
horticulture (Andersson and Hughes, 2012). Prophylaxis in animal rearing can be 
at sub-therapeutic concentrations (Allen and Stanton, 2014) and antibiotics can 
also be used as growth promoters, though this is now banned in some countries 
(Martinez, 2009), including all countries in the EU (Laxminarayan et al., 2013).  
Most antibiotics are not fully metabolised in the body by humans or 
animals, resulting in their excretion as active parent or transformation products; 
in fact, 20 – 90 % of antibiotics excreted are estimated to still be active 
(Andersson and Hughes, 2012). When used for human therapy, these enter 
sewage or waste water treatment plants (treatment does not fully inactivate all 
antibiotics (Daghrir and Drogui, 2013)) and can then enter the environment in an 
active form. Additionally, ‘stabilised solids’ (i.e. treated waste solids) are used as 
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fertiliser or to improve soil quality (Ghosh et al., 2009) which may further facilitate 
dissemination of antibiotics or resistance genes in the environment (Calero-
Caceres et al., 2014). In aquaculture, antibiotics can reach high concentrations 
in local waters and sediments (Kar and Roy, 2012), as around 80 % of ingested 
antibiotics can be excreted or secreted by fish. Excreta or antibiotics can also 
then be dispersed through aquatic environments (Cabello et al., 2013). For 
animals, run off from farms and the deliberate spreading of animal faeces as 
manure contribute to accumulation of active antibiotics and resistance genes in 
farmed and natural environments (Andersson and Hughes, 2012). Antibiotics and 
resistance genes may also pass back to humans via the food chain (CDC, 2013), 
though withdrawal periods are used to try reduce antibiotic concentrations in milk 
or meat before human consumption (Allen and Stanton, 2014). Finally, further 
dissemination may be facilitated by animals or birds, or abiotic factors such as 
wind or water currents (Allen et al., 2010). 
Once in the environment, antibiotics can be degraded by photolysis, 
hydrolysis or thermolysis (breakdown by light, in water, or by heat, respectively), 
and rates for these vary greatly between antibiotics (Kummerer, 2009a). An 
antibiotic can even degrade at different rates in freshwater and salt water (Trovo 
et al., 2009). Bioavailability also differs greatly depending on the environmental 
context. Soil and sediment can act as an antibiotic sink, by removing antibiotics 
from water, and sorption rates (which can reduce antimicrobial potency) vary 
greatly for different compounds (Kummerer, 2009a). Conversely, antibiotic 
persistence increases with soil sorption rate, as when bound to soil particles 
biodegradation is reduced (Baquero et al., 2008). Biodegradation of antibiotics 
(by bacteria) is more common under anaerobic conditions than anaerobic, with 
rates differing once again between antibiotics (Kummerer, 2009a).  
Active antibiotic concentrations tend to be very low in the environment. 
Liquid chromatography coupled to mass spectrometry (‘LC-MS’) as well as 
surface-plasmon resonance can be used as physio-chemical methods for 
detecting low concentrations of antibiotics. Immunological assays can also be 
used, and while they require less specialist equipment than the physio-chemical 
tests, they tend to be more expensive (Liu et al., 2011). It is therefore unsurprising 
that there is a relatively scarce amount of data on the concentrations of antibiotics 
found in the environment, particularly in developing countries. In a systematic 
review of measured pharmaceutical concentrations in freshwater rivers for 
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example, 80 % of the papers were from North America or Europe (Hughes et al., 
2013). 
In general, concentrations of antibiotics are highest in pharmaceutical 
industry (mg/L) and hospital effluents (high μg/L), lower concentrations (low μg/L) 
are found in waste water treatment plant (WWTP) effluent, and even lower 
concentrations (ng/L) are found in surface water, seawater, and ground water 
(Homem and Santos, 2011). Specifically, antibiotic concentrations in WWTP 
effluent is usually between 10 – 1000 ng/L for a range of antibiotics including β-
lactams, sulphonamides and trimethoprim, amongst others (Le-Minh et al., 2010). 
Deblonde et al. (2011) showed that there is little if any difference between WWTP 
influent and effluent antibiotic concentrations by conducting a review of these 
measurements in the literature; Verlicchi et al. (2012) found similarly low antibiotic 
removal by treatment plant processes. Another study found higher levels of both 
antibiotic resistance genes and antibiotics in effluent compared to the receiving 
water (Xu et al., 2014). WWTPs can also impact the concentrations of antibiotics 
within biofilms found downstream, with concentrations ranging from 10.4 ng/g 
(trimethoprim) to 276 ng/g (levofloxacin) (Aubertheau et al., 2016). Higher 
antibiotic concentrations in WWTPs could reduce biodegradation efficacy if the 
bacteria responsible for this process are susceptible to the antibiotic 
concentrations present (Kar and Roy, 2012); for example, methane production 
has been effectively reduced when bacterial communities are spiked with 
antibiotics (Sun et al., 2012). 
In the natural environment, Chen and Zhou (2014) measured the 
concentrations of 20 antibiotics with ultra-high performance liquid 
chromatography-tandem mass spectrometry, at 13 different sites in the Huangpu 
River, in China. Freshwater concentrations varied greatly between the sites, and 
antibiotics associated with veterinary use were higher when measured at sites 
with nearby farms. Average concentrations of sulfamethoxazole were 259.6 ng/L, 
and fluoroquinolone concentrations in general were much lower, between 34.2 
ng/L and 327 ng/L. They also measured antibiotic concentration in river 
sediments. The highest concentration was of erythromycin at 24.6 μg/kg, and the 
lowest was of chloramphenicol at 0.7 μg/kg (Chen and Zhou, 2014).  
Conversely, antibiotic concentrations can be extremely high in 
environments which receive effluent from pharmaceutical production facilities. In 
India, a WWTP serving 90 of these facilities had unprecedented levels of 
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antibiotic residues up to 31 mg/L (Larsson et al., 2007). Though this concentration 
was toxic, it has been shown that other environments contaminated with 
production facility effluent can have much higher resistance gene levels, for 
example an exposed Indian lake had a resistance gene abundance 7000 times 
greater than a comparative Swedish lake (Bengtsson-Palme et al., 2014). 
This vast variability prevents any generalisation across compounds or 
environments, and therefore greater effort is required to quantify actual antibiotic 
concentrations in different environmental compartments, and also to begin to 
consider potentially bioactive transformation products. In summer 2016 an online 
database curated by the German environment agency UmweltBundesamt (UBA) 
went live, which comprehensively lists measured environmental concentrations 
(MECs) of a range of pharmaceuticals (including antibiotics), as part of their 
project “Pharmaceuticals in the environment - occurrence, effects and options for 
action” (UmweltBundesamt, 2016). However, due to the vast variability between 
measurements even in the same environmental compartment for the same 
compound in the same country, continued monitoring of environmental 
pharmaceuticals is necessary. 
 
1.6. What is driving environmental prevalence of AMR – discharge of 
antibiotics or resistant bacteria? 
Environmental antibiotic residues may be a driving force of selection for 
resistance, but conversely, persistence of antibiotic resistance genes (in either 
viable or non-viable bacteria) may be the real threat. Selection for resistant genes 
may occur in the body (human or animal), or even in treatment plants (Zhang et 
al., 2009b), and some of these may enter the environment. There is evidence of 
a clear relationship between the level of pollution and presence of resistance 
genes, for example prevalence of resistance genes and intI1 (a gene which 
facilitates mobilisation) from different sites in a river in China decreased 
concurrently with anthropogenic impact (Chen et al., 2014), and intI1 levels are 
increased in biofilms downstream of WWTPs (Aubertheau et al., 2016). The intI1 
gene has also been proposed as a proxy for antibiotic resistance and thereby 
anthropogenic pollution (Gillings et al., 2015, Berendonk et al., 2015, Berglund, 
2015, Amos et al., 2015). Once through the WWTP system, resistance genes 
have been shown to persist in the environment in the complete absence of 
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anthropogenically introduced antibiotics (Allen et al., 2009, Tamminen et al., 
2011, Muziasari et al., 2014), and half-lives of resistance genes in the 
environment in the absence of antibiotics have been reported as up to three 
months (Burch et al., 2014). Additionally, multi-drug resistance plasmid bearers 
can persist without nutrients at very low antibiotic concentrations (Bien et al., 
2015), and at a range of pH and temperature (Calero-Caceres and Muniesa, 
2016). Resistance gene host identity can also impact persistence, with phage-
associated genes being more persistent than those in bacteria (Calero-Caceres 
and Muniesa, 2016). 
The greatest concern is that resistance genes can persist and be mobilised 
into environmental bacteria (Yang et al., 2013a) and then back into pathogens, 
many of which are naturally competent and can readily uptake extracellular DNA 
(Mao et al., 2014). There is compelling evidence that clinically relevant resistance 
genes originate in environmental bacteria (Walsh, 2013a, Humeniuk et al., 2002, 
Poirel et al., 2004, Poirel et al., 2005, Potron et al., 2011), and have up to 100 % 
sequence similarity to genes in environmental bacteria (Forsberg et al., 2012) 
which worryingly indicates recent HGT transfer between environmental bacteria 
and human pathogens.  
Three steps have been proposed for fixation of environmental resistance 
genes in human pathogens (Martinez, 2009): firstly, resistance evolves in 
environmental bacteria over evolutionary time, secondly, this resistance is 
transferred to human associated bacteria in an environment where they are in 
direct contact with environmental bacteria, and finally this resistance is 
transferred to human pathogens, possibly within the gut or WWTPs which are 
both considered to be HGT hotspots (Broaders et al., 2013, Rizzo et al., 2013). 
Beaches have been suggested as an environment which can allow contact 
between human commensals (faecal indicator organisms) and resistant 
environmental bacteria (Alm et al., 2014), as have recreational waters which can 
contain ESBL-producing, multi-drug resistant bacteria (Blaak et al., 2014, 
Leonard et al., 2015). Additionally, certain human populations are more at risk of 
exposure and transmission e.g. those working in animal farming (Huijbers et al., 
2014), or those with frequent contact with contaminated waters such as surfers 
(Leonard et al., 2015). 
 Antibiotic resistance plasmids have been detected in treated waste water 
(Rahube and Yost, 2010) and resistance genes have been found in greater 
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relative quantities in the effluent than the influent of a WWTP (Marti et al., 2013). 
These increased numbers of resistance genes in the effluent can be similar to 
that in the downstream receiving water (Berglund et al., 2015). This relationship 
is found to hold for the majority of different treatment plants tested (Du et al., 
2014), and even tertiary treated effluent can still contain significant amounts of 
resistance genes (LaPara et al., 2011). 
However, greater than 90 % of integrons present in sewage influent have 
been found to be removed by treatment processes, showing some DNA may be 
successfully eliminated (Zhang et al., 2009a). Even when integrons are not 
removed successfully, gene cassette diversity (frequently antibiotic resistance 
genes) may be reduced by treatment processes (Stalder et al., 2013). Other 
studies have found no significant difference in sulphonamide, tetracycline or beta-
lactam resistance genes following treatment in WWTPs, with different loads and 
different treatment stages having no impact on prevalence (Laht et al., 2014). 
Some studies have directly investigated how effective different treatments 
are at removing resistance genes. Thermophillic treatment can decrease 
resistance gene abundance, whereas mesophillic treatment results in reduced 
removal of the same genes (Ghosh et al., 2009). UV treatments may increase the 
prevalence of antibiotic resistance genes, despite being bactericidal, which may 
be because UV also induces the SOS response, which can increase the number 
of point mutations (Blazquez et al., 2012) and even rates of HGT (Beaber et al., 
2004) and gene cassette recombination within integrons (Guerin et al., 2009, 
Guerin et al., 2010, Guerin et al., 2008). Additionally, upon re-exposure to light, 
the enzyme photolyase may repair damaging DNA lesions (Jungfer et al., 2007, 
Oguma et al., 2001) allowing bacterial survival. Chlorination has also been 
demonstrated to increase antibiotic resistance, in particular to ampicillin, 
cephalothin and tetracycline (Murray et al., 1984, Huang et al., 2013). Bacteria 
can still be viable after treatment (Amos et al., 2014a), including significant clinical 
pathogens such as E. coli ST131 harbouring the resistance gene blaCTX-M-15 
(Dolejska et al., 2011). In fact, numbers of viable, resistant bacteria may increase 
at each stage of treatment, resulting in a significant increase in resistance 
prevalence in the effluent compared to the influent (Zhang et al., 2009b). 
Treatment processes should be assessed for efficacy of resistance gene 
removal; yet recently, pilot studies for new treatment processes still use removal 
of viable enterococci (an indicator of water quality) as a measure of treatment 
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effectiveness (Michael et al., 2012) and fail to take into account removal of genes 
which may be in other host backgrounds or even exist as free DNA. An 
inexpensive post treatment strategy has been suggested using qPCR to screen 
waste water for levels of antibiotic resistance genes before releasing the effluent 
into the environment (Nam et al., 2013).  
Most research conducted to date has been correlative; i.e. it has not been 
empirically determined in controlled experiments whether antibiotics in the natural 
environment select for resistance; or if a given resistance gene becomes more 
widely disseminated due to low fitness cost (or benefit, as a result of other 
potential ecological functions). It has also not been empirically determined 
whether antibiotics influence ‘stochastic’ events such as co-localisation with other 
genes under positive selection (‘co-selection’), or mobilisation into a fitter 
plasmid, etc. In any case, the pertinent issue from a human health perspective is 
when a resistance mechanism is transferred to a human pathogen.  
 
1.7. Mobilisation of resistance genes 
HGT is the movement of DNA between bacteria (which need not be closely 
related (Rodriguez-Rojas et al., 2013)). There are three main mechanisms by 
which HGT occurs (Figure 2). The first, transformation, is when naturally 
competent bacterial cells take up DNA directly from the environment. The second 
involves transport of bacterial DNA by bacteriophage, viruses which infect 
bacteria. Transport of DNA in this way is limited by the type of phage, but the 
length of DNA mobilised can be greater than 100 kb (Muniesa et al., 2013), a 
sufficient length to contain many resistance genes, and phage isolated from 
hospital and urban effluents as well as river water have all been found to harbour 
high numbers of blaCTX-M and qnr genes (Balcazar, 2014). The final mechanism 
involves formation of the conjugation or ‘sex’ pilus, through which some mobile 
genetic elements (MGEs) can be transported (Thomas and Nielsen, 2005, 
Furuya and Lowy, 2006).  
42 
 
 
Figure 2. Taken from Furuya & Lowy (2006). The three main mechanisms of 
horizontal gene transfer ('a, b' and 'c'). 
 
Recent horizontal movement of genes can be detected when genes in 
different species have very high sequence similarity (Chee-Sanford et al., 2009), 
and association with MGEs can be used as an indicator of further mobilisation 
potential. Biofilms, WWTPs or within filter-feeding organisms (Yang et al., 2013a, 
Lupo et al., 2012) are considered ‘hot-spots’ for transfer (as bacteria are in close 
proximity, with ample nutrient sources). Rates of HGT can also be affected by 
physiological factors such as temperature (van Elsas and Bailey, 2002). 
MGEs can include plasmids, integrons, transposons, integrative 
conjugative elements (ICEs), and insertion sequence common regions (ISCRs), 
amongst others. ISCRs are associated with genes conferring resistance to many 
different antibiotics. If inserted adjacent to resistance genes, upon excision they 
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can carry these genes to a new location (Toleman et al., 2006). Transposons are 
sections of DNA which encode a transposase, which allows excision and 
recombination of itself and any associated genes (often antibiotic resistance 
genes (Toleman et al., 2006)). ICEs are chromosomally-located but can still be 
mobilised via conjugation (Wozniak and Waldor, 2010). These MGE’s are not 
covered in any greater detail here; however it is important to note transposons 
cannot undergo conjugation alone (Wozniak and Waldor, 2010) but are frequently 
incorporated into plasmids, and integrons can be found within both transposons 
and plasmids (Rahube and Yost, 2010) and so on. 
Plasmids are extra-chromosomal pieces of DNA, and those conferring 
antibiotic resistance are often large and self-replicating. They can be difficult to 
eradicate, having clear implications for managing spread of antibiotic resistance 
(Carattoli, 2013); in fact, some plasmids exhibit parasitic behaviour, in that they 
are maintained without conferring any benefit to the host (Brown et al., 2013). 
They can be divided into different compatibility groups; incompatible plasmids 
(Inc plasmids) cannot replicate when they are in the same bacterial cell as they 
both have the same replicon and therefore the same replication mechanism 
(Carattoli, 2013). Amplification of plasmid DNA with replicon-specific primers can 
be used to determine different incompatibility groups, though successful primer 
binding is limited (Tennstedt et al., 2003). Additionally, plasmids can have broad 
or narrow host ranges, meaning they can persist in many or only a few bacterial 
species, respectively. Plasmids can also be self-transmissable or mobilisable, 
meaning they can transfer themselves or require a ‘helper’ plasmid, respectively 
(Smillie et al., 2010). Some plasmids ensure their survival during replication by 
encoding ‘addiction systems’ which kill daughter cells that no longer contain the 
plasmid following cell division (Carattoli, 2013).  
All these features can have varying effects on plasmid fitness, which in 
turn affect likelihood of selection for antibiotic resistance. Potentially, a very fit 
plasmid (for example, it is small, autonomously replicating, has a broad host 
range and high compatibility with other plasmids, and encodes an addiction 
system) which may also be carrying one or more antibiotic resistance genes could 
be maintained due to the characteristics of the plasmid itself and not due to the 
resistance being conferred by the antibiotic resistance genes (Carattoli, 2013). In 
addition, in terms of antibiotic resistance, plasmid-mediated resistance has been 
shown on average to confer a smaller fitness cost than chromosomal, mutation-
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based resistance (Vogwill and MacLean, 2015). Antibiotics can in turn also affect 
the success of a plasmid by altering transfer rates, which have been shown to be 
higher at ‘medium’ concentrations of antibiotics (32 – 64 mg/L) compared to very 
high or low antibiotic concentrations (Schuurmans et al., 2014).  
Integrons comprise of the intI1 gene (which encodes the integrase 
enzyme) and an attI recombination site, as well as one or more gene cassettes. 
Gene cassettes exist extracellularly in the environment, often code for antibiotic 
resistance genes and include the palindromic attC recombination site (Hall, 
2012). Integrase facilitates site-specific recombination of any number of gene 
cassettes between the attI and attC sites (Hall, 2012), with more than one gene 
cassette forming an ‘array’ (Partridge et al., 2009). Integrons often carry multiple 
antibiotic resistance gene cassettes, for example, 28 of 30 integron-carrying 
strains isolated from Lake Taihu in China were resistant to more than one 
antibiotic tested (Yin et al., 2013).  
Carriage of arrays which confer resistance to a range of compounds is 
believed to be a mechanism by which co-selection may occur. Co-selection can 
be described in two ways: cross-resistance is selection for a gene because it 
confers resistance to more than one compound (e.g. multidrug efflux pump) and 
only one of those compounds needs to be present for the gene to be maintained 
(Andersson and Hughes, 2011). The second mechanism of co-selection is co-
resistance, whereby a resistance gene can ‘hitchhike’ along with another 
resistance gene, or genetic locus (or loci, e.g. on a plasmid) undergoing positive 
selection (Gullberg et al., 2011, Nesme and Simonet, 2014). 
Gene cassettes can confer resistance to biocides and detergents; for 
example quaternary ammonium compound, or ‘QAC’, resistance is conferred by 
the qacE gene. QacE or its derivatives (e.g. qacEΔ1) are commonly found on 
integrons isolated from the environment (Gaze et al., 2011). So for co-selection 
to occur, a QAC resistance gene located in the same array as an antibiotic 
resistance gene will result in maintenance of this gene cassette when the 
bacterium is exposed to QACs, even if it is not being exposed to antibiotics. A 
paper by Gaze et al. (2011) found more than half of all integrons detected in QAC-
contaminated soil harboured semi-functional qacEΔ1, which is always associated 
with sul1, a sulphonamide resistance gene. In a previous study, bacterial isolates 
from reed-bed soil and river sediment contaminated with QACs had a significantly 
greater proportion containing class 1 integrons compared to controls, and qacE, 
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the fully functional multi-drug efflux pump, was detected in 18 of 19 of class 1 
integron-containing isolates (Gaze et al., 2005). The qacE gene itself is 
significant, as both a multidrug efflux pump to confer cross-resistance (Gaze et 
al., 2005) and because it contains its own promoter (Partridge et al., 2009) it can 
confer a strong co-selective force for antibiotic resistance in the presence of 
biocides, even if it is distal from the integron promoter.  
 
1.8. Issues with current research methods aiming to study resistance in 
the environment 
Evidence suggests resistance genes can be maintained in the environment when 
concentrations of antibiotics are very low, despite their ‘expected’ fitness cost. 
However, it is unknown whether these concentrations can select for resistance in 
situ (Tello et al., 2012). The majority of studies outlined (as mentioned previously) 
have provided only correlative details; for example, the relative increase of 
abundance of resistance genes in effluent from treatment plants compared to the 
influent: Lachmayr et al. (2009) found sewage treatment may enrich for β-
lactamase producing bacteria, but the mechanisms of how this occurred (e.g. 
direct selection, or uptake of free resistance genes, or co-selection) are unknown. 
Another study examined fate of blaTEM genes, which are an abundant family of β-
lactamase encoding genes. The ratio of blaTEM genes to 16S rRNA genes was 
monitored by real-time PCR (qPCR) and found to increase after sewage 
treatment. It is unknown whether this is simply due to enrichment of pre-existing 
resistant bacteria, or resistance acquisition in previously susceptible bacteria, or 
both; and whether this was due to the selective compounds, the fitness costs of 
the genes; or their genetic location was not investigated. 
Transfer experiments have largely neglected the role plasmid fitness may 
play in maintenance or transfer frequency of resistance genes located on 
plasmids (Carattoli, 2013). However, plasmid persistence, virulence, growth and 
fertility (conjugation rate) was investigated for the IncK pCT plasmid, both 
carrying and not carrying bla-CTX-M14 (an ESBL), and no difference in fitness was 
observed (Cottell et al., 2012), indicating in this case, the plasmid itself may be 
responsible for the success of the resistance gene. However, the question 
remains: are transfer rates comparable between the laboratory and the 
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environment, and in particular, in environmental matrices contaminated with 
antibiotics, with a more complex (and therefore realistic) bacterial community? 
In terms of the current methods employed for testing the ecotoxicity of 
antibiotics which inform environmental risk assessment, most studies use the 
standard toxicity tests: measuring CO2 production as a proxy for algal growth or 
bacterial growth, and reduction in bioluminescence of Vibrio fischeri (Donner et 
al., 2013), as well as tests on fish and invertebrates (Verlicchi et al., 2012). Tests 
on more complex organisms seem unlikely to provide information on how 
antibiotics may affect bacteria, and specifically, in terms of selection for 
resistance. Even V. fischeri, as a marine microorganism, lacks the ability to be 
tested in freshwater, is generally sensitive only to higher concentrations of 
compounds (Fatta-Kassinos et al., 2011), and is unaffected by some antibiotics 
(Brandt et al., 2015). Additionally, using CO2 production in bacteria as a proxy for 
toxicity (or selection of resistance) is misleading as bacteria can persist in a 
bacteriostatic state (Demoling et al., 2009). Despite these disadvantages, this is 
the only bacterium described when assessing ecotoxicity of the antibiotics in 
water compartments in a review by Santos et al. (2010).  
There are a few ecotoxicological studies where resistance is considered. 
For example, ecotoxicity of antibiotics commonly used in fish farming was 
assessed by testing on algae, V. fischeri, and activated sludge. Turbidity was 
used as a proxy for toxic effect on the sludge bacteria but 100 % inhibition of 
growth was never observed (Munch Christensen et al., 2006). 
Some studies have used pollution-induced community tolerance (PICT) as 
a proxy for toxicity. If any bacteria in the community are tolerant, they survive and 
therefore the combined tolerance of the community increases. Translated into 
microbial ecological terms, resistant bacteria survive and begin to take over the 
population, or potentially transfer their resistance to previously susceptible 
bacteria. This approach can be used to test tolerance of bacterial communities in 
both aquatic and terrestrial environments (Demoling et al., 2009). In a recent 
review it was recommended that communities used for environmental risk 
assessment should not have been exposed to the test compound previously 
(Brandt et al., 2015), but such a community would be difficult to find and may 
need to be synthetic; and would therefore primarily allow tracking of only de novo 
mutations, and not selection of pre-existing resistance determinants. Conversely, 
if single species were used, the strains would indeed need to be carefully selected 
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based on their susceptibility profile (Brandt et al., 2015), but again this would not 
take into account mobile and / or pre-existing resistance determinants. 
A paper by Isidori et al. (2005) used the SOS chromotest on E. coli (which 
quantitatively measures SOS pathway induction) and the Ames Test (which 
assesses genotoxic potential) on Salmonella Typhimurium to test toxicity of a 
range of antibiotics. Only one antibiotic gave a positive result for the SOS 
chromotest and three of the six antibiotics tested possessed genotoxic potential. 
This is a rational approach as it is a standardised method which could be used to 
assess potential of an antibiotic to select for resistance. However, no ecotoxicity 
papers assess genotoxicity of environmental concentrations of antibiotics or their 
degradation products on a range of environmental (and ideally opportunistically 
pathogenic) bacteria. 
Many ecotoxicological studies also investigate the toxicity of antibiotic 
degradation products generated through different degradation pathways. Some 
products lose their antimicrobial activity, for example photolytic or photocatalytic 
degradation compounds of ciprofloxacin lose their potency with increasing 
treatment when tested against E. coli K12 (Paul et al., 2010). However, some 
degradation products retain their activity and can even be more potent than the 
parent compound, for example photodegraded products of tetracycline exerted 
greater toxic effects on V. fischeri (Jiao et al., 2008), and trimethoprim solar TiO2 
photocatalysis intermediates are still moderately toxic to V. fischeri (Sirtori et al., 
2010).  
Few have considered antimicrobial effects of antibiotic degradation 
products on bacteria. Photodegradation products of different fluoroquinolones 
have been shown to retain antimicrobial activity against clinically relevant strains 
(such as Staphylococcus aureus subsp. aureus, P. aeruginosa, and Klebsiella 
pneumonia subsp. ozaenae) (Kusari et al., 2009) and environmental strains (E. 
coli, Klebsiella oxytoca, Enterobacter cloacae) (Sunderland et al., 2001).  Oxolinic 
acid (used in aquaculture and veterinary medicine) and its transproducts 
produced by photocatalysis both in, and in absence of TiO2 were applied to E. 
coli, and toxicity on V. fischeri was also measured. It was found that the 
degradation products retained antimicrobial activity, but had reduced toxicity on 
V. fischeri (Giraldo et al., 2010), further illustrating the inadequacy of this method 
when aiming to consider a compound’s potential to select for resistance. 
Similarly, ofloxacin and trimethoprim and their degradation products were not 
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toxic to Daphnia magnia at µg/L concentrations (Michael et al., 2012), which 
shows this standard ecotoxicity assay may be ineffective for detecting selection 
of antibiotic resistance, which has been shown to occur at such levels (Gullberg 
et al., 2011, Negri et al., 2000). Inhibition of bacterial luminescence other than V. 
fischeri has also been monitored. Toxicity of antibiotics in pig manure was 
estimated by measuring inhibition of luminescence in Photobacterium 
phophoreum. Reduction of luminescence was observed at ‘trace concentrations’ 
(Sun et al., 2012), suggesting it may be more suitable for risk assessments 
attempting to determine MSCs, though again not necessarily for bacteriostatic 
antibiotics if luminescence is independent of growth.  
Inhibition of growth is another assay used to assess pollutant effect; for 
example, new veterinary antibiotics must have a PEC below 100 μg/Kg, which 
must be tested according to the OECD/OCDE 2000 guidelines. Finally, standard 
test lengths for measuring inhibition of luminescence or CO2 production have 
been suggested to be currently too short for assessing toxicity of antibiotics, as 
they do not reflect the generation times of different bacteria (Kummerer et al., 
2004). 
There appears to be a significant lack of knowledge regarding selection 
for antibiotic resistance in natural environments and little progress towards 
developing a standardised method to test for toxicity of antibiotics and their 
degradation products, and their potential to select for resistance in a range of 
environmental bacteria. This limits the development of rigorous environmental 
risk assessment and mitigation strategies. 
 
1.9. Problems for risk assessment of antibiotics using current methods 
In a review by Roos et al. (2012), ranking methods used to prioritise 
pharmaceuticals for environmental risk assessment were compared. Nine 
different methods defined a total of 32 different pharmaceutical compounds which 
should be prioritised for risk assessment. None of these were antibiotics. This 
suggests the current ranking methods may not be well suited to considering the 
selective effects of antibiotics on bacteria; or that the data in this area is scarce; 
or indeed that the area is largely neglected in ecotoxicity evaluations. The authors 
go on to state: “A first tier prioritisation scheme should be as widely applicable as 
possible and therefore ideally be based on data that is readily available for all 
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pharmaceuticals” (Roos et al., 2012), but data on effects of antibiotics on bacteria 
is considerably lacking. Though all new pharmaceuticals require environmental 
risk assessment during market authorisation, the problem is that current methods 
do not assess the potential to select for resistance (Brandt et al., 2015). Analysis 
of a compound’s ecological effects and exposure potential is essential to risk 
assessment (Aurelien et al., 2013), but without sufficient methods to determine 
the ‘toxicity’ of antibiotics, or probability that antibiotics can select for resistance 
in bacteria, it will be impossible to design an appropriate risk assessment with 
management strategies to reduce antibiotic release.  
Unfortunately, this is not the only example of how current risk assessment 
methods underperform. Assessments of exposure to pharmaceuticals is often 
considered only in terms of the weight of the compound in sales, but more data 
is required to design an accurate risk assessment, for example the  compound’s 
degradation rate, and whether it is removed by treatment plants (Roos et al., 
2012). Additionally, little or no work has investigated entantiomeric antibiotics. 
Enantiomers are two mirror copies of a single compound, and they may have 
different degradation rates and differ in their toxicity (Lopez-Serna et al., 2013). 
For example, ofloxacin is a racemate comprising of the ‘active’ entantiomer, 
levofloxacin, and its inactive entantiomer (Kummerer et al., 2004). Could 
degraded, previously inactive entantiomers become toxic? In these cases, could 
quantification of racemates overestimate exposure risk, or quantification of 
active, parent racemates underestimate risk? 
 Munch Christensen et al. (2006) also highlight the importance of complex 
mixtures of pharmaceuticals versus simple mixtures, which may have different 
“additive, synergistic, and antagonistic effects”. Different effects can occur if the 
group of compounds affect different biological sites with different mechanisms 
(‘concentration addition’), or if they each have independent mechanisms (Munch 
Christensen et al., 2006).  
It has been stated that risk assessment of antibiotics should take into 
consideration the potential for selecting for resistance (Tello et al., 2012). Tello et 
al. (2012) calculated the wild-type cut-off value (COWT) for bacterial growth 
inhibition using previously determined MICs, and compared this to the 
environmental concentrations of a range of antibiotics measured in different 
environmental compartments, including waste water and sewage treatment 
plants, manure and streams. Their results suggested the current cut-off value 
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outline by the Veterinary International Conference on Harmonisation (VICH) 
phase I guidance document (VICH, 2000) for the discontinuation of veterinary 
drug development (<1 part per billion in water, and <100 part per billion in soil) is 
not low enough to prevent selection for resistant bacteria (Tello et al., 2012). 
However, predicted environmental concentrations and predicted no effect 
concentrations (‘PECs’ or ‘PNECs’) are the standard approaches to assessing a 
drug’s risk to the environment (Roos et al., 2012). They are used to determine 
the ‘Risk Quotient’ (‘RQ’ obtained by dividing PEC by PNEC), which if equal to or 
greater than 1, a significant environmental risk is assigned to the compound 
(Aurelien et al., 2013, Jesus Garcia-Galan et al., 2009). 
As little work has investigated whether sub-inhibitory concentrations of 
antibiotics select for resistance (Gullberg et al., 2011, Negri et al., 2000), the 
‘effect’ of these PNEC’s is likely cell death or cell survival; not mutations or 
resistance gene acquisition or maintenance. In fact, pharmaceuticals for human 
use only require Phase II risk assessment (that is, investigation of their fate and 
environmental effects) if their PEC in surface water is greater than 0.01 µg/L 
(Bialk-Bielinska et al., 2011), and though all new pharmaceuticals require 
environmental risk assessment during market authorisation, current methods do 
not assess the potential to select for resistance (Brandt et al., 2015). For example, 
PEC, PNEC and RQ values were calculated for a range of pharmaceuticals 
including antibiotics, from hospital waste water. The antibiotic with the highest 
RQ of 0.8 (assigned as an ‘insignificant’ risk) was amoxicillin, with a PEC of 499 
µg/L in the hospital effluent (Escher et al., 2011), which is much higher than sub-
inhibitory concentrations of antibiotics shown to select for resistance (Gullberg et 
al., 2011). This RQ approach is inadequate for antimicrobial stewardship in a time 
when novel antibiotics are few and far between. Other measures of antimicrobial 
activity may be more suitable, for example EC10 (concentration at which 10 % of 
bacterial growth is inhibited) or EC50 values, which can be sensitive down to the 
µg/L level when assessing antibiotic toxicity of sulphonamides to soil microcosms 
and activated sludge (Jesus Garcia-Galan et al., 2009). 
It is clear “current methods do not monitor effects of chemicals on 
microbes well” (Backhaus et al., 2012) and the best approach for developing a 
meaningful risk assessment of antibiotics requires a combination of current 
ecoxtoxicity approaches (in that a standardised test yielding reproducible results 
needs to be created to generate enough data to inform the risk assessment), and 
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other methods which are more tailored to investigating bacteria in detail. It has 
been suggested an assay should be developed to measure MSCs, which can be 
used in risk assessment to determine a threshold level for development of 
antibiotic resistance (Ashbolt et al., 2013). This must first be approached with an 
‘experimental evolution’ method, which allows monitoring of evolution under 
highly controlled, easily manipulated laboratory conditions in order to separate 
cause and effect (Jansen et al., 2014), before being applied to more 
environmentally relevant conditions. Development of such an assay is the 
primary focus of this PhD. 
 
1.10. New microbiological methods to inform risk assessment 
In order to design an assay for the risk assessment of antibiotics for selection for 
resistance, low cost, high throughput, transferable methods are required that can 
generate reproducible results across different laboratories. 
 Methods can be culture dependent or culture independent. The former 
requires growth of bacteria in laboratory media which can present significant bias 
when investigating antibiotic resistant bacteria from natural populations (Garcia-
Armisen et al., 2013). Additionally, culture based methods generally cannot be 
used as a substitute for environmental microcosms, where nutrient levels and 
physiological conditions are very different. However, laboratory-based culture 
dependent methods are necessary to unravel the complex processes occurring 
(Jansen et al., 2014), in natural communities. 
Culture independent methods are free from culture bias, but often require 
a priori knowledge of targets. For example, conventional molecular methods such 
as polymerase chain reaction (PCR) and qPCR require knowledge of previously 
characterised and sequenced resistance genes. Yin et al. (2013) investigated the 
resistance profile of Lake Taihu in China and found a high prevalence of ampicillin 
(β-lactam) resistance through standard culturing methods. However, only 8 of the 
total 28 resistant isolates yielded positive results for PCR amplifying blaTEM and 
blaSHV (both coding for β-lactamases), meaning the majority of resistance genes 
or mutations were not identified in this study.  
There are ways to circumvent this issue, for example if integrons are 
targeted. Primers designed for different integron classes based on differences in 
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the intI1 gene (Hall, 2012) can allow tracking of resistance gene movement and 
allow sequencing of potentially novel genes, with no prior knowledge required of 
the resistance genes’ sequence present in the gene cassette(s) (Rizzo et al., 
2013). However, these methods are currently laborious and do not yield long 
enough products to study large arrays. Integrons have been suggested as a 
potential indicator of human impact on the mobilome (Ashbolt et al., 2013, Gillings 
et al., 2015) and as markers for antibiotic resistance (Amos et al., 2015). In 
general, MGE’s isolated from HGT hot-spots can be argued as better targets then 
antibiotic resistance genes for this reason (Lupo et al., 2012). HGT hot-spots, for 
example in sewage sludge, can have continuously increasing rates of HGT when 
exposed to antibiotic concentrations from the ng/L level to lethal concentrations 
(Kim et al., 2014a). 
QPCR can be used to track abundance or expression levels of 16S rRNA 
genes to indicate the number of bacteria present in the sample. This can then be 
used to calculate percentage of resistant bacteria, through comparing its relative 
abundance or expression with that of the 16S rRNA genes, as well as information 
on bacterial species diversity. 16S rRNA gene sequences differ between species, 
but broad-range primers can still target the gene for amplification (Grice and 
Segre, 2012). However, when comparing relative gene abundance, it is 
necessary to consider that some bacterial isolates carry more than one copy of 
the 16S rRNA gene (Lachmayr et al., 2009). Similarly, when performing qPCR or 
PCR, it should be considered that some bacteria can harbour more than one copy 
of the same resistance gene, which would increase the expression or number 
observed respectively (Volkmann et al., 2004). DNA quality is crucial for PCR 
reactions (Rizzo et al., 2013), and it is likely when amplifying directly from 
environmental samples (to take into account unculturable bacteria), the reaction 
will be inhibited by environmental contaminants which could affect PCR 
efficiency. However, this can be mitigated by generating environmental DNA 
dilution standards (Lachmayr et al., 2009, Marti et al., 2013), or through addition 
of extra reagents such as bovine serum albumin (BSA), to bind inhibitors. 
There has recently been an increase in next generation sequencing 
methods (e.g. Illumina HiSeq, PacBio, Oxford Nanopore) facilitating more 
metagenome wide sequencing efforts. Metagenomic analyses has been used 
successfully to elucidate the resistance profile of bacterial communities (Yang et 
al., 2016), but the process is relatively new and still has some limitations. Large 
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amounts of data are produced which exceed standard computational storage and 
power to analyse; and gene identification depends upon the presence of similar 
genes already annotated in the database, necessitating careful and time-
consuming analysis of the sequences and vigilant database curation. 
Unfortunately, the quality appraisal of these is not always sufficient. 
Functional metagenomics is a bridge between ‘classical’ culturing 
microbiology methods and the newer sequencing approach, which allows 
phenotypic and molecular characterisation of all bacteria in an environmental 
sample, by cloning all DNA into an expression vector in a culturable organism 
(usually E. coli). This is another method which can overcome culture bias, but still 
allows functional screening which is infinitely more useful than sequencing based 
approaches alone, as gene function can be experimentally determined 
concurrently. 
The best methods to investigate this area would combine all of the above, 
to represent both culturable and unculturable bacteria, to allow investigation for 
novel genes, whilst being able to alter the level of complexity of the assay 
(number of species, nutrient levels and physiological conditions). In terms of an 
ecotoxicological assay - simplicity, reproducibility, accuracy and applicability to a 
wide range of compounds and environments is desirable. 
 
1.11. Thesis overview 
While competition assays focusing on single species are an elegant method to 
determine MSCs, they do have limitations in their ability to predict what occurs in 
natural environments. The use of a natural, bacterial community inoculum would 
provide a more realistic representation of what may occur in the environment.  
It would also be useful from a regulatory perspective to determine if there 
is a relationship between MSC and MIC, and whether this varies with host, 
antibiotic class, or individual antibiotic compounds. If a relationship can be 
elucidated, it will greatly facilitate toxicity testing of antibiotics and subsequently 
risk assessment. Therefore the main body of work in this thesis is based around 
an experimental evolution system, where a natural, complex community is 
exposed to varying concentrations of different antibiotics over several days, and 
compared to single host species competition assays using culture dependent and 
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independent methods. This forms chapter two. A simpler growth based assay 
based on this work that could be used for environmental risk assessment was 
also evaluated, which comprises chapter three.  
 As mentioned previously, class 1 integrons can be used as markers for 
anthropogenic pollution and for antimicrobial resistance in the environment 
(Ashbolt et al., 2013, Gaze et al., 2011, Gillings et al., 2015, Berendonk et al., 
2015). Could rate of recombination of novel gene cassettes containing resistance 
genes into the integron - or shuffling of pre-existing resistance gene cassettes 
closer to the promoter, increasing the strength of their expression – be affected 
by different antibiotic concentrations? This was investigated with a new long 
range PCR method and PacBio sequencing in combination, which forms chapter 
four. 
 To further investigate co-selection by QACs, functional metagenomic 
libraries generated from biocide contaminated environments were screened for 
QAC resistance. These underwent transposon mutagenesis to simultaneously 
allow functional screening and sequencing to identify novel biocide resistance 
genes. The resistant clones were screened on a range of antibiotics to determine 
whether co-selection occurs in biocide-contaminated environments. This study 
forms chapter five. 
 
1.11.1. Co-authored papers 
In addition to the papers resulting from and outlined for each chapter, I was also 
co-author on four other publications during my PhD studies.  
I am co-author on the cross-sectional study assessing the risk of coastal 
water exposure leading to colonisation of surfers and non-surfers by antibiotic 
resistant bacteria (‘The beach bum survey’). For this, I performed several hundred 
PCRs to determine the phylotype of Escherichia coli isolated from bathing water 
samples, to assess potential pathogenicity. 
I will be second author on the paper which will publish the long term 
experimental data for macrolides used in chapter three. I contributed through 
designing the long term experimental assay and the plating experiment which 
confirmed the experimental system did not bias towards Gram negative 
organisms; and advised on all aspects of data collection and data analyses. 
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The final two papers, the first of which I was second author, and the 
second of which I was first author, was on a side project in collaboration with the 
Microbiology Department of the Royal Cornwall Hospital Treliske. The first paper 
confirmed a zoonotic opportunistic pathogen (Staphylococcus pseudintermedius) 
was routinely unidentified using the standard, clinical microbiological testing of 
infections (Lee et al., 2015). For this I performed PCR of two housekeeping 
genes, sequenced these and performed sequence and phylogenetic analyses, 
as well as several standard clinical microbiology phenotypic tests. The second 
paper was based on my observation that one of the strains from a non-local 
patient was highly diverse, and might be a new species. This was confirmed by 
whole genome sequencing, and I named the species Staphylococcus starkensis. 
This is due to the species being isolated from a patient from the North of England, 
and potentially in a previous publication from Norway (though it was not confirmed 
as a new species). ‘Stark’ensis refers to one of the key family of characters in the 
popular book series and TV show Game of Thrones, the ‘Starks’, which rule in 
the North.  
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Chapter two: Selection and co-selection for antibiotic resistance in a 
complex community, at low antibiotic concentrations 
 
2.1. Introduction 
This study comprises two main parts – Minimal Selective Concentration (MSC) 
determination in a natural complex community, and studying indirect selection for 
susceptible bacteria. 
 
2.1.2. MSC determination 
The concept of sub-lethal or sub-inhibitory selection contradicts many long-
standing concepts about resistance. The primary issue is the presumption that 
selective pressure (i.e. the antibiotic concentration) must be sufficient to offset 
the fitness cost of resistance. In the ‘traditional selective window’ (Gullberg et al., 
2011), resistance is perceived as being so costly it is only beneficial in a scenario 
where the antibiotic concentration is sufficiently high, so that all susceptible 
organisms are killed or inhibited. However, this is based on a false assumption 
that resistance is always costly, and that these costs are always substantial. In 
fact, there are several studies which have shown that harbouring resistance 
confers no measurable fitness cost on the host organism (Enne et al., 2005); and 
in some cases resistance genes themselves (Michon et al., 2011) or the plasmids 
they are carried on can actually confer a fitness benefit (Carattoli, 2013). 
Additionally, compensatory mutations can arise which may offset the cost of 
resistance (Andersson and Hughes, 2012).  
Once it is accepted that resistant bacteria are not always at a significant 
disadvantage compared to their susceptible competitors, it is conceivable that 
some resistant bacteria would have a slight fitness advantage compared to these 
competitors, at low selective pressures (i.e. low antibiotic concentrations). 
Therefore, resistance mechanisms that have low or neutral fitness cost could be 
selected for at low as well as high antibiotic concentrations. This may explain the 
presence of some clinically important resistance genes in the environment or the 
human microbiome in the absence of antibiotic selection (e.g. blaCTX-M bearing E. 
coli (Canton and Coque, 2006)).  
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Despite all of these possible mechanisms to mitigate or reduce the cost of 
resistance, it has long been assumed that selection for antibiotic resistance 
occurs only above the MIC of the susceptible bacteria of the population and below 
that of the resistant bacteria in the population ((Gullberg et al., 2011) Figure 3). 
In this ‘Traditional Selective Window’, high antibiotic concentrations are required 
in order for the resistance to be maintained despite its fitness cost. However, 
selection for resistance at sub-inhibitory antibiotic concentrations was 
demonstrated in an elegant study by Gullberg et al. (2011), which used isogenic 
susceptible and resistant, fluorescently tagged mutants that were counted by 
fluorescently-activated cell sorting (FACS). An increase in the numbers of 
resistant bacteria indicated positive selection, and the lowest concentration which 
selected for resistance was termed the MSC. The most concerning possibility 
arising from this finding is that selection could occur along a massive spatial and 
temporal range, from point of use (including antibiotic concentration gradients in 
different compartments in the human (or animal) body (Pena-Miller et al., 2013)), 
all the way through passage through waste water treatment plants (WWTPs) into 
soil and aquatic environments. Gullberg et al. (2014) later determined MSCs for 
resistance genes on a clinically isolated multi-drug resistant plasmid, illustrating 
sub-lethal selection can act on entire genes and mobile genetic elements (MGEs) 
which, in theory, confer a substantial fitness cost. This proof of concept has paved 
the way for several other studies, including the one below, which aims to further 
explore sub-inhibitory selection. 
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Figure 3. Schematic showing the traditional selective (antibiotic concentration 
>MIC of the susceptible strain) and sub-inhibitory selective (antibiotic 
concentration <MIC susceptible strain) windows. The MSC is defined as the 
lowest antibiotic concentration where the growth rate of the susceptible strain is 
reduced, to be the same as the growth rate of the resistant strain. 
 
2.1.3. The environmental aspect 
Environmental concentrations of antibiotics are very low, generally ranging from 
low ng/L to low µg/L (Homem and Santos, 2011). Therefore, it was generally 
accepted that measured environmental concentrations of antibiotics (MECs) 
were too low to be selective, and therefore there was no danger of selection 
occurring in the environment (in situ). Now, it is recognised environmental risk 
assessment of antibiotics is incomplete as it currently does not consider the 
selective potential of the compound. This has led to a call for MSC data (to be 
generated with a similar assay, or novel assays) to determine if MECs could 
indeed be selective (Ashbolt et al., 2013, Brandt et al., 2015). 
However, single species, in vitro assays are not likely to be a good 
representation of the complex interactions occurring in a natural community 
(Berglund, 2015). A more recent paper (Lundstrom et al., 2016) approached sub-
inhibitory selection from an environmental perspective and attempted to improve 
upon the single species evolution experiments by Gullberg et al., by using a 
 
 
 
This image has been removed by the author of this thesis/dissertation 
for copyright reasons 
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natural complex community. Waste water bacterial communities and tetracycline 
were passed over glass slides allowing biofilms in an attempt to determine the 
MSC. Several methods for determining effect concentrations were compared, 
including qPCR, metagenomics, species diversity (through 16S rRNA amplicon 
sequencing) and pollution-induced community tolerance assays (PICT). QPCR 
was assigned as the most sensitive method, showing differences in tetracycline 
resistance gene copy number at concentrations as low as 1 µg/L.  
However, as noted by the authors, this is not an MSC in the strictest sense 
(Lundstrom et al., 2016) as the biofilms were constantly exposed to potentially 
resistant organisms through the continual addition of treated waste water. 
Additionally, as the MSC was based upon qPCR data which simply compared 
prevalence of resistance genes at the end of the experiment without comparing 
this to prevalence in the original inoculum; it is entirely possible the differences 
observed were in fact increased persistence of resistance genes, as opposed to 
actual positive selection of resistance genes. In other words, without using the 
resistance gene prevalence at time zero, it is unknown whether the total 
resistance gene prevalence increased over time with tetracycline exposure 
compared to the no antibiotic control; or if there was a higher resistance gene 
prevalence in exposed samples at the end of the experiment, but these had 
decreased from time zero. To express this as terms of selection coefficients, it is 
possible the increase in prevalence observed by Lundstrom et al. is a result of 
the cost of resistance decreasing (Figure 4, A), but not to the point where 
resistance confers advantage over the susceptible bacteria (Figure 4, B and C).  
 
60 
 
 
Figure 4. Theoretical selection coefficient graph, the black dotted line is the x-axis 
which crosses the y axis at 0 (i.e. a selection coefficient of 0, meaning any trait 
with a selection coefficient of exactly 0 is perfectly neutral in terms of fitness). A 
= The cost of resistance is decreasing, but the resistance determinant is not yet 
conferring a fitness advantage (selection coefficients are still <0, i.e. gene 
prevalence is decreasing over time). B = Where the line of best fit crosses the x 
axis is the MSC – this is also where the first selection coefficient is >0, meaning 
at this point, the resistance determinant is conferring at slight fitness advantage 
at that antibiotic concentration. C = at even higher antibiotic concentrations, the 
resistance determinant is now conferring a significant fitness advantage 
(selection coefficient much >0, i.e. gene prevalence is increasing over time). 
 
Inappropriate statistical methods also increased the significance of their 
findings: a one-tailed T-test was used to determine if there was a significant 
difference between treatment and the no-antibiotic control – however, it is equally 
feasible there could be a decrease in the numbers of resistance genes following 
antibiotic exposure as an increase. It can therefore be argued the first actual MSC 
in a complex community yet remains to be determined. 
 
2.1.4. Indirect selection 
Indirect selection can be defined as selection for a susceptible bacterium at 
antibiotic concentrations exceeding its own MIC, due to presence of an antibiotic 
degrader (e.g. an extended spectrum β-lactamase (ESBL) producing bacterium) 
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which degrades extracellular antibiotic, thereby benefitting all bacteria in that 
population regardless of susceptibility / resistance profile.  
Several recent studies have investigated β-lactamases in terms of indirect 
selection. For example, by noting satellite colonies of susceptible bacteria which 
grow around a β-lactamase producer on antibiotic plates, it was suggested that 
bacteriostatic antibiotics can allow the ‘persistence’ of susceptible cells which can 
grow once the antibiotic is ‘detoxified’ below a certain level (Medaney et al., 
2015). Additionally, in competition assays in liquid culture it was shown β-
lactamase producers protect susceptible bacteria to well above their own MIC, 
reaching an equilibrium fraction irrespective of the starting ration of resistant to 
susceptible bacteria. This fraction is also proportional to the antibiotic 
concentration divided by the cell density (Yurtsev et al., 2013). This phenomenon 
is confined to resistance mechanisms which degrade the antibiotic (Nicoloff and 
Andersson, 2016), and can also occur for resistance mechanisms which act only 
intracellularly (Sorg et al., 2016). 
This has clear implications for antibiotic therapy, where colonisation with 
a β-lactamase producer could render treatment of a susceptible pathogen 
ineffective. What remains unclear from these studies is the extent to which 
producers can ‘protect’ (indirectly select for) susceptible bacteria, and how this 
affects selection for resistance at sub-lethal and clinical levels.   
 
2.2. This study 
The blaCTX-M genes encode ESBLs, which cleave the β-lactam ring of β-lactam 
antibiotics, rendering them inactive (Livermore, 1995). This gene class was 
chosen as the selective marker in this study as ESBL-producing 
Enterobacteriaceae pose a ‘serious’ threat to the clinic according to the Centre 
for Disease Control (CDC, 2013), but they have also been found in several 
environmental compartments including surface waters and soil (Sidrach-Cardona 
et al., 2014, Hartmann et al., 2012). Most importantly, they have been shown to 
be more prevalent downstream of WWTPs than upstream (Amos et al., 2014a), 
suggesting heavy loads of CTX-M-producing bacteria in influent; and/or selection 
within the WWTP itself. Indeed, though the vast majority of ESBL-producing E. 
coli can be removed by treatment, it has been estimated that 6 billion ESBL-
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producing E. coli can be released into downstream rivers daily (Brechet et al., 
2014). 
Cefotaxime was chosen as the selective agent, as it is a World Health 
Organisation (WHO) designated ‘essential’ human medicine (WHO, 2011, WHO, 
2015). As a third generation cephalosporin β-lactam, cefotaxime’s mode of action 
is to prevent peptidoglycan cross-linkage by interacting with penicillin binding 
proteins (PBPs), thereby preventing cell wall synthesis; and at higher 
concentrations, causing bacterial cell lysis (Reygaert, 2011).  MECs of cefotaxime 
range from 0.001 µg/L in surface water (UmweltBundesamt, 2016), to 1.1 µg/L in 
WWTP influent (Gulkowska et al., 2008), and up to a maximum of 150 µg/L in 
hospital effluent (Gomez et al., 2007). The lowest, estimated predicted no effect 
concentration for resistance (PNECR) for cefotaxime is 0.125 µg/L (Bengtsson-
Palme and Larsson, 2016), indicating all of these environments are likely to 
experience in situ selection. However, experimentally defined lowest observed 
effect concentrations (LOECs) have yet to be determined. 
In this study, a natural, complex bacterial community (untreated waste 
water) was exposed to a range of cefotaxime concentrations. The untreated 
waste water was selected to be representative of both the human gut, hospital 
effluent and WWTP influent; all of which will face a range of sub-inhibitory 
antibiotic concentrations. Experimental evolution microcosms were passaged 
daily for 8 days and qPCR at the beginning and end of the experiment determined 
prevalence of blaCTX-M genes, and the two most common groups within this class 
(blaCTX-M-1- and blaCTX-M-9), which are found worldwide (Canton and Coque, 2006).  
Numbers of E. coli and other enterics were enumerated by qPCR to 
identify any potential trends in blaCTX-M host abundance. Phenotypic clinical 
resistance to cefotaxime was also quantified to see if this correlated with blaCTX-
M prevalence, and chemical quantification was performed at selected time points 
to evaluate the stability of cefotaxime during the experiment and in the presence 
and absence of the bacterial community, and to highlight any disparity between 
expected (nominal) assay antibiotic concentration, and actual measured 
antibiotic concentration. Metagenomic analyses were performed on communities 
evolved at selected concentrations at the end of the experiment. qPCR has been 
shown as the most sensitive method for determining MSCs previously 
(Lundstrom et al., 2016), but metagenomics was also performed to primarily 
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determine if any other resistance genes were being co-selected; and to quantify 
other gene classes which also confer 3GC resistance.  
Alongside the complex community experiment, a single species 
competition experiment between laboratory strain J53 and the multi-resistant, 
non-conjugative plasmid pEK499 containing variant (NCTC 13451 strain, 
publically available from Public Health England) was conducted to elucidate if 
single species assays could be useful for extrapolating to complex community 
scenarios.  
Based on the data generated by the single species experiment, a final 
experiment was conducted that investigated indirect selection, in terms of the 
protective effect of excreted ESBLs. Briefly, the susceptible J53 strain was grown 
with different volumes of supernatant from an overnight culture of the ESBL 
producer NCTC 13451, at several cefotaxime concentrations. This 
simultaneously determined the minimum amount of excreted ESBL required for 
indirect selection; and the maximum antibiotic concentration at which indirect 
selection was observed. 
 
2.2.1. Primary aims of this study 
 Determine if a group of clinically relevant antibiotic resistance genes 
(blaCTX-M) can be selected for at low concentrations of a clinically important 
antibiotic in a complex community. 
 Test whether community and single species MSCs are comparable. 
 Determine if cefotaxime can co-select for resistance at low concentrations. 
 
2.2.2. Secondary aims of this study 
 Assess the importance of chemical quantification during MSC 
determination. 
 
2.3. Author contribution 
I designed the final experimental evolution protocol for the complex community 
and single species experiments. I designed the ESBL supernatant experiment. I 
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performed all the experiments, and collected and analysed all data. Chemical 
extraction protocols were designed by Dr Maciek Trzndael and Dr Malcolm 
Hetheridge (University of Exeter), and LC-MS analyses and data collection were 
performed by Dr Maciek Trznadel. I analysed the chemical data. Metagenomics 
analysis in the ARGS-OAP pipeline was performed by Xiaole Yin in the research 
group of Dr Tong Zhang of the University of Hong Kong, I performed all 
subsequent data analysis. 
 
2.4. Materials and Methods 
2.4.1. Sample collection, storage and preparation 
Sewage influent from Falmouth, Cornwall (UK), was collected on the morning of 
27th October 2015. This WWTP serves a population size of around 43,000 and 
treats primarily domestic sewage but also a small outpatient hospital. Single use 
aliquots were mixed in a 1:1 ratio with 20 % glycerol, vortexed and stored at -80 
°C until use. Before use, samples were spun down at full speed for 10 minutes, 
the supernatant removed, and the pellet resuspended in equal volume of 0.85 % 
NaCl twice to prevent nutrient/chemical carry over. 
 
2.4.2. Strains 
NCTC 13451 (the E. coli lab strain J53 plus plasmid pEK499) was ordered from 
Public Health England and cultured according to instructions, with 4 mg/L 
cefotaxime as the selective agent. J53 for the non-resistant control was grown 
under the same conditions, but without cefotaxime.  
 
2.4.3. Minimum Inhibitory Concentration (MIC) determination 
The MIC of cefotaxime for J53 and NCTC 13451 was determined in a broth 
microdilution assay. Overnight cultures of each strain were diluted to an optical 
density (OD, 600 nm) of 0.01 in Iso-sensitest (Sigma) broth with cefotaxime at 
different concentrations in a 96 well plate. There were 4 replicates for each 
treatment for each antibiotic, with an antibiotic free control, and a blank broth 
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assay control. The plate was incubated in a Varisokan Flash plate reader for 24 
hours, at 37 °C, with background shaking at 160 rpm at 3 mm. The MIC was 
considered as the lowest concentration at which no growth was visible after 24 
hours (Andrews, 2001). 
 
2.4.4. Antibiotics 
Cefotaxime (Molekular) stocks were prepared in autoclaved and filtered, 
deionised water. Single-use aliquots were stored at -80 °C until use to prevent 
degradation by repeated freeze-thawing. 
 
2.4.5. Pilot experiments  
2.4.5.1. Experimental evolution experiment 
Firstly, the appropriate amount of inoculum to use in the week long assay was 
determined. In this initial pilot experiment, a 96 well plate was inoculated with Iso-
sensitest Broth (SigmaAldrich) containing one of the following; no bacteria (sterile 
0.85 % NaCl added as a control), overnight culture of a positive control (blaCTX-M 
bearing E.coli) strain diluted 100x, or waste water diluted 10x or 100x in sterile 
0.85 % NaCl, to a total volume of 200 μl. Antibiotic concentrations were 100,000, 
32,000, 10,000, 2000, 1000, 500, 250, 125, 62.5, 32.25L, 15.62 and 0 μg/L for 
each different inoculum. The plate was incubated in a Varisokan Flash plate 
reader at 37 °C for 24hours, with background shaking at 160 rpm at 3 mm, with 
OD readings at 600 nm every hour. 
Following results from the pilot experiment, the 10x diluted waste water 
inoculum was selected for use in the week long assay and for the cefotaxime 24 
hour degradation experiment (alongside degradation in the absence of bacteria) 
due to the fact it had the most standard growth curve with the least variation (see 
Appendix). 
 
2.4.5.2. Cefotaxime 24 hour degradation 
66 
 
A pilot experiment for the 24 hour degradation experiment was performed, with 
chemical quantification and growth (OD readings) taken at 0, 4, 8, and 24 hours. 
Results indicated more frequent sampling time points were required.  
 
2.4.6. Supernatant experiment 
Two pilot experiments were carried out to optimise conditions of the supernatant 
experiment. In the first, it was verified the supernatant was sterile, and that it could 
confer protection of the susceptible strain to a cefotaxime concentration 
exceeding its own MIC. Briefly, J53 and NCTC 13451 were grown overnight at 
37°C, shaking at 180 rpm in Iso-sensitest broth (supplemented with 2 mg/L 
cefotaxime for NCTC 13451). This concentration was chosen on the basis it was 
greater than the J53 MIC (see 2.5. Results), and that it would be fully degraded 
in an ESBL producing community (as shown from the degradation experiment).  
The supernatant from both overnight cultures was spun down at full speed 
for 2 minutes twice, and then filtered through a 0.22 μM filter. J53 was then 
inoculated at a starting optical density of 0.01 into fresh Iso-sensitest broth and 
antibiotic / supernatant was added as appropriate. A blank control (to check 
general aseptic technique), broth with each supernatant control (to verify the 
supernatant was sterile); and J53 in broth both with and without antibiotic (to 
deduce effects of nutrient dilution) were included in all plates as controls. The 
assay comprised of J53 in broth with 100, 75, 50 and 25 μl of either J53 or NCTC 
13451 supernatant, in both the presence and absence of cefotaxime at a final 
concentration of 1 mg/L. 
The second pilot plate was as above, but 20, 10, 5 and 1 μl of each 
supernatant was added, to determine the lowest volume of supernatant which 
indirectly selected for J53. 
 
2.4.7. Cefotaxime 24 hour degradation experiment 
For this experiment, washed, untreated waste water was diluted 10x in 25ml Iso-
sensitest broth aliquots spiked with cefotaxime concentrations of 0, 15.625, 
31.25, 62.5, 125, 250, 500 or 2000 µg/L. These were incubated at 37 °C, 180 rpm 
shaking in between sampling. Chemical extractions (see below) and destructive 
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sampling for OD readings were performed at time 0, then every 3 hours for 24 
hours. OD measurements were carried out in a spectrophotometer (Jenway) at 
the same time points at 600 nm. Any OD readings with a value greater than 1 
were diluted 10x in Iso-sensitest broth and then remeasured.  
 
2.4.8. Waste water (complex community) microcosm experiment 
Iso-sensitest broth was inoculated with a 10x dilution of washed, untreated waste 
water. This was separated into 30ml aliquots and appropriate amounts of 
cefotaxime stocks were added. This was then separated further into 5ml aliquots 
of 5 replicates for each of the cefotaxime assay concentrations: 2000, 1000, 500, 
250, 125, 62.5, 32.25, 15.625 and 0 μg/L.  
All replicates were immediately sampled for the day 0 sampling time point: 
2 x 1 ml of each was spun down at full speed for 3 minutes, the supernatant 
removed and pellet resuspended in 500 μl 20 % glycerol followed by storage at -
80 °C. All other samples for DNA extraction were taken after incubation overnight 
at 37 °C, 180 rpm shaking, as above but 500 μl was sampled. 
After each incubation, 50 μl of each microcosm was introduced into 5 ml 
fresh media with fresh antibiotic, and samples were taken as above, every day 
for total of 8 days. Remnants of the assay after the eighth day were spun down 
and stored as above. 
A second complex community assay was then conducted, as above, but 
with higher cefotaxime concentrations. The concentrations used were 0, 2, 4, 8, 
16, 32, 64 and 128 mg/L. 
 
2.4.9. Single species microcosm experiment 
Overnight cultures of NCTC 13451 and J53 from a single colony were combined 
into a 1:1 ratio based on OD600 readings. A 1000x dilution of this (as in Gullberg 
et al. (2011)) was added to Iso-sensitest broth, and 1000x dilutions thereafter. 
The same cefotaxime concentrations in two separate experiments as the 
complex community assays were used (see 2.4.8. Waste water (complex 
community) microcosm experiment). These samples were processed as above 
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except samples were only collected at day 0 and day 8, and 1 ml was spun down 
at day 8. 
 
2.4.10. Chemical extraction 
Waste water microcosms were sampled at day 0, after the first 24 hours, at the 
beginning of day 7, and at the end of the experiment (day 8). Antibiotic stocks 
were also analysed at the beginning and the end of the experiment. The single 
species microcosms were only sampled at the beginning of day 8, alongside the 
stocks. 
The extraction procedure was as follows: 400 μl of culture was mixed with 
400 μl HiPerChromosolv Acetonitrile in a 2 ml 96 well plate, and spun at 3500 
rpm for 30 minutes. 100 μl of this supernatant was then mixed with 900 μl of 1:4 
Acetonitrile to HPLC-grade water in a fresh plate, and stored in the fridge. 
Antibiotic stocks were diluted to a final concentration of 100 ng/L in 1:4 
Acetonitrile. Extractions were kept at -20 °C or 4 °C until processing. 
 
2.4.11. Chemical analysis 
Each concentration had a minimum of two chemical replicates from at least two 
of the biological replicates. Stocks were single replicate only. Chemical 
quantification was performed at the University of Exeter Streatham Campus by 
Maciek Trnzadel. 
 
2.4.12. QPCR 
Frozen samples / untreated waste water were thawed and DNA extracted using 
the MBio UltraClean DNA extraction Kit according to instructions; with initial 
spinning time elongated to 3 minutes. DNA was stored at -20 °C. 
GBlock synthetic genes (IDTDNA - Table 1) were used as standards for 
the complex community experiment; these were resuspended in TE buffer 
according to the manufacturer’s instructions and were stored at -80 °C. For the 
single species experiment, 1 ml of overnight culture of NCTC 13451 underwent 
DNA extraction as above, and was used as the standards for both 16S and blaCTX-
M qPCRs for the single species experiment. For 16S, the cfu/ml was multiplied by 
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7 to account for the multiple copies present in E. coli, whereas blaCTX-M copy 
number was left unchanged.  
All DNA standards were 10x serially diluted in TE buffer and stored at -20 
°C before use. Every PCR plate was always run with 5 serial dilutions of 
standards in duplicate (and a duplicate negative control). Provided the efficiency 
for the reaction was between 90 % and 110 %, the average CT’s for the duplicate 
technical replicates for each sample was used to calculate the copy number 
based on a ‘gold standard’ standard dilution series, where the DNA concentration 
had been quantified by QuBit and the copy number per μl quantified immediately 
prior to cycling.  
Standards were first verified using qPCR conditions described below, with 
a melt curve in SYBR assays. Brilliant qPCR SYBR Green reagents (Agilent) 
were used in 20 μl reactions comprising of 10 μl master mix, 2 μl primer pair (10 
μM for 16S, Enterobacteriaceae and E. coli primers, 18 μM for blaCTX-M primers), 
0.2 μl BSA (20 mg/ml), 0.4 μl dye (20 µM), 5 μl diluted DNA template and filtered, 
sterilised water to a total volume of 20 μl. The qPCR programme for all SYBR 
reactions was 95 °C for 3 minutes, followed by 40 cycles of 95 °C for 10 seconds 
and 60 °C for 30 seconds, except blaCTX-M which was 58 °C for 1 minute. Relative 
numbers of blaCTX-M copies were divided by cell number (16S) to determine 
numbers of blaCTX-M per copy number of 16S (a molecular ‘prevalence’). 
To determine relative numbers of blaCTX-M groups 1 and 9, a TaqMan 
assay was performed. 20 μl reactions containing 10 μl Life Technologies TaqMan 
master mix for environmental samples, 2 μl CTX-M consensus primer pair (18 
μM), 0.2 μl BSA (20 mg/ml), 1 μl CTX-M1/9 probe (4 or 2 μM, respectively), 5 μl 
diluted DNA template and filtered, sterilised water to a total volume of 20 μl. 
Primer sequences and original references are shown in Table 1. 
 
Table 1. Sequences and length of the different primers, probes and gBlocks used 
in this study, with original references or the accession number used where 
applicable. 
Name Sequence Siz
e 
(bp
) 
Accession 
number 
Referenc
e 
16S 
gBlock 
ACGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC
GTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGTA
GCTTAACCTTCGGGAGGGCGCTTACCACTTTGTGATT
CATGACTGGGGTGAAGTCGTAACAAGGTAACCG 
144 - This 
study 
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CTX-M 
gBlock 
GATGTGCAGCACCAGTAAAGTGATGGCCGCGGCCGC
GGTGCTGAAGAAAAGTGAAAGCGAACCGAATCTGTTA
AATCAGCGAGTTGAGATCAAAAAATCTGACCTTGTTAA
CTATAATCCGATTGCGGAAAAGCACGTCAATGGGACG
ATGTCACTGGCTGAGCTTAGCGCGGCCGCGCTACAGT
ACAGCGATAACGTGGCGATGAATAAGCTGATTGCTCA
CGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGCCCG
ACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACC
GAGCCGACGTTAAACACCGCCATTCCGGGCGATCCG
CGTGATA 
338 - This 
study 
Group 1 
CTX-M 
gBlock 
ACTGGGTGTGGCATTGATTAACACAGCAGATAATTCG
CAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGTG
CAGCACCAGTAAAGTGATGGCCGTGGCCGCGGTGCT
GAAGAAAAGTGAAAGCGAACCGAATCTGT 
TAAATCAGCGAGTTGAGATCAAAAAATCTGACTTGGTT
AACTATAATCCGATTGCGGAAAAGCACGTCGA 
TGGGACGATGTCACTGGCTGAGCTTAGCGCGGCCGC
GCTACAGTACAGCGATAACGTGGCGATGAATAAG 
CTGATTTCTCACGTTGGCGGCCCGGCTAGCGTCACCG
CGTTCGCCCGACAGCTGGGAGACGAAACGTTCC 
GTCTCGACCGTACCGAGCCGACGTTAAACACCGCCAT
TCCGGGCGATCCGCGTGATACCACTTCACCTCG 
GGCAATGGCGCAAACTCTGCGTAATCTGACGCTGGGT
AAAGCATTGGGTGACAGCCAACGGGCGCAGCTG 
 
490 KJ484641
.1 
This 
study 
Group 9 
CTX-M 
gBlock 
GCTGGGCGTCGCGCTCATCGATACCGCAGATAATACG
CAGGTGCTTTATCGCGGTGATGAACGCTTTCCA 
ATGTGCAGTACCAGTAAAGTTATGGCGGCCGCGGCG
GTGCTTAAGCAGAGTGAAACGCAAAAGCAGCTGC 
TTAATCAGCCTGTCGAGATCAAGCCTGCCGATCTGGT
TAACTACAATCCGATTGCCGAAAAACACGTCAA 
CGGCACAATGACGCTGGCAGAACTGAGCGCGGCCGC
GTTGCAGTACAGCGACAATACCGCCATGAACAAA 
TTGATTGCCCAGCTCGGTGGCCCGGGAGGCGTGACG
GCTTTTGCCCGCGCGATCGGCGATGAGACGTTTC 
GTCTGGATCGCACTGAACCTACGCTGAATACCGCCAT
TCCCGGCGACCCGAGAGACACCACCACGCCGCG 
GGCGATGGCGCAGACGTTGCGTCAGCTTACGCTGGG
TCATGCGCTGGGCGAAACCCAGCGGGCGCAGTTG 
 
490 HF545433
.1 
This 
study 
E. coli 
gBlock 
GCAGTCTTACTTCCATGATTTCTTTAACTATGCCGGGA
TCCATCGCAGCGTAATGCTCTACACCACGCCGAACAC
CTGGGTGGACGATATCACCGTGGTGACGCATGTCGC
GCAAGACTGTAACCACGCGTCTGTTGACTGGCAGGTG
GTGGCCAATGGTGATGTCAGCGTTGAACTGCGTGATG
CGGATCAACAGGTGGTTGCAACTGGACAAGGCACTAG
CGGGACTTTGCAAGTGGTGAATCCGCACCTCTGGCAA
CCGGGTGAAGGTTATCTCTATGAACTGTGCGTCACAG
CCAAAAGCCAGACAGAGTGTGATATCTACCCGCTTCG
CGTCGGCATCCGGTCAGTGGCAGTGAAGGGCGAACA
GTTCCTGATTAACCACAAACCGTTCTACTTTACTGGCT
TTGGTCGTCATGAAGATGCGGACTTGCGTGGCAAAGG
ATTCGATAACGTGCTGATGGTGCACGACCACGCATTA
ATGGACTGGATTGGGGCCAACTCCTACCGTACCTCGC
ATTA 
522 NC_0009
13.3 
This 
study 
Enteric 
23s 
rRNA 
gBlock 
TGCCGTAACTTCGGGAGAAGGCACGCTGATATGTAGG
TGAAGTCCCTCGCGGATGGAGCTGAAATCAGTCGAAG
ATACCAGCTGGCTGCAACTGTTTATTAAAAACACAGCA
CTGTGCAAACACGAAAGTGGCAGTATCAGGTGTGACA
CCTGCCCGGTGCCGGAAGGTTAATTGATGGGGTTAGC
GGTAACGCGAAGCTCTTGATCGAAGCCCCGGTAAACG
GCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATT
CCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTA
ATGATGGCCAGGCTGTCTCCACCCGAGACTCAGTGAA
ATTGAACTGCGTGTGAAGATCGAGTGTACCCGCGGCA
AGACGGAAAGACCCCGTGAACCTTTACTATAGCTTGA
CACTGACACTTGACGATTGA 
428 - This 
study 
16S F 
(1396F) 
CGGTGAATACGTTCYCGG 142 - (Suzuki et 
al., 2000) 
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16S R 
(1492R) 
GGWTACCTTGTTACGACT 142 - 
CTX-M 
consens
us F 
ATG TGC AGY ACC AGT AAR GTK ATG GC ~30
0 
-  
 
(Birkett et 
al., 2007) CTX-M 
consens
us R 
ATC ACK CGG RTC GCC XGG RAT ~30
0 
- 
Group 1 
probe 
MGB-CCCGACAGCTGGGAGACGAAACGT-FAM ~30
0 
- 
Group 9 
probe 
MGB-CTGGATCGCACTGAACCTACGCTGA-VIC ~30
0 
- 
E.coli F 
(YccTR-
F) 
GCATCGTGACCACCTTGA 522 - (Clifford 
et al., 
2012) 
E.coli R 
(YccTRT
-R) 
CAGCGTGGTGGCAAAA  522 - 
Enteric 
F (En-
ISu3F) 
TGCCGTAACTTCGGGAGAAGGCA 428 - (Matsuda 
et al., 
2007) 
Enteric 
R (En-
Isu3’R) 
TCAAGGCTCAATGTTCAGTGTC 428  
 
2.4.13. Minimal Selective Concentration (MSC) determination 
The LOECs were determined statistically (see 2.4.16. Statistics), and MSCs by 
using selection coefficients, as previously (Gullberg et al., 2014, Gullberg et al., 
2011). Selection coefficients were determined with the following equation: 
“[ln(R(t)/R(0))]/[t]”; where R = the ratio of resistant to susceptible (i.e. resistance 
gene prevalence) at the beginning (‘R(0)’) or end (‘R(t)’) of the experiment and t 
= time (i.e. length of the assay, in days).  All 5 selection coefficients representing 
each biological replicate for each antibiotic concentration were averaged. These 
were then plotted against antibiotic concentration (a maximum of 6 antibiotic 
concentrations, as used previously (Gullberg et al., 2014, Gullberg et al., 2011)) 
with a line of best fit. Where this line crosses the x-axis is the MSC. 
 
2.4.14. Plating for phenotypic resistance 
The complex community assay was also plated at the beginning and end of both 
high and low concentration experiments on Chromocult Enhanced Selectivity 
agar (Merck), with and without cefotaxime at the clinical breakpoint concentration 
for Enterobacteriaceae ((EUCAST, 2014), equating to 2 mg/L). Equal volumes of 
all biological replicates were combined and diluted in 0.85 % saline solution. 
Plating was performed in duplicate or triplicate for each tenfold dilution (for the 
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low and high concentration assays, respectively). Higher replication was possible 
for the higher concentration experiment as there was a smaller concentration 
range. This enabled enumeration of average total numbers of resistant 
presumptive E. coli, other enterics, and other Gram negatives based on colour. 
The percentage of each group of bacteria that was resistant was also determined 
for day 0 and day 8 of the higher concentration experiment, and at day 0 only for 
the lower concentration experiment (plates without cefotaxime were 
contaminated at day 8).  
 
2.4.15. Metagenome analyses 
Three replicates were chosen at random from the no antibiotic, 125, 500 and 
2000 µg/L treatment at day 8 to undergo sequencing on the MiSeq2 v2 platform 
at University of Exeter Sequencing Service (ESS). These concentrations were 
selected based on the qPCR results (see 2.5.2. Results) and corresponded to the 
LOEC, blaCTX-M prevalence peak, and clinical breakpoint concentrations. 
DNA was extracted from 1 ml of frozen overnight culture using the MoBio 
extraction kit according to manufacturer’s instructions. DNA was cleaned and 
concentrated using Ampure™ beads. Firstly, 2 µl of 20 mg/ml RNAse A (Qiagen) 
was added to 50 µl DNA and incubated for 10 minutes at 37 °C. 50 µl of Ampure™ 
beads were mixed with the DNA / RNAse solution gently by pipetting, then 
incubated at room temperature for 5 – 10 minutes. Following pulse centrifugation 
to collect droplets, tubes were placed on a magnetic stand and left until all beads 
had precipitated to the side of the tube. Supernatant was removed and beads 
were washed two times with 300 µl freshly prepared 80 % ethanol. Beads were 
air dried briefly (1 – 2 minutes), resupsended in 10 µl 10 mM Tris-HCL and then 
incubated for another 10 minutes at 50 °C. Following pulse centrifugation and 
bead precipitation, DNA was transferred into a fresh tube and stored at -20 °C 
until library preparation and sequencing.  
The 12 Nextera Library preparations, quality control, sequencing and 
primary sequencing analysis (including trimming reads of the barcodes) was 
performed by ESS. Data was then run through the “online analysis pipeline for 
antibiotic resistance genes detection from metagenomic data using an integrated 
structured antibiotic resistance gene database”, namely the  ARGs-OAP (Yang 
et al., 2016) pipeline by Xiaole Yin in the research group of Dr Tong Zhang. This 
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provides the abundance of different resistance gene classes and subtypes within 
these groups normalised by parts per million, 16S copy number, and per cell. For 
all subsequent analysis, data normalised by 16S copy number was used to allow 
comparison with qPCR data. The negative control sequencing sample had no hits 
for any resistance genes. 
Heat maps were generated in using python packages matplotlib, pandas 
and seaborn (Hunter, 2007, McKinney, 2010, Waskom, 2016) for resistance gene 
class and β-lactam resistance gene subtype.  
 
2.4.16. Statistics 
All statistics were performed in RStudio (2015). A Kruskal Wallis was used to 
compare: total 16S, blaCTX-M gene copy number and blaCTX-M gene prevalence at 
day 0 (to verify replicates were not significantly different at day 0), and at day 8. 
For determining LOECs, Dunn’s test was used to determine if there was a 
significant difference between treatment (with cefotaxime) and the no antibiotic 
control. 
Spearman’s rank was performed to determine if there was a significant, 
monotonic relationship between antibiotic concentration and average blaCTX-M 
prevalence for both the complex community and single species experiments. This 
was for all concentrations across both experiments, using the no antibiotic control 
and the 2 mg/L treatment from the lower concentration experiment. 
 
2.5. Results 
2.5.1. BlaCTX-M genes are selected for at low cefotaxime concentrations in a 
complex community 
These results relate to the primary hypothesis that clinically important resistance 
genes are selected for in a complex community at low antibiotic concentrations. 
This was investigated with qPCR by tracking resistance gene prevalence (total 
blaCTX-M, blaCTX-M group 1, blaCTX-M group 9 and 16S rRNA copy numbers) over 
time at different cefotaxime concentrations, to determine MSCs (Minimal 
Selective Concentrations, with the selection coefficient method) and LOECs 
(Lowest Observed Effect Concentrations, using a statistical approach).  
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There was no significant statistical difference in blaCTX-M prevalence 
between any of the treatments at day 0 (p > 0.05, Kruskal Wallis, Figure 5). 
However, at day 8 there was a significant statistical difference in blaCTX-M 
prevalence at concentration 125 µg/L, and all the treatments above compared to 
the no antibiotic control (p < 0.05, Dunn’s Test). This is termed the LOEC. 
However, the increase in blaCTX-M prevalence was not monotonic (i.e. there was 
no dose response relationship between prevalence and cefotaxime 
concentration, Spearman’s rank, rs = 0.48, p > 0.05).  
 
 
 
Figure 5. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M gene 
prevalence at the beginning and end of the lower cefotaxime concentration 
complex community experiment, shown with standard error bars. Prevalence 
calculated by dividing blaCTX-M gene copy number by 16S copy number for each 
biological replicate. There is a significant increase in blaCTX-M gene prevalence 
from 125 µg/L, and all treatments above (p < 0.05, Dunn’s test ‘*’). 
 
The selection coefficient method for MSC determination was also used (Figure 
6), as previously (Gullberg et al., 2014, Gullberg et al., 2011). The MSC was 
calculated as 0.4 µg/L.  
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Figure 6. Average (biological replicate n=5, qPCR replicate n=2) selection 
coefficients based on the qPCR blaCTX-M prevalence data at day 0 and day 8, 
shown with standard error bars and polynomial (order 2) line of best fit. The MSC 
is where the line crosses the x-axis - at 0.4 µg/L. 
 
There was no statistical difference between any of the treatments at day 0 
or day 8 for 16S copy number (p > 0.05, ANOVA and Kruskal Wallis, 
respectively), allowing for analysis of the blaCTX-M gene copy number (which 
would not be biased by changes in overall community numbers). The data is 
presented in Figure 7 but the statistical difference still emerged at the 125 µg/L 
treatment.  
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Figure 7. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M gene 
copy number at day 0 and day 8 in the lower cefotaxime concentration complex 
community experiment. The 125 µg/L treatment and all treatments above were 
significantly different to the no antibiotic control (p < 0.05, Dunn’s test ‘*’). 
 
The blaCTX-M group specific TaqMan assay (Figure 8) showed that group 1 
blaCTX-M genes were always more prevalent than group 9, even in the no antibiotic 
control; however, there was a more pronounced increase in group 9 blaCTX-M 
genes when exposed to cefotaxime (though this was still not a significant 
difference). Again, a significant difference to the no antibiotic control was 
observed at 125 µg/L and all the concentrations above for both blaCTX-M group 1 
and group 9. There was no significant difference observed between treatments 
for group 1 and group 9 blaCTX-M genes at the beginning of the experiment 
(Kruskal Wallis tests, p > 0.05, data not shown). 
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Figure 8. Average (biological replicate n=5, qPCR replicate n=2) copy number for 
group 1 and group 9 blaCTX-M genes following 8 days cefotaxime exposure. Shown 
with standard error bars, on a logged y axis. The 125 µg/L treatment and all 
treatments above were significantly different to the no antibiotic control (p < 0.05, 
Dunn’s test ‘*’). 
 
Additional qPCR data was also generated for the day 1 and day 4 time 
points, to evaluate the change in blaCTX-M prevalence over time (Figure 9). For all 
concentrations except 1000 and 2000 µg/L, average blaCTX-M prevalence 
increased steadily overtime. The LOEC was determined as 125 µg/L at day 1, 
and at 250 µg/L at day 4 (Dunn’s test, p < 0.05).  
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Figure 9. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M 
prevalence at day 0, 1, 4 and 8 of the lower cefotaxime concentration complex 
community experiment. 
 
2.5.2. The increase in blaCTX-M genes is not due to an enrichment for 
Enterobacteriaceae 
An E. coli and enteric specific qPCR was used to determine if their respective 
percentages in the community changed following cefotaxime exposure. Results 
showed that there was no significant difference in the numbers of E. coli or total 
enterics across the treatments, indicating blaCTX-M genes are not confined only to 
these bacterial groups (Figure 10). 
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Figure 10. Average (biological replicate n=5, qPCR replicate n=2) numbers of E. 
coli and enterics in the complex community following 8 days cefotaxime 
exposure, using SYBR green qPCR. Shown with standard error bars. 
 
2.5.3. BlaCTX-M prevalence does not reach 1 even at extremely high 
cefotaxime concentrations 
Following the plateau observed in blaCTX-M prevalence at 500 µg/L and above, an 
additional experiment was performed at higher cefotaxime concentrations (Figure 
11). The blaCTX-M gene prevalence for all cefotaxime treatments were significantly 
different at day 8 compared to the no antibiotic control (p < 0.05, Dunn’s test). 
The highest average blaCTX-M prevalence of 0.79 was at 64 mg/L; then blaCTX-M 
prevalence decreased at the highest assay concentration of 128 mg/L. The 
prevalence data for time 0 and at day 8 for the no antibiotic control and the 2 mg/L 
treatment were highly comparable with the prevalence data obtained for these 
treatments in the lower cefotaxime concentration experiment. Both data sets 
were combined to test for monotonic increase in blaCTX-M gene prevalence with 
antibiotic concentration, which was not the case (rs = 0.48, p > 0.05). 
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Figure 11. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M gene 
prevalence in the complex community before and after exposure to the higher 
cefotaxime concentrations. Shown with standard error bars. BlaCTX-M gene 
prevalence calculated by dividing the blaCTX-M gene copy number by 16S copy 
number for each biological replicate.  
 
The blaCTX-M gene group numbers varied at the end of the experiment 
following exposure to higher cefotaxime concentrations (Figure 12). Group 9 
blaCTX-M genes were more prevalent at 2, 4 and 16 mg/L, but were absent (or 
below detection limit) at 32, 64 and 128 mg/L.  
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Figure 12. Average (biological replicate n=5, qPCR replicate n=2) blaCTX-M gene 
copy number for group 1 and group 9 blaCTX-M genes. Shown with standard error 
bars. 
 
2.5.4. Phenotypic clinical resistance in Enterobacteriaceae agrees with 
LOEC 
As in a previous study (Lundstrom et al., 2016), phenotypic and qPCR selective 
endpoints were compared. Figure 13 shows the average (n=2) numbers of 
resistant (MIC > 2 mg/L) E. coli, enterics and other Gram negatives in the original 
sewage inoculum (‘Sewage’) and following 8 days cefotaxime exposure in the 
low concentration experiment. The cfu/ml of resistant E. coli plus enterics remains 
high for all cefotaxime concentrations, but increases significantly at 125 µg/L (p 
< 0.05, Dunn’s test) and at 1000 µg/L, with a trend for significance (p = 0.09) at 
2000 µg/L. Interim concentrations are not significantly different to the no antibiotic 
control. Numbers of resistant enterics are absent in the no antibiotic treatment, 
which is not observed in the higher concentration experiment (Figure 14). 
Numbers of resistant other Gram negatives decrease drastically compared to the 
numbers in the original inoculum, again not observed in the higher concentration 
experiment (Figure 15). 
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Figure 13. The average (biological replicate n=5 combined, plating replicate n=2) 
colony forming units (cfu) per ml of presumptive E. coli, other enterics and other 
Gram negatives quantified on Chromocult Coliform Enhanced Selectivity agar 
supplemented with the clinical breakpoint concentration of cefotaxime (2000 
µg/L, (EUCAST, 2014)), at the end of the lower cefotaxime concentration, 
complex community experiment. Shown with standard error bars. 
 
In the higher cefotaxime concentration experiment, again, the total 
numbers of resistant Enterobacteriaceae for all cefotaxime concentrations were 
significantly different to the no antibiotic control as with the genotypic data (p < 
0.05, Dunn’s test) at day 8 (Figure 14). However, average (plating replicates n=3) 
numbers of resistant Gram negatives and enterics remained constant throughout, 
until resistant enterics disappeared at 32 mg/L and all concentrations above. In 
terms of percentage of clinical resistance (Figure 15), all enterics present at 2 
mg/L and above were resistant (MIC >2 mg/L). At 64 and 128 mg/L, 100 % of E. 
coli and other Gram negatives were resistant. The increase in percentage of 
resistance for all three types of coliforms was dramatic, with the no antibiotic 
control having less than 5 % of each group resistant, and the lowest percent 
resistance for cefotaxime exposure treatments being for E. coli at 8 mg/L, at 40 
%.  
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Figure 14. Average (biological replicate n=5 combined, plating replicate n=3) 
colony forming units (cfu) per ml of presumptive E. coli, other enterics and other 
Gram negatives quantified on Chromocult Coliform Enhanced Selectivity agar 
supplemented with the clinical breakpoint concentration of cefotaxime (2 mg/L, 
(EUCAST, 2014)), at the end of the higher cefotaxime concentration, complex 
community experiment. Shown with standard error bars. 
 
 
Figure 15. Percentage of coliforms at the end of the higher cefotaxime 
concentration, complex community experiment that were resistant (MIC > 2 mg/L) 
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to cefotaxime. Percentage calculated by taking the average numbers of resistant 
bacteria (Figure 14) and dividing by the average total coliform count, multiplied 
by 100. 
 
2.5.5. Co-selection for different gene classes occurred 
To assess the co-selective potential of cefotaxime, metagenome analyses using 
the ARGS-OAP pipeline was performed on three randomly selected replicates 
from day 8 from the no antibiotic control, LOEC, blaCTX-M prevalence peak and 
clinical breakpoint concentrations. These analyses showed several resistance 
gene classes were enriched alongside the β-lactam resistance gene class (Figure 
16), namely genes conferring aminoglycoside, sulphonamide, trimethroprim, 
tetracycline, macrolide and (to a lesser extent) vancomycin resistance. 
Concurrently, some resistance gene class abundances decreased, such as those 
for chloramphenicol, fosfomycin and fosmidomycin. Intriguingly, quinolone 
resistance was enriched at 500 µg/L but then lost again at 2000 µg/L. Resistance 
genes for carbomycin, fusaric-acid, fusidic-acid, promycin, rifamycin, 
spectinomycin and tetracenomycin-C were undetected at all antibiotic 
concentrations. 
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Figure 16. Average (biological replicate n=3) resistance gene class abundance, 
normalised by 16S copy number. 
 
 The sum of different resistance gene subtypes within the β-lactam 
resistance gene class were also analysed (Figure 17). Almost all major β-
lactamases were enriched by cefotaxime exposure, including blaCTX-M, blaOXA, 
blaTEM, and other Class A and Class C β-lactamases. The blaCTX-M gene class 
was enriched the most, with an increase in abundance of over 70 times in the 
2000 µg/L treatment compared to the no antibiotic control, meanwhile the next 
highest increase in abundance was for blaOXA and blaTEM, which both increased 
by over 8 times. 
Class B β-lactamases were present in the no antibiotic control at a very 
low abundance, but were undetectable in the cefotaxime treatments. BlaSHV β-
lactamases were present in the 0 and 125 µg/L treatments at relatively low 
abundance, but were absent at higher cefotaxime concentrations. Other Class D 
β-lactamases and metallo-β-lactamases were undetected in all of the treatments, 
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including the no antibiotic control. There was no noticeable increase, and most 
frequently there was a decrease, in the abundance of other resistance gene 
subtypes such as PBPs (penicillin binding proteins). A variety of other β-
lactamases were detected at varying abundances (Figure 17).  
 
Figure 17. Average (biological replicate n=3) β-lactam resistance gene subtype 
abundance, normalised by 16S copy number. Only detected resistance gene 
subtypes are shown. Resistance gene key for encoded enzymes: ACT = AmpC 
type β-lactamase, CAZ = ceftazidimase, CFE-1 = AmpC type β-lactamase, CGB-
1 = Ambler Class B β-lactamase, CMY = Ambler Class C β-lactamase, CTX-M = 
ESBL, CfxA = Divergent Ambler Class A β-lactamase, DHA = AmpC type β-
lactamase, FOX = AmpC type β-lactamase, KLUY = chromosomally-encoded β-
lactamase, LEN = chromosomally-encoded β-lactamase, MIR = AmpC type β-
lactamase, MOX = AmpC type β-lactamase, OXA = Ambler Class D β-lactamase, 
PBP = penicillin binding protein, PDC = AmpC type β-lactamase, SHV = Ambler 
Class A β-lactamase or ESBL, TEM = Ambler Class A β-lactamase or ESBL, 
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Toho-1 = Ambler Class A mutant β-lactamase, AmpC = Ambler Class C β-
lactamase, blaZ = Staphylococcus aureus β-lactamase, CcrA = Ambler Class B 
metallo-β-lactamase, FmtC = membrane-associated protein, MecA = penicillin 
binding protein, PenA = Ambler Class A secreted β-lactamase.  
 
 
Figure 18. The change in average major β-lactamase gene abundance 
(normalised by 16S copy number) for each of the cefotaxime (‘TAX’) 
concentrations, in µg/L. On average, blaTEM genes were most prevalent in the 
2000 µg/L treatment, though the increase from 0 to 2000 µg/L was largest for the 
blaCTX-M genes. 
 
On average, blaTEM genes were most prevalent in the 2000 µg/L treatment, 
though the increase from 0 to 2000 µg/L was largest for the blaCTX-M genes (Figure 
18). The blaCTX-M prevalence determined by metagenomics was an order of 
magnitude lower than that determined by qPCR. BlaSHV genes were the only β-
lactamase genes detected which decreased in relative abundance with 
increasing antibiotic concentration. Both blaCTX-M and blaTEM gene abundances 
significantly increased with cefotaxime exposure at 500 µg/L. 
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2.5.6. Single species assays are not representative of complex 
communities 
To assess the utility of single species assays for determining MSCs in complex 
communities, a single species competition experiment was performed in the 
same experimental system. The MIC of J53 was > 0.25 mg/L and < 0.5 mg/L, 
and for strain NCTC 13451 it was > 256 mg/L and < 512 mg/L. The single species 
assay using susceptible J53 and J53 bearing the multidrug resistance plasmid 
pEK499 was performed in two separate low and high cefotaxime concentration 
experiments. There were no significant differences between any of the treatments 
for either experiment at day 0 for 16S gene copy number, blaCTX-M gene copy 
number or blaCTX-M gene prevalence.  
There were no significant differences in blaCTX-M prevalence between 
treatments at the beginning or the end of the experiment (Figure 19). The overall 
prevalence was much lower than in the complex community experiment, with a 
peak of 0.05 compared to a peak of 0.4. 
 
 
 
Figure 19. Average (biological replicate n=3, qPCR replicate n=2) blaCTX-M gene 
prevalence at the beginning and end of the lower cefotaxime concentration single 
species experiment, shown with standard error bars. Prevalence calculated by 
dividing blaCTX-M gene copy by 16S copy number. There are no significant 
differences between treatments. 
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 The higher cefotaxime concentration experiment (Figure 20) showed a 
dose-dependent increase (Spearman’s rank, rs = 0.57, p = 0.02) in blaCTX-M gene 
prevalence from 8 mg/L to 64 mg/L, which peaks at a prevalence of 0.18. The 
prevalence at all these concentrations were also significantly different to the no 
antibiotic control (p <0.05, Dunn’s test). The prevalence decreased at 128 mg/L. 
This decrease was due to a decrease in blaCTX-M gene copy number (Figure 21), 
not in 16S copy number (which remained constant, with no significant difference 
between treatments at day 8, Kruskal Wallis).  
 There was no selection coefficient MSC determined for the J53 
competition experiment as all selection coefficients were >0, meaning the line of 
best fit never crossed the x axis (Figure 22). Therefore the blaCTX-M gene 
(resistance plasmid) was under positive selection even in the absence of a 
selective pressure (cefotaxime exposure).  
 
 
 
Figure 20. Average (biological replicate n=3, qPCR replicate n=2) blaCTX-M gene 
prevalence at the beginning and end of the higher cefotaxime concentration 
single species experiment, shown with standard error bars. Prevalence 
calculated by dividing blaCTX-M gene copy by 16S copy number. There were 
significant differences between 8 mg/L and all concentrations above compared 
to the not antibiotic control (p < 0.05, Dunn’s test). 
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Figure 21. Average (biological replicate n=3, qPCR replicate n=2) blaCTX-M gene 
copy number at day 0 and day 8 in the higher cefotaxime concentration single 
species experiment. The 8 mg/L treatment and all treatments above were 
significantly different to the no antibiotic control (p < 0.05, Dunn’s test). 
 
 
Figure 22. Average (biological replicate n=5, qPCR replicate n=2) selection 
coefficients based on day 0 and day 8 blaCTX-M prevalence data in the low and 
high cefotaxime concentration single species selection experiment, using both 
data points for the no antibiotic control and 2 mg/L treatments. All selection 
coefficients are positive, so no MSC was determined.  
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2.5.7. Cefotaxime is readily degraded, mostly via biodegradation 
To assess the need for chemical quantification to determine accurate MSCs, 
stability of cefotaxime during the complex community was assessed. Table 2 
shows the nominal (expected) cefotaxime assay concentrations and the 
measured concentration at the beginning of the day and after 24 hours (i.e., upon 
transfer into fresh medium and antibiotic). Measured assay concentrations were 
consistently lower than expected, with the lowest assay concentration of 15.625 
µg/L being below the detection limit. After 24 hours, almost all the cefotaxime was 
degraded for nearly all the assay concentrations, even the very highest. 
 
Table 2. The expected (nominal) cefotaxime concentration, actual measured 
cefotaxime concentration immediately sampled and following 24 hours incubation 
in the complex community assay. Averages of 2 biological replicates (chosen at 
random) and 2 chemical replicates. The two cefotaxime stock concentrations 
were also quantified. 
Nominal Concentration 
(µg/L) 
Measured concentration (µg/L) Measured concentration 
after 24hours (µg/L) 
15.625 0 0 
31.25 25.5 0 
62.5 26.75 6 
125 46.25 0 
250 205 0 
500 438 2.6 
1000 830 0 
2000 1686 4 
   
Stock 1 = 1250 1272 - 
Stock 2 = 78.125 51.56 - 
 
This prompted further experiments to analyse the degradative capacity of 
the complex community compared to degradation in the experimental system (i.e. 
lability). Figure 23 shows the degradation of cefotaxime over 24 hours in the 
presence and absence of the complex community. Here, all cefotaxime is 
completely degraded after 24 hours in the presence of the community. Around 40 
% of cefotaxime is degraded abiotically in the absence of the community. 
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Figure 23. Single biological replicate, duplicate chemical replicate of cefotaxime 
degradation over 24 hours, sampling at 0, 4, 8 and 24 hours, in the presence (AB) 
and absence (A) of the complex community. 
 
A final experiment increased the number of sampling points over the 24 
hour period and compared this to growth of the complex community (measured 
by optical density (OD)) – Figure 24 A and B respectively. Degradation for all 
assay concentrations coincided with the exponential growth phase of the complex 
community.  
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Figure 24. Single biological replicate, duplicate chemical replicate chemical 
quantification of cefotaxime (‘Measured cefotaxime concentration µg/L) every 3 
hours for 24 hours at different concentrations (µg/L) in the presence of the 
complex community (A). (B) The growth (optical density measured at 600 nm) 
from the same sampling time points, single replicate only. 
 
 As an aside, aliquots of the sample were frozen down for all concentrations 
at 6, 9 and 12 hours. Cultures were analysed with qPCR to determine blaCTX-M 
gene copy number (Figure 25), 16S copy number (Figure 26), and blaCTX-M 
prevalence (Figure 27). Please note all these experiments are based on single 
biological replicates. Increases in blaCTX-M gene copy number and blaCTX-M gene 
prevalence increase over time, although not concurrently. Meanwhile, 16S gene 
copy number appears to stabilise at 12 hours.  
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Figure 25. BlaCTX-M gene copy number at different time points (6, 9 and 12 hours) 
during the cefotaxime 24 hour degradation experiment. Single biological replicate 
only, qPCR replicate n=2. 
 
 
Figure 26. 16S gene copy number at different time points during the cefotaxime 
24 hour degradation experiment. Single biological replicate only, qPCR replicate 
n=2. 
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Figure 27. BlaCTX-M gene prevalence (blaCTX-M gene copy number/16S copy 
number) at different time points during the cefotaxime 24 hour degradation 
experiment. Single biological replicate only, qPCR replicate n=2. 
 
2.5.8. Relatively small amounts of ESBLs can protect susceptible bacteria 
to very high antibiotic concentrations 
The relatively low blaCTX-M prevalence in the single species assays (compared to 
the complex community assays), and the confirmation that the majority of 
cefotaxime is biodegraded, and that this degradation coincides with exponential 
growth lead to the assumption that biodegradation (performed by extra-cellular 
β-lactamases) benefits the community as a whole (see 2.6. Discussion). A simple 
experiment quantified the amount of supernatant (i.e. β-lactamase) that could 
protect (i.e. indirectly select) for susceptible bacteria at cefotaxime concentrations 
above the susceptible bacterium’s MIC.  
Figure 28 shows the growth of susceptible J53 strain at a range of 
cefotaxime concentrations exceeding J53 MIC (< 0.25 mg/L), incubated with 25 
µl (equating to 12.5 % of the final volume) of supernatant taken from the overnight 
culture of the pEK499 bearing (i.e. β-lactamase producing) J53 resistant strain. 
This allowed J53 to grow up to 32 mg/L without a significant difference in final OD 
(i.e. at 24 hours) compared to the no antibiotic control, also containing the NCTC 
13451 supernatant (p >0.05, Kruskal Wallis test).  
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Figure 28. Average (n=4) growth of susceptible J53 at different cefotaxime 
concentrations, without (A) and with (B) ESBL-containing supernatant (i.e. 
supernatant from susceptible J53 and resistant J53, respectively) at different 
cefotaxime concentrations. “Jsp0AB” or “Nsp 0AB” represents the no antibiotic 
control bearing the ESBL free (J53) and ESBL-containing (NCTC 13451) 
supernatant respectively. Shown with standard deviation bars. 
 
2.6. Discussion 
In this study the first ever MSC in a complex community was determined using 
the worldwide, clinically important resistance gene group blaCTX-M, as the 
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endpoint. QPCR methods have been used previously to determine the MSC in a 
community biofilm (Lundstrom et al., 2016), but this was not strictly an MSC as 
discussed in the introduction. 
The MSC of cefotaxime, the only antibiotic tested in this chapter (see 
chapter three for further work), was very low at 0.4µg/L. More replication would 
increase confidence in the estimated MSC, but qPCR analysis is costly and time 
consuming (see chapter three for a new method). Whilst the MSC of 0.4 µg/L 
(nominal) exceeds the majority of cefotaxime MECs (UmweltBundesamt, 2016), 
there are isolated cases of MECs exceeding this concentration in certain 
environmental compartments, such as hospital effluent (Gomez et al., 2007). This 
indicates selection for resistance may be occurring in situ in certain hotspots, and 
that appropriate monitoring practices may be required to identify such hotspots 
and ensure MECs do not exceed the MSC determined in this study (see chapter 
three for more details).  
For the most part, blaCTX-M prevalence increased over time except for the 
1000 µg/L and 2000 µg/L treatments, where prevalence decreased between day 
1 and 4. This is similar to the ‘overshoot’ observed in the resistant fraction from 
the paper by Yurtsev et al. (2013). However, unlike their single species 
experiment, in the complex community the prevalence then increased further, 
rather than continuing to decrease to a stable level (termed the ‘equilibrium 
fraction’). The gradual increase over time for all other treatments suggests that if 
the experiment were continued over a longer time frame the MSC would 
decrease, as selection has a longer time to act on gene prevalence. It would be 
interesting to continue the experiment indefinitely to determine if resistance 
prevalence would reach an ‘equilibrium fraction’, and what this fraction may be at 
different concentrations; or if eventually carriage could reach 100 % at even low 
concentrations.  
This research also demonstrated that MSCs derived in single species 
competition assays like those conducted previously (Gullberg et al., 2014, 
Gullberg et al., 2011) are, as expected, unrepresentative of the MSC determined 
in a community (Brandt et al., 2015, Berglund, 2015). This is the first time single 
species and complex community experiments have been directly compared in the 
same experimental system, and indicates that for real world applicability, any 
assays developed for environmental risk assessment must include a community 
aspect.  
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Indeed, in the case of cefotaxime, the LOEC in the single species assay 
was 20,000x greater than the MSC in the complex community. Though it is 
difficult to compare the LOEC and MSC as the former is a statistical approach 
and the latter an estimate, it is not possible to compare both MSCs as even in the 
absence of antibiotic treatment, the resistant strain (or resistance plasmid) 
conferred a small fitness advantage. This is a prime example of how the genetic 
and community context of a resistance gene can influence its fitness.  
The pEK499 plasmid, though large (> 100 kb) and non-conjugative, was 
not fully outcompeted by the plasmid free strain most likely due to the five different 
maintenance systems encoded on pEK499, which was hypothesised to result in 
maintenance even in the absence of selection (Woodford et al., 2009). This 
seems to be such a case where the plasmid, rather than the resistance gene 
itself, is responsible for positive selection (Carattoli, 2013). This raises concerns 
of whether plasmids such as pEK499 could be selected for in patients and then 
persist even after antibiotic treatment is ceased. An additional concern is that 
plasmids carrying ESBLs have been shown to increase the virulence of their host 
(Schaufler et al., 2016). Were pEK499 conjugative, it is likely the MSC would 
decrease due to mobilisation to the susceptible strain. This is because firstly, the 
plasmid has a fitness benefit in the absence of selection; secondly, the presence 
of resistance genes will provide an additional benefit to the recipient host in the 
presence of antibiotic; and third because in general, HGT may be induced by sub-
inhibitory concentrations (Kim et al., 2014b, Moon et al., 2005). 
As well as the LOEC in the single species assay being much higher than 
in the complex community, the prevalence of blaCTX-M at each concentration 
(peaking at 0.18 at 64 mg/L) was much lower than in the complex community 
assay (peaking at 0.79 at 64 mg/L). It can be hypothesised that this is due to 
indirect selection for susceptible bacteria (see 2.1.4. Indirect selection), which 
has been shown to occur solely for resistance mechanisms which are degradative 
in nature (Nicoloff and Andersson, 2016). To verify this and determine the level 
to which susceptible bacteria could be ‘protected’ (indirectly selected for), 
supernatant experiments were performed to first validate that: 1.) the resistant 
(plasmid bearing) strain excreted active β-lactamases, and 2.), relatively low 
volumes (which supports the low blaCTX-M prevalence observed in the single 
species experiment) could protect the susceptible bacteria.  
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The final supernatant experiment showed that while J53 lag phases 
extended with increasing cefotaxime concentration, growth at 24 hours (the 
endpoint typically used clinically when determining susceptibility profiles), even 
up to 32 mg/L, was not significantly different to the no antibiotic control. The fact 
that growth inhibition of J53 (in the form of an extended lag phase) was observed 
at even the lowest concentration tested, calls into question current MIC 
determination methods for particularly labile compounds. Here, 40 % of 
cefotaxime was shown to be degraded in sterile culture over 24 hours. Therefore, 
it is likely the dose response relationship observed between J53 growth and 
cefotaxime concentrations is due to abiotic degradation of cefotaxime to a sub-
inhibitory level. However, by considering the endpoint only (i.e. OD at 24 hours), 
the MIC is determined to be 500 µg/L which is much higher than the MSC of 0.4 
µg/L determined in the complex community experiment. This is likely to be similar 
for MICs determined on solid media, though these may have even greater 
disparity between expected and actual antibiotic concentration due to complexing 
with the agar. It may be that a significant increase in length of lag phase compared 
to the no antibiotic control, or continual addition of antibiotic to ensure a constant 
exposure concentration, would be improvements to the current MIC microdilution 
method.  
In the supernatant experiment, a difference was observed between the no 
antibiotic controls with and without supernatant. This is most likely a nutrient 
effect, reducing growth as the growth medium was diluted with nutrient-depleted 
medium (i.e. the supernatant). It is also proposed that while susceptible bacteria 
can be indirectly selected for, it is plausible that bacteria resistant to antibiotics 
other than those the population are exposed to may be indirectly selected for as 
well. I have termed this ‘protective co-selection’, another mechanism by which 
antibiotic resistance can be co-selected for (Figure 29). To prevent indirect 
selection during antibiotic treatment, clinical assays similar to the microarray 
developed to quickly screen for presence of a panel of resistance genes from 
saliva and faeces (Card et al., 2014), should be used to identify patients most at 
risk (i.e. those colonised with β-lactamase producing bacteria).  
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Figure 29. The three mechanisms of co-selection. 1. Cross-resistance - when a 
single gene confers resistance to multiple compounds, e.g. a multi-drug efflux 
pump. 2 Co-resistance - selection for one or more genes which are genetically 
linked (e.g. on a plasmid). Only one gene need be under positive selection for the 
plasmid and therefore all genes to be selected for. 3. Protective co-selection – 
this occurs when resistant bacteria (pink) produce a degradative (blue) enzyme 
(A), which binds to the (red triangle) antibiotic (B). Following antibiotic 
degradation (C), the antibiotic (red circle) is inactive (D), allowing both susceptible 
bacteria and susceptible bacteria carrying different resistant mechanisms (green) 
to grow (E). 
 
The use of β-lactamase inhibitors (βLIs) has counteracted indirect 
selection in the clinic to an extent, though resistance to βLIs has also emerged 
(Drawz and Bonomo, 2010). Even more concerning is that it has been shown 
experimentally that inclusion of βLIs at suboptimal levels can select for β-lactam 
resistance (Yurtsev et al., 2013). This is intuitive, as β-lactamases are found both 
intracellularly and extracellularly (Livermore, 1995), and it has been hypothesised 
that there must be some fitness benefit to being a producer, otherwise producers 
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would go extinct in the absence of a selective pressure – however this is not the 
case when such interactions are modelled (Dugatkin et al., 2003); nor was it the 
case in this study. If βLIs do not fully saturate all the active sites of the β-
lactamases, and as it is likely that the majority of saturation would occur in the 
media (in extracellular β-lactamases), this means intracellular β-lactamases 
remain more active compared to extracellular β-lactamases. This would then 
allow growth of the resistant strain whilst simultaneously preventing growth of the 
susceptible strain, which is still being inhibited (as extracellular ESBLs are βLI-
bound and unable to degrade the β-lactam). 
Cefotaxime concentrations in different body compartments greatly exceed 
the MSC determined in the complex community in this study, but are within the 
concentration range shown to indirectly select for susceptible bacteria. For 
example, blood serum concentrations for intramuscular injections of 1g of 
cefotaxime are 20 – 25 mg/L (FDA, 2007). Therefore, extrapolating the results 
from this study, blood serum concentrations of cefotaxime would not be 
sufficiently high to prevent indirect selection (shown here to occur at 32 mg/L), let 
alone diffuse concentrations in different body compartments. 
It should also be noted, however, that the MSCs quoted throughout this 
discussion are based on the nominal (i.e. expected) cefotaxime concentrations. 
In reality, all cefotaxime was degraded after 24 hours in the presence of the 
complex community in most of the treatments which were chemically quantified. 
This degradation coincided with the exponential growth phase of the bacterial 
community, meaning that for over half of the treatment time during each day 
(including part of the exponential growth phase) the bacteria were not exposed 
to any cefotaxime at all. 
The actual exposure concentrations during the complex community 
experiment were much lower than the nominal concentrations. Therefore, when 
taking this into account, the predicted MSC of 0.4 µg/L is likely to be much lower. 
Based on measured concentrations at the beginning of the experiment, the LOEC 
would actually be 46.25 µg/L. Together, these suggest cefotaxime may pose a 
risk of selection for resistance evolving in situ due to high similarity to MECs 
(UmweltBundesamt, 2016). Clearly more work should investigate the best way to 
determine the MSC or LOEC of labile antibiotics, but currently the selection 
coefficient method using measured assay concentrations seems the most 
protective approach. 
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The qPCR data from this degradation experiment, while based on data 
from a single replicate only, would inform any future experiments. Most 
interestingly, a change in blaCTX-M gene copy number and prevalence was 
observed over time, meanwhile the 16S copy number reached what could be an 
equilibrium at 12 hours, which coincided with the end of the exponential growth 
phase (Figures 25 and 27). At 12 hours blaCTX-M prevalence increased 
dramatically at 250 µg/L, compared to the LOEC in the long term experiment, 
which was 125 µg/L at day 1 suggesting selection occurs beyond the exponential 
growth phase. The dose-response relationship observed between exponential 
growth and cefotaxime concentration whilst collecting the data led to investigation 
of indirect selection, and the supernatant experiment, as well as the basis for 
chapter three. More replicates would be a necessity to perform statistical 
analyses, and generate selection coefficients for selection over 24 hours as 
opposed to over several days. If in agreement, this could allow more rapid 
generation of MSC data.  
The metagenome data was the least sensitive of all methods used for 
determining MSCs, as shown previously (Lundstrom et al., 2016). Selection for 
blaCTX-M genes was statistically significant at 125 µg/L using qPCR data, but a 
significant increase in blaCTX-M relative abundance was only observed at 500 µg/L 
in the metagenome data. Sequencing of the metagenome is still useful however, 
as it highlights other resistance gene classes under co-selection. 
A major concern arising from this study from both a clinical and 
environmental perspective is the co-selection for resistance to other antibiotic 
classes. Relative abundance of genes conferring resistance to aminoglycosides, 
sulphonamides and trimethoprim all increased under cefotaxime exposure, in a 
dose-dependent manner. Genes conferring resistance to these antibiotic classes 
are all commonly found on integrons (Partridge et al., 2009) (mobile genetic 
elements which harbour and express gene cassette arrays often comprised of 
antibiotic resistance genes, see chapters one and four) which may have been 
enriched by cefotaxime exposure, facilitating further selection for these genes 
and others. It would be useful if integron prevalence were quantified alongside 
resistance gene classes in the ARGS-OAP pipeline, as integrons have been 
suggested, on numerous occasions, as excellent indicators of selection for 
resistance and anthropogenic impact ((Amos et al., 2015, Rizzo et al., 2013, 
Gillings et al., 2015, Berglund, 2015), and see chapter three and chapter four). 
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As integrons also often carry other antimicrobial resistance genes such as the 
multi-drug qac efflux pump gene variants (Partridge et al., 2009), co-selection by 
sub-inhibitory cefotaxime concentrations could also reduce the efficacy of other 
antimicrobials, such as biocides. However, selection for qacA, qacB and qacG 
(the only qac genes quantified in the ARGS-OAP pipeline) were absent, or below 
the limit of detection.  
There was also co-selection for other resistance gene classes not 
commonly associated with integrons, such as those conferring macrolide 
resistance. This demonstrates for the first time the magnitude of the co-selective 
potential of sub-inhibitory concentrations of cefotaxime in a complex microbial 
community. A number of macrolides have recently been added to the first ever 
Watch List of Hazardous Compounds by the European Commission as part of 
the Environmental Quality Standards Water Framework Directive (Carvalho et al., 
2015), as MECs are often found to exceed PNECs. However, this work also 
demonstrates the importance of considering selection for resistance more 
holistically, as selection for resistance to one compound does not necessarily 
depend on the MEC of the compound it confers resistance to. 
Most interestingly, in terms of β-lactam resistance, the metagenome 
analyses showed that of all the resistance mechanisms quantified, β-lactamases 
were enriched the most, even outcompeting some other resistance mechanisms 
(e.g. PBPs), which decreased with cefotaxime exposure. BlaCTX-M abundance 
increased the most of all the β-lactamases under sub-MIC selection, which may 
explain the rapid dissemination of blaCTX-M genes across the globe (Canton and 
Coque, 2006), particularly if they are preferentially selected for in the environment 
at (Gaze et al., 2005, Gaze et al., 2011, Sidrach-Cardona et al., 2014, Hartmann 
et al., 2012) low antibiotic concentrations or in the human or animal gut 
(Hammerum et al., 2014, Woerther et al., 2013). However, there was significant 
variation between the three sequenced replicates (for both gene subtype and 
resistance gene class), which might be expected due to the inherent variability in 
a natural, complex system. More research is required to confirm that blaCTX-M 
genes are enriched over all other β-lactamases, and to determine if it is the case 
for all β-lactam antibiotics; or even all 3rd generation cephalosporins. 
Reassuringly, the strong selection for blaCTX-M supports its choice as the 
appropriate resistance gene to be used for the qPCR endpoints, used here for 
MSC determination.  
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The ARGS-OAP pipeline can identify the resistance gene subtype with 
high confidence, but not the exact genes within each subtype (T. Zhang, pers. 
comm.). The TaqMan qPCR assay provided information on the dynamics of 
blaCTX-M group selection in the complex community, indicating very similar genes 
can be differentially selected at different antibiotic concentrations. For example, 
group 1 blaCTX-M were most prevalent at the lower concentrations, but group 9 
blaCTX-M increased the most overall. Conversely at higher concentrations, group 
9 blaCTX-M were more abundant until the 32 mg/L concentration and above - at 
which point they were lost (or were at numbers below the limit of detection). 
However, there was some difficulty with reproducibility of the TaqMan assay, 
despite repeated optimisation, which can be seen in the disparity between effects 
at 2 mg/L in the lower and higher concentration experiments. This seems unlikely 
to be an artefact of different inocula, as the SYBR assay data were very similar. 
Therefore, these findings should be interpreted with caution, and preferably the 
experiments should be repeated. 
The phenotypic data at the end of the complex community experiments 
was less sensitive than qPCR for predicting MSC, which has also been shown 
previously (Lundstrom et al., 2016). However, phenotypic and qPCR LOECs 
were in agreement. This is unsurprising as clinical resistance was quantified in 
coliforms only. Though these were assumed to be the most prevalent family 
present in the community due to both the experimental conditions and the high 
prevalence of blaCTX-M genes in Gram negatives, E. coli and enteric qPCR showed 
these species only made up a very small percentage of total bacterial population. 
This data also showed the experimental system was not biased towards 
proliferation of E. coli and other enterics. 
 
2.7. Conclusions 
2.7.1. The clinical implications 
The MSC of cefotaxime determined in this study indicates that when antibiotic 
concentrations reach sub-inhibitory levels in the body (as discussed is sometimes 
the case), selection for CTX-Ms, other β-lactamases and resistance to other 
antibiotic classes may occur in vivo. The selection was cumulative over time, 
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highlighting the importance in minimising the % T < MIC during antibiotic 
treatment.  
The extent to which blaCTX-M genes are selected for at low concentrations 
may partly explain their rapid dissemination worldwide, and persistence both in 
the gut and in the environment. These results agree with others (Bottery et al., 
2016) in that the resistance mechanism could be key for predicting MSC 
depending on gene sociality.  
Excreted substances from resistant bacteria (presumed to be β-
lactamases), were shown to allow growth of susceptible bacteria well above their 
own MICs. This ‘protective effect’ (indirect selection) could extend not only to 
bacteria that are fully susceptible, but also bacteria harbouring other resistance 
mechanisms to other selective compounds - a new mechanism of co-selection 
termed protective co-selection (Figure 29). Indirect selection was observed up to 
very high antibiotic concentrations. This is concerning, as theoretically, the higher 
the antibiotic concentration, the longer the window of opportunity exists for the 
resistant bacteria to grow and overtake the population. Blood plasma 
concentrations of patients treated with cefotaxime are within the concentration 
window for indirect selection according to this study.  
Current antibiotic treatment strategies should be further refined, to ensure 
sufficiently high concentration to prevent sub-inhibitory selection and co-
selection.  
 
2.7.2. The environmental implications 
This research confirms that selection for blaCTX-M genes are likely to occur at 
concentrations in the same order of magnitude as MECs (low μg/L). The disparity 
between LOECs and selection coefficient based MSCs can be explained by the 
large variability between replicates, expected in a natural system. Increasing the 
number of replicates may increase the power of the statistical tests.  
Cefotaxime is known to be readily degradable, and this is why MECs are 
extremely low (UmweltBundesamt, 2016). In this experimental system, 
cefotaxime was fully degraded after 24 hours with all degradation occurring within 
the first 12 hours. This, combined with lower initial measured concentrations than 
expected, indicates that the average exposure concentrations during the 
experiment were actually much lower than the nominal values presented. This 
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demonstrates the absolute necessity of chemical quantification in MSC assays, 
if combining with MECs to determine a Risk Quotient.  
The complex community inoculum contained coliforms resistant at the 
clinical breakpoint concentration of cefotaxime. As coliforms are used as water 
quality measures (Michael et al., 2012), this assay could be applicable for 
assessing the potential risk for selection of resistance in waste water treatment 
plants. This experiment could feasibly be modified to assess risk of selection in 
other aquatic systems simply by changing the culturing conditions to a minimal 
media, and lowering the temperature. 
 
2.7.3. Final comments 
This work indicates that blaCTX-M genes, other β-lactamase genes and genes 
conferring resistance to several other antibiotic classes are selected and co-
selected for at low concentrations of a clinically important antibiotic. Therefore, 
selection for multiple resistance genotypes in the environment and in the body is 
likely. Additionally, there is a risk for indirect selection during antibiotic therapy. 
These findings should be verified as reproducible with different inocula and under 
a wider range of experimental conditions to more confidently identify the risk to 
the environment and human health. 
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Chapter three: Development of a simple assay to detect effect 
concentrations of antimicrobials 
 
3.1. Introduction  
This chapter directly addresses the thesis title: “Development of a novel assay to 
detect effect concentrations of micropollutants”. The introduction is framed 
around this objective. 
 
3.1.1. Development of a novel assay 
Current environmental risk assessment (ERA) guidelines dictate that the toxic 
effects of antibiotics (both human and veterinary) on microbes should be 
determined using three standardised tests. The soil nitrogen transformation test 
(used to assess the effect of antibiotics on nitrification in soil-dwelling bacteria) 
and growth inhibition of cyanobacteria test are both required for human and 
veterinary antibiotics. Additionally, human antibiotics are further assessed using 
the activated sludge respiration inhibition test (ASRIT), to assess the risk 
antibiotics may pose when undergoing the waste water treatment process 
(Brandt et al., 2015). 
Whilst using microbial endpoints is a necessity when assessing the risk of 
antibiotics (as bacteria are the target species), none of the current tests currently 
assess the ‘selective potential’ of a compound - i.e. its ability to select for 
antimicrobial resistance. In light of the sub-inhibitory selection first observed by 
Gullberg et al. (2011), this now appears to be a significant oversight in antibiotic 
ERA. Therefore, an immediate need has been identified for a novel assay which 
can be used for this purpose (Ashbolt et al., 2013, Brandt et al., 2015, Berglund, 
2015). This is so sufficient data can be generated which can be used in the ERA 
of antibiotics, to determine whether antibiotics pose a ‘selective hazard’ or 
‘selective risk’ (i.e. select for resistance) in the environment. 
Recently, predicted no effect concentrations (PNECs) for resistance 
(PNECRs) were estimated using the publically available EUCAST MIC data 
(Bengtsson-Palme and Larsson, 2016). This produced a large data set that could 
be used to inform environmental regulation, and indicated that PNECs generated 
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from current ecotoxicological tests were often not protective of the estimated 
PNECR. However, as noted by the authors, generation of experimental data is 
still required (Bengtsson-Palme and Larsson, 2016), both to verify these 
predicted PNECRs and to continue to inform regulatory practice. 
Indeed, there is a scarcity of experimental, minimal selective concentration 
(MSC) data, with only three data papers published to date. These were discussed 
in chapter two (Lundstrom et al., 2016, Gullberg et al., 2014, Gullberg et al., 
2011). Only the single species experiments designed by Gullberg et al. (2011, 
2014), which determined MSCs based on selection coefficients (increase in 
numbers of resistant bacteria overtime) have been used more than once. This 
method proved suitable for MSC determination for both chromosomally-encoded 
resistance mutations, and entire resistance genes encoded on a clinically-
isolated, multi-drug resistance plasmid. However, as single species experiments 
they have little predictive power for determining MSCs in the natural environment. 
Chapter two discussed indirect selection, which is just one of the many possible 
community interactions which makes selection for resistance much more 
complex in a natural community than in a single species system. Additionally, the 
quantification of resistant bacteria used fluorescently activated cell sorting 
(FACS), which although offers a high level of accuracy, is not well-suited to inter-
laboratory testing, as it is not a standard piece of lab equipment and requires 
fluorescent protein tagging of experimental strains. 
The paper by Lundstrom et al. (2016) did use a natural complex 
community, but was subject to other issues discussed more thoroughly in chapter 
two. In addition, the experimental conditions were complex and therefore not 
easily replicable. The set-up of multiple open system microcosms, and the 
harvesting of multiple biofilm replicates, does not lend itself to the rapid 
generation of data, or again to inter-laboratory replication. This would make 
validation of this method according to OECD guidelines difficult (OECD, 2005). 
Additionally, as discussed in chapter two, chemical quantification is necessary for 
determining truly accurate MSCs. Biofilm-based microcosms would be a difficult 
matrix from which to extract the compounds for quantification. However, the study 
did investigate several different endpoints for assessing selection for resistance, 
including qPCR, metagenomics, phenotypic data and pollution-induced 
community tolerance (PICT) assays. QPCR was determined as the most 
sensitive, which is the method used primarily in this chapter and chapter two.  
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This study used selection coefficients determined by qPCR as the ‘gold 
standard’ to which the novel assay (based on difference in growth) is compared, 
though statistical derivation of LOECs (Lowest Observed Effect Concentrations) 
is also explored. The different methods used to estimate MSC (i.e. selection 
coefficient approach) or LOEC (i.e. statistical approach) were compared 
statistically using Bland-Altman plots (Bland and Altman, 1986). These assess 
the level of agreement between measurements derived from the two methods; 
as opposed to a correlation which, though commonly used, simply assesses the 
strength of the relationship between two measurements, and not how much they 
may differ (Giavarina, 2015). 
 
3.1.2. Effect concentrations of micropollutants (antimicrobials) 
The antimicrobials used in the long term experiments forming this study were the 
β-lactam antibiotic cefotaxime (TAX), the macrolide clarithromycin (CLA), 
trimethoprim (TRMP), and the fluoroquinolone ciprofloxacin (CIP). Compounds 
were chosen to assess a range of antibiotic classes, which have been detected 
at varying concentrations in the environment; which are widely prescribed and 
which have clinically relevant resistance genes present in the environment. All 
the antibiotics described below have been included as ‘essential’ medicines by 
the WHO (WHO, 2017). The in-depth rationale for selecting these compounds is 
described subsequently, as well as a selection of available PNECs and MSCs 
(Table 3).  
The growth rate experiments were also used to estimate the MSC of 
azithromycin (AZ) and erythromycin (ERY), on the basis that long term data would 
soon be available for these compounds (forming part of the thesis of another 
student). The quaternary ammonium compound (QAC) benzalkonium chloride 
(BKC) was also chosen as single example to ascertain if this assay could also be 
used to determine MSCs for biocides, or other antimicrobials. 
 
3.1.3. Clarithromycin (CLA) 
The macrolides AZ, CLA and ERY, as a group, were recently included amongst 
the 10 compounds posing the highest risk in the first ever Watch List developed 
110 
 
by the Environmental Quality Standards Directive (Carvalho et al., 2015). This is 
because the predicted environmental concentration (PEC) exceeds the PNEC for 
these compounds, resulting in a risk quotient (RQ) of > 1 (derived by PEC/PNEC). 
However, this data is based on the standard ecotoxicological tests, and so it is 
unknown if these will be protective of resistance selection. Additionally, the PEC 
was based solely on human consumption. Therefore, it is likely that the actual 
measured environmental concentration (MEC) will be much greater (Carvalho et 
al., 2015) as ERY is also used extensively in agriculture (Pyörälä et al., 2014) 
which will increase load in aquatic systems through, for example, run-off of animal 
excreta from farm land. The only MSCs determined so far for any of these 
compounds was for ERY in a competition experiment between a susceptible E. 
coli lab strain and an isogenic, resistance-plasmid bearer (Gullberg et al., 2014).  
The macrolides have been used for decades against primarily Gram 
positive bacteria, with some efficacy against intracellular Gram negatives and 
Gram negative cocci. There are three main pathways to resistance: through 
modification of drug target (the ribosome), for example the erm genes; drug efflux, 
for example by the msr or mef genes; and drug inactivation, by for example the 
mph and lin genes (Leclercq, 2002). In this study, ermF was selected as the gene 
target, as a recommended antibiotic resistance gene marker to assess resistance 
selection in situ (Berendonk et al., 2015). 
 
3.1.4. Ciprofloxacin (CIP) 
CIP is a fluoroquinolone, and the only other antibiotic to be included on the Watch 
List by the Environment Quality Standards Directive (Carvalho et al., 2015). The 
fluoroquinolones are broad spectrum, with great potency against both Gram 
positive and Gram negative bacteria, primarily targeting topoisomerase IV and 
DNA gyrase, respectively; and interfering with the otherwise highly regulated 
DNA supercoiling and uncoiling. The result of inhibition of either enzyme is that 
DNA replication is severely impaired at lower concentrations, and at higher 
concentrations the result is cell death (Redgrave et al., 2014).  
CIP can increase intra-chromosomal recombination in E. coli, which can 
in turn increase the potential for novel resistance determinants arising (Lopez et 
al., 2007); or increase rates of HGT (Guerin et al., 2008, Guerin et al., 2010, 
Guerin et al., 2009, Beaber et al., 2004). CIP is the most frequently prescribed 
111 
 
fluoroquinolone (Pico and Andreu, 2007). It has greater microbial inhibition in 
water than in soil (due to sorption) but can remain biologically active in soil over 
time (Girardi et al., 2011) as it is not readily biodegradable (Cabello, 2006, 
Kummerer, 2009a). CIP MSCs have been determined (Table 3) for chromosomal 
point mutations previously (Gullberg et al., 2011). 
Like macrolide resistance, fluoroquinolone resistance is mediated by 
target modification (e.g. gyr genes), or efflux (of which there are many examples, 
including but not limited to NorA). In addition, fluoroquinolone resistance can be 
conferred by reduced cell wall permeability, or carriage of plasmid-mediated 
quinolone resistance genes (PMQRs), such as the qnr genes. The Qnr proteins 
bind to topoisomerase IV and prevent fluoroquinolone binding (Redgrave et al., 
2014). Initially, qnrS was selected for quantification as it is mobile (Redgrave et 
al., 2014), has been found on numerous occasions in the environment, and is 
also the second most common qnr gene quantified in clinical Enterobacteriaceae 
(Strahilevitz et al., 2009).  
However, following suboptimal results using the qnrS target (3.3.2.3. 
Results and 3.4. Discussion), the intI1 gene was used to determine CIP MSC and 
LOEC as qnr genes can be associated with these genetic elements (Partridge et 
al., 2009). The intI1 gene encodes the class 1 integrase, the gene in class 1 
integrons which facilitates homologous recombination of gene cassettes. Class 1 
integrons are common to both clinical and natural environments and often 
harbour a selection of antibiotic resistance genes in gene cassette arrays which 
can be readily interchanged; and as such, they are frequently cited as being good 
indicators for both anthropogenic impact and presence of antimicrobial resistance 
genes (Berglund et al., 2014, Kotlarska et al., 2014, Gillings et al., 2009, Gaze 
WH, 2011, Gaze et al., 2005, Abella et al., 2015b, Gillings MR, 2008, Gillings et 
al., 2015, Amos et al., 2015, Jechalke et al., 2013). In this context, targeting intI1 
for MSC determination can determine not only the selective potential of a 
compound but the co-selective potential as well; as numerous other resistance 
genes are likely to be harboured on a single integron. 
 
3.1.5. Trimethoprim (TRMP) 
TRMP is most often used in combination with the sulphonamide antibiotic 
sulfamethoxazole, as the compound co-trimoxazole. This is not fully metabolised 
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in the body (Yang et al., 2011), and so is commonly used to treat urinary tract 
infections. TRMP’s target is dihydrofolate reductase, and resistance arises due 
to alteration of this enzyme encoded by the dfr genes. 30 dfr genes have been 
recorded, and they are frequently associated with class 1 and class 2 integrons. 
Following the increase in resistance over recent years and consequent 
increasingly ineffective treatment, a study investigated the effects on TRMP 
resistance by reducing TRMP use over two years. Despite this, dfr gene 
prevalence did not decrease, suggesting the genes confer a low fitness cost and 
or these genes are readily co-selected (Brolund et al., 2010). Importantly, TRMP 
is excreted unchanged in urine (Brolund et al., 2010) and can reach 
concentrations of up to 162 µg/L in WWTP influent and 100 µg/L in surface water 
(UmweltBundesamt, 2016). It also cannot be biodegraded (Sirtori et al., 2010) 
which may make it a significant driver of antibiotic resistance in  the environment. 
Due to the many dfr variants and their association with integrons, the intI1 
gene was used as the target for the long term selection experiments. 
 
3.1.6. Cefotaxime (TAX) 
TAX is a third generation cephalosporin, and a β-lactam antibiotic. β-lactam 
antibiotics prevent cell membrane synthesis, resulting in cell lysis, by binding 
membrane-bound transpeptidases (or ‘penicillin-binding proteins’: PBPs) which 
cross-link peptidoglycan. Resistance mechanisms include modified PBPs, 
changes in outer membrane permeability, efflux pumps (for example, MexXY in 
Pseudomonas aeruginosa) and enzymes (β-lactamases) which degrade the 
antibiotic by hydrolysing the β-lactam ring (Reygaert, 2011).  
There are over 1000 β-lactamases described to date, and they are 
common in pathogens (Walsh, 2013b). They can be divided into classes A and 
B, which are found in Gram positive and Gram negative bacteria respectively 
(Reygaert, 2011); and 2 groups, the first comprising of three classes of serine β-
lactamases, and the second including 2 groups of metallo-β lactamases which 
require a bivalent metal ion catalyst (Bush, 1998). The blaCTX-M genes encode for 
extended spectrum β-lactamases (ESBLs), and can be associated with a range 
of MGE’s, including plasmids, IS’s, ISCR’s and integrons. BlaCTX-M containing 
plasmids are often multi-drug resistant. These features may account for their 
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rapid dissemination worldwide, with the blaCTX-M-15 gene being the most common 
(Canton and Coque, 2006).  
Used extensively in the clinic for treating problematic multidrug resistant 
Gram negative pathogens, TAX is readily degradable and as such the parent 
compound is found only at very low concentrations in the environment, ranging 
from 1.1 μg/L in untreated WWTP influent, to as low as 0.001 μg/L in surface 
water (UmweltBundesamt, 2016). However, TAX concentrations have been 
measured as high as 150 µg/L in hospital effluent (Gomez et al., 2007). Despite 
this, blaCTX-M-15 genes have been found in a variety of environmental 
compartments including soil (Hartmann et al., 2012), river water, river sediment 
(Dhanji et al., 2011, Marti et al., 2013, Sidrach-Cardona et al., 2014, Amos et al., 
2014a), and even in recreational waters (Blaak et al., 2014). This disparity 
between environmental concentration and presence of resistance genes in the 
environment makes TAX an interesting selective agent, as it prompts deeper 
investigation of fitness effects at the gene level and potential co-selective effects 
of other more persistent compounds. 
 
Table 3. The compounds used in this study, with a selection of available PNECs 
and all available MSCs, with corresponding references. Concentrations with a * 
are toxicity data, i.e. with a safety factor added (normally 10 for chronic and 1000 
for acute (Straub, 2013)).  
Compound PNEC(s) (µg/L) Reference(s) MSC(s) 
(µg/L) 
Reference(s) 
Azithromycin  
(AZ) 
0.09 
 
0.15 
(Carvalho et al., 2015) 
(Kümmerer and 
Henninger, 2003) 
No data  
Cefotaxime  
(TAX) 
0.04 (Kümmerer and 
Henninger, 2003) 
0.4 Chapter One 
Ciprofloxacin  
(CIP) 
0.089 
 
0.02 
(Carvalho et al., 2015) 
(Kümmerer and 
Henninger, 2003) 
0.1 
 
2.5 
(Gullberg et al., 
2011) 
(Gullberg et al., 
2011) 
Clarithromycin 
(CLA) 
0.013 
0.04 
(Carvalho et al., 2015) 
(Kümmerer and 
Henninger, 2003) 
No data  
Erythromycin 
(ERY) 
0.2 
 
0.04 
(Carvalho et al., 2015) 
(Kümmerer and 
Henninger, 2003) 
3000 (Gullberg et al., 
2014) 
Trimethoprim 
(TRMP) 
1 
 
5.1* (acute) 
240* (chronic) 
(Kümmerer and 
Henninger, 2003) 
(Straub, 2013) 
(Straub, 2013) 
33 (Gullberg et al., 
2014) 
Benzalkonium 
chloride 
(BKC) 
3.9 
 
 
0.032* (chronic) 
(EnvironmentCanada 
and HealthCanada, 
2009) 
(Guo et al., 2016) 
500 Lihong Zhang, pers. 
comms 
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0.28* (acute)  
(Guo et al., 2016) 
 
3.1.7. Primary aims of the study 
 Determine selective endpoints (MSCs and / or LOECs) using long term 
experiments and the growth experiment, for several antibiotics. 
 Compare these data to assess the reliability of the growth assay for 
predicting LOECs generated using the long term assay.  
 Compare these MSC and LOEC data to PNECs and determine if current 
ecotoxicological endpoints are protective of resistance selection. 
 Define the RQs of these antibiotics to determine the risk for resistance 
selection in situ.  
 
MSCs and LOECs are defined in chapter two, but redefined here for clarity. 
Briefly, MSCs are estimated selective endpoints, determined by calculating 
selection coefficients based on change of resistance gene prevalence over time. 
LOECs are selective endpoints defined statistically, by determining the lowest 
concentration where resistance gene prevalence is significantly different to the 
no antibiotic control at the end of the experiment.  
 
3.2. Materials and Methods 
3.2.1. Sample collection, storage and preparation 
Sewage influent from Falmouth, Cornwall (UK), was collected on the morning of 
27th October 2015. Sewage effluent from Camborne, Cornwall (UK) was collected 
on 3rd February 2017 at the point of entry into the environment (following primary 
treatment, activated sludge). The waste water treatment plants serve populations 
of 43,000 and 73,000, respectively. 
Single use aliquots were mixed in a 1:1 ratio with 20 % glycerol, vortexed and 
stored at -80 °C until use. Before use, samples were spun down at full speed for 
10 minutes, the supernatant removed, and the pellet resuspended in equal 
volume of 0.85 % NaCl twice to prevent nutrient/chemical carry over. 
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3.2.2. Antibiotics 
TAX (Molekular) and CIP (Sigma) stocks were prepared in autoclaved and 
filtered, deionised water; TRMP (Sigma) in DMSO, AZ (Sigma) in ethanol, CLA 
(Molekular) in acetone, ERY (Acros Organics) in ethanol; and BKC (Sigma) in 
sterile, filtered deionised water. Single-use aliquots were stored at -80 °C until 
use to prevent degradation by repeated freeze-thawing. 
 
3.2.3. Growth rate experiments  
These were used to inform the concentration ranges in the long term selection 
experiments, where appropriate. A broth microdilution assay was performed for 
each antibiotic, with 6 or 7 twofold antibiotic dilutions. This was in a final volume 
of 200 µl comprising Iso-Sensitest broth, wastewater (10 % volume) and each 
antibiotic, starting from the clinical breakpoint (EUCAST, 2014) concentration for 
Enterobacteriaceae (where possible). When the lowest concentration showed a 
significant difference, the experiment was run again with a new, lower 
concentration series which included the concentration which showed the 
significant difference in the previous plate. Only data where decreased growth 
rate was determined, but not at the lowest assay concentration, are shown. All 
plates also contained a no antibiotic control, as well as a sterile control. There 
were 6 replicates for each treatment. Plates were incubated immediately in a 
Varisokan Flash plate reader, at 37 °C with background shaking at 180 rpm at 3 
mm. Optical density (OD) was measured at 600 nm, every hour, for 24 hours. 
 
3.2.4. Pilot effluent experiment  
The growth rate assay was also performed with effluent. This was used as the 
complex community inoculum in a pilot growth rate experiment, as above, using 
sub-inhibitory concentrations of TAX (encompassing the LOECs determined by 
both growth rate and long term assays; and the MSC as determined by long term 
experiments - see 3.3. Results). The assay concentrations were 625, 312.5, 
156.25, 78.13, 39.06 and 19.53 µg/L, as well as a no antibiotic and sterile controls 
as previously described. Culturing conditions were as previously described. 
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3.2.5. Pilot low temperature and low nutrient experiment 
Influent and effluent were diluted to a 10 % volume / volume of either iso-sensitest 
broth or M9 buffer, in a total volume of 30 ml. There was one replicate for each. 
All four samples were incubated at 20 °C, shaking at 180 rpm for several days. 
Samples were taken intermittently and OD at 600 nm was determined using a 
Jenway spectrophotometer. When necessary, cultures exceeding an OD of 1 
were diluted 10-fold and remeasured. Sampling ceased when the growth curves 
appeared to reach stationary phase. 
 
3.2.6. Long term waste water (complex community) microcosm 
experiments 
The data for TAX is taken directly from chapter two. Methods are as described in 
chapter two, but with different antibiotics. Iso-sensitest broth was inoculated with 
a 10x dilution of washed, untreated waste water. This was separated into 25 ml 
aliquots and appropriate amounts of antibiotic stocks were added, which was then 
diluted twofold in a further 25 ml broth with waste water for the required number 
of dilutions.  
The concentrations selected for the long term experiments were based on 
the growth rate data results where appropriate (i.e. where a significant difference 
growth rate was observed, and 2 concentrations below). Concentration series 
were two-fold dilutions, with 0 µg/L as a negative (no antibiotic) control. For CIP 
the concentrations were 1000 μg/L down to 0.98 µg/L; and for TRMP the 
concentrations were 4000 µg/L down to 7.81 µg/L. For CLA, the concentrations 
were 0, 100, 250, 500, 750, 1000, 10,000 and 100,000 µg/L. 
All replicates (n=5 for TAX, CIP, TRMP and CLA unless otherwise 
indicated) were immediately sampled for the Day 0 sampling time point: 2 x 1 ml 
of each was spun down at full speed for 3 minutes, the supernatant removed and 
pellet resuspended in 500 μl 20 % glycerol followed by storage at -80 °C. The 
remaining sample was incubated overnight at 37 °C, 180 rpm. Following 
overnight incubation, 50 μl of each microcosm was introduced into 5 ml fresh 
media and antibiotic; this was repeated for a total of 7 days (except for the TAX 
experiment, see chapter two, which was 8 days).  
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3.2.7. QPCR 
The qPCR protocol was the same as that used in chapter two: frozen samples / 
untreated waste water were thawed and DNA extracted using the MBio 
UltraClean DNA extraction Kit according to instructions; with initial spinning time 
elongated to 3 minutes. DNA was stored at -20 °C. 
gBlock synthetic oligonucelotides (IDTDNA, Table 4) were used as 
standards; these were resuspended in TE buffer according to the manufacturer’s 
instructions and were stored at -80 °C. All DNA standards were 10x serially 
diluted in TE buffer and stored at -20 °C before use. Every PCR plate was always 
run with 5 serial dilutions of standards in duplicate (and a duplicate negative 
control). For blaCTX-M and 16S gene copy number, provided the efficiency for the 
reaction was between 90 % and 110 %, the average CTs for the duplicate 
technical replicates for each sample were used to calculate the copy number 
based on a ‘gold standard’ standard dilution series, where the DNA concentration 
had been quantified by QuBit and the copy number per μl quantified immediately 
prior to cycling. For all other gene targets, standards within the plate were used 
for absolute copy number quantification. 
Standards were first verified using qPCR conditions described below, with 
a melt curve in SYBR assays. For the TAX and CLA experiments (see chapter 
two, and Author Contributions), Brilliant qPCR SYBR Green reagents (Agilent) 
were used in 20 μl reactions comprising of 10 μl master mix, 2 μl primer pair (10 
μM for 16S and ermF primers, 18 μM for CTX-M primers), 0.2 μl BSA (20 mg/ml), 
0.4 μl dye (20 µM), 5 μl diluted DNA template and filtered, sterilised water to a 
total volume of 20 μl. The qPCR programme was 95 °C for 3 minutes, followed 
by 40 cycles of 95 °C for 10 seconds and 60 °C for 30 seconds, except CTX-M 
which was 58 °C for 1 minute.  
For qnrS and intI1 gene targets, PrimerDesign PrecisionPLUS MasterMix 
with pre-added ROX was used in a 20 µl reactions comprising of 10 µl mastermix, 
2 µl primer pair (4.5 µM for both), 0. 2µl BSA (20 mg/ml), 5 µl diluted DNA 
template and filtered, sterilised water to a total volume of 20 µl. The qPCR 
programme was 10 minutes at 95°C, followed by 40 cycles of 15 seconds at 95 
°C and 1 minute at 60 °C. This mastermix was compared with the Agilent 
mastermix, and there was no significant difference between copy numbers 
determined for the same test template. The PrimerDesign mastermix was used 
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as it was heavily discounted following my PrimerDesign Silver Student 
Scholarship award, which ran from January 2015 to January 2016. 
The primers and gBlocks used in this chapter are in Table 4. All targeted 
genes’ copy numbers were divided by 16S copy number to determine a molecular 
‘prevalence’ of each resistance gene. 
 
Table 4. Sequences and length of the different primers, probes and gBlocks used 
in this study, with original references or the accession number used where 
applicable. 
Name Sequence Size 
(bp) 
Accession 
number 
Reference 
16S 
gBlock 
ACGGTGAATACGTTCCCGGGCCTTGTAC
ACACCGCCCGTCACACCATGGGAGTGGG
TTGCAAAAGAAGTAGGTAGCTTAACCTTC
GGGAGGGCGCTTACCACTTTGTGATTCA
TGACTGGGGTGAAGTCGTAACAAGGTAA
CCG 
144 CP018770.2 This study 
CTX-M 
gBlock 
GATGTGCAGCACCAGTAAAGTGATGGCC
GCGGCCGCGGTGCTGAAGAAAAGTGAAA
GCGAACCGAATCTGTTAAATCAGCGAGTT
GAGATCAAAAAATCTGACCTTGTTAACTA
TAATCCGATTGCGGAAAAGCACGTCAAT
GGGACGATGTCACTGGCTGAGCTTAGCG
CGGCCGCGCTACAGTACAGCGATAACGT
GGCGATGAATAAGCTGATTGCTCACGTT
GGCGGCCCGGCTAGCGTCACCGCGTTC
GCCCGACAGCTGGGAGACGAAACGTTCC
GTCTCGACCGTACCGAGCCGACGTTAAA
CACCGCCATTCCGGGCGATCCGCGTGAT
A 
338 KX452391.1 This study 
intI1 
gBlock 
GGCCTTGATGTTACCCGAGAGCTTGGCA
CCCAGCCTGCGCGAGCAGCTGTCGCGT
GCACGGGCATGGTGGCTGAAGGACCAG
GCCGAGGGCCGCAGCGGCGTTGCGCTT
CCCGACGCCCTTGAGCGGAAGTATCCGC
GCGCCGGGCATTCCTGGCCGTGGTTCTG
GGTTTTTGCGCAGCACACGCATTCGACC
GATCC 
198 CP020934.1 See author 
contributions 
qnrS 
gBlock 
TTCGACGTGCTAACTTGCGTGATACGACA
TTCGTCAACTGCAAGTTCATTGAACAGGG
TGATATCGAAGGCTGCCACTTTGATGTCG
CAGATCTTCGTGATGCAAGTTTCCAACAA
TGCCAACTT 
125 KY421937.1 See author 
contributions 
ermF 
gBlock 
TCTGATGCCCGAAATGTTCAAGTTGTCGG
TTGTGATTTTAGGAATTTTGCAGTTCCGA
ATTTCCTTTCAAAGTGGTGTCAAATATTCT
TATGGCATTACTTCCGATATTTTCAAAATC
TGATGTTTGAGAGTCTTGGAAATTTTCTG
GGAGGTTCCATTGTCCTTCAATTAGAACC
TACACAAAAGTTATTTTCGAGGAAGCTTT
ACAATCCATATACCGTTTTCTATCATACTT
TTTTTGATTTGAAACTTGTCTATGAGGTA
GGTCCTGAAAGTTTCTTGCCACCGCCA  
294 CP021206.1 See author 
contributions 
16S F 
(1396F) 
CGGTGAATACGTTCYCGG 142 - (Suzuki et al., 
2000) 
16S R 
(1492R) 
GGWTACCTTGTTACGACT - 
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CTX-M 
consensu
s F 
ATG TGC AGY ACC AGT AAR GTK ATG 
GC 
~300 - (Birkett et al., 
2007) 
CTX-M 
consensu
s R 
ATC ACK CGG RTC GCC XGG RAT - 
intI1-L1 GCCTTGATGTTACCCGAGAG 196 - (Barraud et al., 
2010) intI1-L5 GATCGGTCGAATGCGTGT - 
qnrS UP CGACGTGCTAACTTGCGTGA 118 - (Colomer-
Lluch et al., 
2014) 
qnrs LP GGCATTGTTGGAAACTTGCA - 
ermF F TCTGGGAGGTTCCATTGTCCT 56 CP021206.1 See author 
contributions ermF R ACTTTCAGGACCTACCTCATAGA CP021206.1 
 
3.2.8. Minimal Selective Concentration (MSC) determination 
Effect concentrations were determined both statistically (see 3.2.9. Statistics) by 
generating LOECs and by using selection coefficients to estimate MSCs, as 
previously (Gullberg et al., 2014, Gullberg et al., 2011, Lundstrom et al., 2016). 
Details for selection coefficient determination can be found in chapter two.  
 
3.2.9. Statistics 
All statistics were performed in RStudio (2015). A range of statistical tests were 
used to investigate the data.  
The growth based LOEC was based on the lowest antimicrobial 
concentration which was significantly different to the no antibiotic control (Dunn’s 
test), at a single time point during exponential growth phase. Spearman’s rank 
was performed to determine if there was a significant, monotonic relationship 
between antimicrobial concentration and average growth (growth based 
experiment); and between antimicrobial concentration and average target gene 
prevalence.  
A Kruskal Wallis test was used to compare target gene ‘prevalence’ at day 
0 (to verify replicates were not significantly different at day 0), and at the end of 
the experiment. For the longer term experiments, two different methods for LOEC 
determination were used – Dunn’s test, and / or a general linearised model (GLM) 
approach. Details of GLM types were data set specific and are summarised in the 
results.  
Bland-Altman plots were also generated using R using the R package 
‘Bland-Altman-Leh’, to compare the different methods for determining effect 
concentrations. As the differences between the two end points were non-normally 
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distributed (according to a Shapiro Wilks test for normality), data were log 
transformed, to be in keeping with the test assumptions (Bland and Altman, 1986, 
Giavarina, 2015). Log transformed data were used for the Bland-Altman plots 
shown in the results. 
 
3.2.10. Author Contributions 
The idea behind this chapter is based on my observations during the degradation 
experiments from chapter two. I performed the long term experiments (culturing 
and qPCR) for TAX and CIP, and all the qPCRs for these and the TRMP long 
term experiment. Isobel Stanton (fellow PhD student) and two visiting college 
students Alana Dalton and Jessica Wright performed the TRMP experiment 
under my direction. Isobel Stanton performed the CLA long term experiment and 
qPCR, also with my input, as part of her thesis; as well as designing the primers 
and gBlock for ermF. Lihong Zhang designed the gBlock primers for intI1 and 
qnrS gene targets. I designed and conducted all growth rate experiments, as well 
as designing and performing all data analysis and statistical analyses (both for 
long term and growth experiments). 
 
3.3. Results 
3.3.1. Growth based experimental results  
The dose-response relationship between complex community growth and 
antibiotic concentrations observed during the degradation experiment in chapter 
two lead to the hypothesis that growth assays may be rapid, cheap alternatives 
to long term experiments for determining selective endpoints. To test this 
hypothesis, more MSC and LOEC data were generated for additional antibiotics, 
both by using the growth assay and the long term evolution experiment.  
All growth based experiments were run over 24 hours (Figures 31 – 37). 
During exponential growth phase it was noted that there was a dose-response 
relationship between antimicrobial concentration and complex community growth 
(Figure 30), which was most apparent at 6 hours.  
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Figure 30. Average (n=7) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/L) of 
cefotaxime, over 6 hours. Shown with standard deviation bars. 
 
 
Figure 31. Average (n=7) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (µg/L) of 
cefotaxime, over 24 hours. Shown with standard deviation bars. 
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Figure 32. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (mg/L) of 
azithromycin, over 24 hours. Shown with standard deviation bars. 
 
 
Figure 33. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (mg/L) of 
clarithromycin, over 24 hours. Shown with standard deviation bars. 
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Figure 34. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (mg/L) of 
erythromycin, over 24 hours. Shown with standard deviation bars. 
 
 
Figure 35. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (mg/L) of 
ciprofloxacin, over 24 hours. Shown with standard deviation bars. 
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Figure 36. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (mg/L) of 
trimethoprim, over 24 hours. Shown with standard deviation bars. 
 
 
Figure 37. Average (n=6) growth (optical density measured at 600 nm) of the 
complex community in the presence of different concentrations (mg/L) of 
benzalkonium-chloride, over 24 hours. Shown with standard deviation bars. 
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Spearman’s rank correlation coefficients were determined by comparing 
antibiotic concentrations and growth at the 6 hour (beginning of exponential 
growth phase), 9 hour (end of exponential growth phase), 12 hour (stationary 
phase) and final time points. This was performed for all antimicrobials, and 
consistently the 6 hour time point had the highest negative rho (rs) value, and the 
lowest p value – except for TAX which had a higher negative rs value at 9 and 12 
hours; and ERY, which had the highest negative rs value at 9 hours (Table 5). 
The rs and p values were averaged for all antimicrobials at each time point, 
and the average rs and p values were plotted against the different time points to 
visualise the decrease in the dose-response relationship (Figure 38). Based on 
this analysis, the 6 hour time point was used for determining LOECs, using a 
Dunn’s test. The results from this are shown in Table 6.  
 
Table 5. Rho (rs Spearman's rank) values (in bold) and p values (italicised) to test 
for a dose response relationship between complex community growth and 
antimicrobial concentration, at different time points during different growth 
phases. 
Antimicrobial 6 hours 9 hours 12 hours Final 
TAX -0.4185773 
7.42e-05 
-0.5249639 
2.953e-07 
-0.4879846  
2.496e-06 
-0.1565931  
0.1549 
AZ -0.954791 
< 2.2e-16 
-0.9404587 
< 2.2e-16 
-0.4758091  
0.0006307 
-0.3861504 
0.006711 
CLA -0.5240322 
0.000132 
-0.133268 
0.3665 
0.1855787 
0.2066 
-f0.005690067 
0.9694 
ERY -0.756902 
4.84e-10 
-0.9710926 
< 2.2e-16 
-0.2742971 
0.05921 
-0.1471211 
0.3183 
CIP -0.8451171  
4.23e-14 
-0.3277629  
0.02296 
-0.04179557 
0.7779 
0.08895718  
0.5477 
TRMP -0.6097578 
1.815e-05 
-0.1698345 
0.2823 
-0.2042268 
0.1945 
-0.2159928 
0.1695 
BKC -0.6933572 
4.696e-08 
-0.4785285 
0.000581 
-0.2395782  
0.101 
0.136359 
0.3554 
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Figure 38. Average (n = 8) p values and rho (rs) values from Spearman's rank 
correlation analysis of growth (optical density) against increasing antibiotic 
concentration, at 4 different time points. Shown with standard deviation bars. 
 
Table 6. The growth based effect concentration, experimentally derived using 
average growth data (n=6) at 6 hours growth. Determined using Dunn's test 
(significance = p < 0.05).  
Antimicrobial Growth based LOEC (µg/L) 
TAX 31.25 
AZ 1000       
CLA 5000    
ERY 25,000      
CIP 1.95 
TRMP 31.25 
BKC 4000 
  
3.3.2. Long term selection experiment results  
MSCs and LOECs were determined for several antibiotics using the long term 
evolution experiment, to allow comparison to growth LOECs and to compare the 
MSC and LOEC method for determining long term selective endpoints.  
 
3.3.2.1. Cefotaxime (TAX) 
The results for the TAX long term experiment (both qPCR graph and selection 
coefficient graphs) are shown in Figures 5 and 6 in chapter two. The MSC was 
0.4 µg/L. There was no dose-response relationship between blaCTX-M prevalence 
at day 8 and cefotaxime concentration. 
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To make the statistical analyses of the data as comparable as possible, 
the qPCR data at day 8 was also analysed using a GLM approach. However, 
despite assessing all possibly error families and links both with the day 8 
prevalence data, and the square root transformed day 8 prevalence data, there 
was not a suitable model which did not significantly violate the assumption that 
the residuals should be normally distributed (the highest p value for the Shapiro 
Wilks test for residuals was 0.0002, using transformed data).  
The Dunn’s test was performed on the untransformed data as in chapter 
two, there was a significant increase (p < 0.05) in blaCTX-M prevalence at 125 µg/L, 
and all concentrations above. Therefore, the statistically derived LOEC is 125 
µg/L. 
 
3.3.2.2. Clarithromycin (CLA) 
The qPCR data for the CLA experiment can be seen in Figure 39, and the MSC 
in Figure 40, which was 65 µg/L. There was no significant difference in day 0 
ermF prevalence between treatments (ANOVA). There was no significant dose-
response relationship between ermF prevalence and CLA concentration 
(Spearman’s rank, p > 0.05). 
As with TAX, multiple GLMs with different error families and link functions 
were explored; however there was no model, even with transformed data, which 
did not fail on one or more GLM assumptions. Therefore a Dunn’s test was used 
to find the LOEC (CLA concentration at which ermF prevalence was significantly 
different to that without antibiotic) – in this case, 750 µg/L (Dunn’s test, p < 0.05). 
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Figure 39. The qPCR data (technical replicate, n=2) for the long term evolution 
experiment for clarithromycin. Shown is average (n=5, except day 7 250 µg/L 
n=4) ermF prevalence (ermF gene copy number divided by 16S copy number) at 
day 0 and day 7. Shown with standard error bars. 
 
 
Figure 40. Average (biological replicate n=5 except day 7 250 µg/L n=4, qPCR 
replicate n=2) selection coefficients based on the qPCR ermF gene prevalence 
data at day 0 and day 7, shown with standard error bars and polynomial (order 
2) line of best fit. The MSC is where the line crosses the x-axis – at 65 µg/L.  
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3.3.2.3. Ciprofloxacin (CIP) 
Initially, the qnrS gene was targeted to determine the MSC of CIP. The qPCR 
data is shown in Figure 41. There was no clear association of qnrS prevalence 
with CIP concentration – in the majority of treatments qnrS prevalence decreased 
over time, and there was extremely high variability between replicates despite 
repeated qPCR. For these reasons, the intI1 gene was targeted. 
 
 
Figure 41. The qPCR data (technical replicate, n=2) for the long term evolution 
experiment for ciprofloxacin. Shown is average (n=5) qnrS prevalence (qnrS 
gene copy number divided by 16S copy number) at day 0 and day 7. Shown with 
standard error bars. 
 
The intI1 qPCR data for the ciprofloxacin experiment is shown in Figure 
42, and the MSC in Figure 43. The MSC was 1.3 µg/L. Using the qPCR data, 
there was no significant difference in intI1 prevalence at day 0 between 
treatments (Kruskal Wallis). There was a significant dose-response relationship 
between intI1 prevalence at day 7 and ciprofloxacin concentration (Spearman’s 
rank, g = 0.7, p = 4.622e-10).  
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Figure 42. The qPCR data (technical replicate, n=2) for the long term evolution 
experiment for ciprofloxacin. Shown is average (n=5) intI1 prevalence (intI1 gene 
copy number divided by 16S copy number) at day 0 and day 7. Shown with 
standard error bars.  
 
 
Figure 43. Average (biological replicate n=5, qPCR replicate n=2) selection 
coefficients based on the qPCR intI1 gene prevalence data at day 0 and day 7, 
shown with standard error bars and polynomial (order 4) line of best fit. The MSC 
is where the line crosses the x-axis - at 10.5 µg/L. 
 
A range of GLM models and respective links were explored using the 
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Akaike Information Criterion (AIC) value of -53, indicating an excellent fit, and the 
residuals were normally distributed (Shapiro Wilks test, p = 0.055). However, the 
deviance of residuals was 90 and there was slight overdispersion (1.8). The 
quasi-poisson model indicated a better fit due to the deviance of residuals being 
18; however, the residuals were slightly non-normally distributed (Shapiro Wilks 
test, p = 0.043). The quasi-poisson model also suffered from slight 
underdispersion (0.37); however this is preferable as it increases the chances of 
underestimating significance (as opposed to overdispersion, which may lead to 
overestimation of significance (Thomas et al., 2017)).  
To combat the non-normalcy of the data, prevalence at day 7 was 
transformed (square root). The data was still non-normal following transformation 
(Shapiro Wilks test p = 1.76e-05 and p = 0.001, respectively), but was used in 
different GLMs. Again, the Gamma and quasi-poisson GLMs provided the best 
fit, and using the transformed data reduced the deviance of residuals to 29 and 
9, respectively. Concurrently, the AIC for the Gamma model reduced to 14. 
However, the residuals for the Gamma model were not-normally distributed 
(Shapiro Wilks test, p = 0.02). Using the transformed data, the residuals for the 
quasi-poisson were normally distributed (Shapiro Wilks test, p = 0.86); however, 
there was greater underdispersion (0.18) than with the previous quasi-poisson 
model. 
The ciprofloxacin LOEC (where a significant difference (p <0.05) in intI1 
prevalence was observed) was 15.63 µg/L for the quasi-poisson non-transformed 
data; however, with the transformed data, there was only a trend for significance 
at 15.63 µg/L (p < 0.1). This reduction in significance is likely due to the increased 
underdispersion when using the transformed data. Therefore, based on these 
findings, the quasi-poisson GLM with square root link function for the 
untransformed data was chosen to determine the statistically derived LOEC. 
There was a significant difference (p < 0.05) in intI1 prevalence at day 7 at the 
ciprofloxacin concentration of 15.63 µg/L, and all concentrations above (Quasi-
poisson GLM, F = 18.26, df = 11, 48, p = 1.415e-13, adjusted R2 = 0.76).  
 
3.3.2.4. Trimethoprim (TRMP) 
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The qPCR data for the TRMP experiment is shown in Figure 44, and the MSC in 
Figure 45. The MSC was 24 µg/L. Using the qPCR data, there was no significant 
difference in intI1 prevalence between treatments at day 0 (Kruskal Wallis). There 
was a significant dose-response relationship between intI1 prevalence at day 7 
and TRMP concentration (Spearman’s rank, rs = 0.91, p < 2.2e-16). 
 
 
Figure 44. The qPCR data (technical replicate, n=2) for the long term experiment 
evolution experiment for trimethoprim. Shown is average (n=5, except 4000 µg/L 
which was n=3) intI1 prevalence (intI1 gene copy number divided by 16S copy 
number) at day 0 and day 7. Shown with standard error bars. 
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Figure 45. Average (biological replicate n=5, qPCR replicate n=2) selection 
coefficients based on the qPCR intI1 gene prevalence data at day 0 and day 7, 
shown with standard error bars and linear line of best fit. The MSC is where the 
line crosses the x axis, here at 24 µg/L.  
 
 A range of GLM models were fit to the intI1 prevalence data at day 7. The 
best was a Gamma GLM model with square root link, using transformed data 
(square root). Residuals were normally distributed (Shapiro Wilks test, p = 0.20), 
it had the lowest deviance of residuals of all models tested, and the lowest AIC 
value (-34) of all models tested (where applicable). Residuals were also 
homoscedastic. Using this GLM, day 7 intI1 prevalence was significantly different 
(p < 0.0001) to 0 at the trimethoprim concentration of 62.5 µg/L and above 
(Gamma GLM, F = 26.85, df = 9, 38, p = 7.939e-14, adjusted R2 = 0.83). 
To be comparable with the cefotaxime data, a Dunn’s test was also 
performed. Using this test, concentrations at 62.5 µg/L and above were 
significantly different to the control (p < 0.05). 
 
Table 7. Summary of the statistical tests performed for each antimicrobial and the 
endpoints determined. For Spearman's Rank column, values in bold are the rs 
value, italics is the corresponding p value. ‘KW’ = Kruskal Wallis test, * = with 
ANOVA.  
Antimicrobial Spearman’s 
Rank 
Day 0 prevalence 
KW 
Statistical LOEC 
(µg/L) 
MSC (µg/L) 
TAX 0.681258 0.4716 125 30 
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2.594e-07  
CLA 0.02906765  
0.8606 
 
0.8* 
 
750 65 
 
CIP 0.7005894 
4.622e-10 
0.2496 
 
15.625 10.5 
TRMP 0.9139325 
< 2.2e-16 
0.4276 62.5 24 
 
Table 8. The estimated MSCs and experimentally derived LOECs in µg/L, derived 
in this study. TAX = cefotaxime, CLA = clarithromycin, CIP = ciprofloxacin, TRMP 
= trimethoprim. Also shown is the fold difference between the two values 
(LOEC/MSC, rounded to 1 decimal place). Experimentally derived MSCs marked 
with a * were determined by Dunn’s test; all others were fit to GLMs. Significance 
= p <0.05.  
Antimicrobial MSC (µg/L) Experimentally 
derived 
LOEC(µg/L) 
Growth 
based 
LOEC 
(µg/L) 
Fold difference 
(LOEC/ MSC) 
Fold difference 
(growth LOEC/ 
MSC) 
TAX 0.4 125* 31.25 312.5 78.13 
CLA 65 750* 5000 11.54 76.92 
CIP 10.5 15.63 1.95 1.49 0.19 
TRMP 24 62.5 31.25 2.60 1.30 
 
3.3.3. Statistical comparison of methods 
Bland-Altman plots were generated to compare the endpoints determined using 
the three different approaches – long term selection coefficient MSCs, long term 
LOECs, and growth based LOECs. This demonstrates whether the variation 
between two sets of measurements are constant, as opposed to whether a 
significant relationship exists (or not) between two measurements from two 
different methods (which would be determined with a correlation). Plots where 
the line of equality of differences (0 on the y axis) resides within the 95 % 
confidence intervals (shown here in brown) around the mean of the differences 
(shown here in red), indicate good agreement between the two methods of 
measurement (i.e. acceptable bias (Giavarina, 2015)). The light blue and dark 
blue lines represent the upper and lower 95% agreement limits; and upper and 
lower 95% confidence limits for these agreement limits, respectively.  
Figures 46 – 48 are Bland-Altman plots comparing: MSCs with long term 
statistically derived LOECs, MSCs with growth based LOECs, and long term 
statistically derived LOECs with growth based LOECs (respectively). All three 
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methods are in good agreement with each other, but the smallest critical 
difference was between the long term and growth based LOECs, indicating these 
provide the most similar endpoints (Figure 48). 
 
 
Figure 46. Bland-Altman plot with 95 % confidence intervals (shown in brown and 
blue), using the log transformed MSC and statistical LOEC for the long term data. 
The 95 % confidence intervals (brown, dashed lines) around the mean 
differences (red dashed line) must encompass 0 on the y axis (i.e. complete 
equality between measurements) in order for the bias between measurements to 
be acceptable.  
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Figure 47. Bland-Altman plot with 95 % confidence intervals (shown in brown and 
blue), using the log transformed MSC and the growth LOEC data. The 95 % 
confidence intervals (brown, dashed lines) around the mean differences (red 
dashed line) must encompass 0 on the y axis (i.e. complete equality between 
measurements) in order for the bias between measurements to be acceptable. 
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Figure 48. Bland-Altman plot with 95 % confidence intervals (shown in brown and 
blue), using the log transformed LOECs from the long term and growth 
experiments. The 95 % confidence intervals (brown, dashed lines) around the 
mean differences (red dashed line) must encompass 0 on the y axis (i.e. complete 
equality between measurements) in order for the bias between measurements to 
be acceptable. 
 
3.3.4. Utility of the growth based assay with different bacterial communities 
As a brief pilot experiment, the growth based assay was repeated with TAX using 
untreated waste water or treated waste water (effluent). The growth of these two 
complex communities is shown in Figure 49 and 50. The initial starting bacterial 
density was much lower in the effluent (Wilcoxon rank sum test, p < 0.001), 
leading to a longer lag phase. As with the influent experiments for multiple 
compounds, selected time points (namely 6, 9, 12 and 24 hours) were assessed 
for the strength of a dose-response relationship using a Spearman’s rank test for 
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correlation. The rs and p values for the relationships for both the influent and 
effluent communities are summarised in Table 9. The dose response relationship 
was apparent at 6 hours for the influent and 9 hours for the effluent; however, the 
dose-response relationship was apparent in effluent up until the 24 hour time 
point. Interestingly, at 12 hours, there was a significant positive correlation 
between growth and antibiotic concentration (Spearman’s rank, rs = 0.54, p = 
0.002). This means there was higher growth with antibiotic than without – which 
is also apparent until 24 hours (though the correlation is no longer significant by 
this point) for the majority of concentrations (Figure 49). This is the case for all 
concentrations exceeding 39.06 µg/L.  
Dunn’s tests were used to calculate the growth based LOEC at the time 
point with the most significant negative correlation between growth and TAX 
concentration, for both influent and effluent. LOECs in both complex communities 
were 39.06 µg/L using this approach (Dunn’s test, p < 0.005). For the influent 
community, Dunn’s tests performed at the other time points yielded different or 
no significant differences; whereas in the effluent community, the LOEC 
remained the same no matter the time point chosen.  
 
 
Figure 49.  Average (n=6) growth (optical density measured at 600 nm) of the 
influent community in the presence of different concentrations (µg/L) of 
cefotaxime, over 24 hours. Shown with standard deviation bars. 
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Figure 50. Average (n=6) growth (optical density measured at 600 nm) of the 
effluent community in the presence of different concentrations (µg/L) of TAX, over 
24 hours. Shown with standard deviation bars. 
 
Table 9. The rs (bold) and p (italicised) values for Spearman's rank correlations 
performed at different time points during growth rate assays of influent and 
effluent complex communities under TAX exposure. 
Community 6 hours 9 hours 12 hours 24 hours 
Influent -0.6522644 
2.866e-06 
 
0.1271957 
0.4221 
 
0.5382491 
0.0002362 
 
0.1158957 
0.4648 
 
Effluent -0.5173414  
0.0004508 
 
-0.7652939 
3.582e-09 
 
-0.7141509  
1.093e-07 
 
-0.6443013 
4.138e-06 
 
 
3.3.5. Pilot test at lower temperature and lower nutrient levels 
A brief pilot experiment was conducted to assess the growth of the influent and 
effluent complex communities at lower temperature (20 °C), in broth and also M9 
buffer (lower nutrient). As this was a simple pilot study, data in Figure 51 are 
based on a single replicate only. At lower temperatures but still with high nutrient 
levels, both effluent and influent communities reach exponential phase within a 
day. However, in M9 buffer, exponential growth phase begins around the same 
time (a day), but growth thereafter is much slower. The effluent community grew 
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better than the influent community in M9, with a higher final OD and longer 
exponential growth phase. 
 
 
Figure 51. Growth of influent and effluent complex communities at low 
temperature (20°C) in broth (A) and M9 buffer (B), over time. Single replicate 
only. 
 
3.4. Discussion 
 
3.4.1. Targeted genes 
The qnrS gene proved to be a poor gene target for determining an MSC for CIP, 
with prevalence frequently decreasing over time, and high variability between 
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the fact qnr copy number can greatly influence fluoroquinolone MIC (Redgrave et 
al., 2014), and perhaps the qnr gene family should have been targeted instead of 
a single variant. In addition, the reduction on MIC by qnrS is small, and can result 
in increased levels of resistance by facilitating mutation-based resistance to arise 
(e.g. gyrA (Kehrenberg et al., 2007)). It may also be a result of the variety of 
resistance genes present in the complex community – where other resistance 
mechanisms, perhaps with lower fitness costs or that conferred increased 
resistance, were preferentially selected for over qnrS.  
However, the intI1 gene proved to be a good target for both CIP and 
TRMP, exhibiting a dose response relationship with antibiotic concentration. 
Selection for this gene aIso indicates co-selective potential of a compound, as 
gene arrays within class 1 integrons often harbour multiple different resistance 
genes conferring resistance to multiple antibiotic classes (Partridge et al., 2009). 
Use of intI1 compared to other gene targets should be assessed, as it may be a 
suitable proxy for all resistance genes. This concurs with previous literature which 
propose intI1 prevalence as a marker of anthropogenic impact and resistance 
gene prevalence (Berglund et al., 2014, Kotlarska et al., 2014, Gillings et al., 
2009, Gaze WH, 2011, Gaze et al., 2005, Abella et al., 2015b, Gillings MR, 2008, 
Gillings et al., 2015, Amos et al., 2015, Jechalke et al., 2013). 
 
3.4.2. MSCs and PNECRs 
The MSCs and LOECs determined in this chapter using long term data were 
compared to previously available MSCs, PNECs and MECs. The MSCs would be 
more protective against resistance selection in the environment than statistically 
derived LOECs based on gene prevalence, as they are less effected by large, 
inherent variations in complex bacterial community treatment replicates. They are 
also based on qPCR data, shown previously to be the most sensitive methods 
used to determine effect concentrations (Lundstrom et al., 2016).  
Conversely statistically derived LOECs are empirical (not estimated). As 
they are based on direct, quantitative measures, they could be considered as an 
acute effect concentration, and an assessment factor of 1000 (Straub, 2013) 
could be used to calculate an acute PNECR. Table 10 shows the MSCs and 
PNECRs (long term LOEC/1000) determined in this chapter, alongside the 
previous predicted PNECR (Bengtsson-Palme and Larsson, 2016). 
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The CLA MSC was 65 µg/L and the LOEC was 750 µg/L. PNECs reported 
here are over 100 and 1000x lower than these two values, indicating the 
ecotoxicological PNECs may be protective. Even with the LOEC converted to a 
PNECR (0.75 µg/L), the ecotoxicological PNECs remain protective. 
The CIP MSC was 10.5 µg/L. This in within the range of MSCs determined 
previously for chromosomal resistance mutations (Gullberg et al., 2011); however 
it exceeds the reported PNECs by around 2 orders of magnitude. The long term 
LOEC was higher, at 15.63 µg/L. In which case, both the MSC and statistical 
LEOC as a PNECR would indicate current ecotoxicological tests are protective 
against resistance gene selection.  
For TRMP, the MSC was 24 µg/L. The previously derived MSC using a 
resistance plasmid harbouring a dhfr gene was 33 µg/L (Gullberg et al., 2014). 
Although these values are very similar, community effects may reduce MSCs; 
this was observed when comparing the single species and community data in 
chapter two; though this large disparity was probably due to indirect selection due 
to the sociality of the resistance mechanism. Compared to the previously reported 
PNECs presented at the beginning of this chapter, the acute toxicity PNEC is 
protective against selection (using the MSC endpoint); however, the chronic 
PNEC is not. The calculated PNECR based on the above data (i.e. the LOEC with 
safety factor applied), suggests the reported ecotoxicological PNEC is not 
protective of resistance selection for neither acute nor chronic exposure.  
When comparing PNECRs to previously estimated PNECs for resistance 
(Table 10), remarkably, the cefotaxime PNECR and estimated PNEC for 
resistance were identical (both 0.125 µg/L). Unfortunately when considering all 
compounds tested in this study, neither the PNECR (this study) nor predicted 
PNECR (Bengtsson-Palme & Larsson, 2016) were consistently the most 
protective indicating that though the estimates appear useful in guiding 
experiments to determine MSCs or LOECs, actual experimental data is still 
required in order to be fully protective of the environment. 
 
3.4.3. Assessing the risk of resistance selection in situ 
The risk quotient (RQ) is determined as the either the Predicted Environmental 
Concentration (PEC) or MEC/PNEC. If >1, there is an estimated, or real risk to 
the environment, respectively. Table 10 summarises the lowest MSCs and 
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PNECRs (LOEC/safety factor of 1000) determined in this study; previously 
estimated PNECRs (Bengtsson-Palme and Larsson, 2016), MECs and calculated 
‘real’ RQs. This captures the different possibilities to analyse effect 
concentrations, in terms of real world implications.  
CLA poses the most significant risk to the environment in terms of 
resistance selection, with extremely high RQs for both the MECs reported here 
(the highest MECs for the respective environments, according to the 
UmweltBundesamt database (2016)), irrespective of effect concentration used 
(i.e. MSC or PNECR). CIP also poses a significant risk to the environment as it 
has extremely high RQs, regardless of environmental compartment or whether 
the MSC or PNECR is used. Conversely, the selective potential of TRMP is only 
hazardous when using PNECR data. The risk of TAX selecting for resistance in 
hospital effluent is incredibly high when using PNECR data, indicating this could 
be a hotspot for resistance selection. However, there is a possible risk even in 
waste water effluent when using PNECR to calculate the RQ. 
 
Table 10. Table showing the MSCs and PNECRs determined in this study 
alongside previously estimated PNECRs. MECs shown are the highest reported 
MECs for a particular environmental compartment in the Umweltbundesamt 
database (2016); or by Gomez et al. (2007) (indicated by ‘*’). RQs are derived by 
MEC/MSC or PNECR: red, yellow and green RQ’s represent unacceptably high, 
medium and low risk respectively. 
Antibiotic MSC 
(µg/L) 
PNECR 
(µg/L) 
This 
study 
PNECR (µg/L) 
(Bengtsson-
Palme and 
Larsson, 
2016) 
MEC in µg/L 
(environmental 
compartment)  
RQ 
(MSC) 
RQ 
(PNECR, 
this 
study) 
RQ (PNECR, 
Bengtsson-
Palme and 
Larsson, 
2016) 
TAX 0.4 0.125 
 
0.125 150 (hospital 
effluent)*  
0.09 (waste 
water) 
375 
 
0.225 
1200 
 
0.72 
1200 
 
0.72 
CLA 65 0.75 0.25 14,600 (WWTP 
effluent) 
100 (surface 
water) 
224.61 
 
1.54 
19466.67 
 
133.33 
58400 
 
400 
CIP 10.5 0.156 
 
0.064 54.05 (hospital 
effluent) 
5.15 
 
346.47 
 
844.5 
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3.7 (waste 
water)  
0.35 23.72 57.81 
TRMP  24 0.063 0.5 1.5 (hospital 
effluent) 
1.81 (waste 
water) 
0.06 
 
0.08 
23.81 
 
18.73 
3 
 
3.62 
 
3.4.4. Growth based assays for rapid data generation 
The MSCs estimated for the long term assay data using selection coefficients 
were consistently lower than using statistical based LOEC methods. This is likely 
due to the extremely high variation between replicates meaning that traditional 
statistical techniques underestimate the threshold at which biological effects 
occur. Though this is expected in a natural, complex community, this no doubt 
affects the power of the statistical test. This could be overcome by increasing 
replication; however this would also greatly increase sample processing time 
(which may compromise the data quality, i.e. if day 0 samples were incubated 
with antibiotic for a prolonged time period before being processed), as well as 
data generation costs (increase number of samples requiring qPCR analysis).  
This problem does not apply to the growth rate assay as during the 
exponential growth phase, samples within each treatment exhibit, in relative 
terms, extremely low variability (Figures 31 - 37, which show standard deviation). 
Furthermore, if additional replicates were required, this could be easily be 
achieved with the growth based assays, which are conducted in 96 well plates. 
In this chapter, six replicates were sufficient to generate LOECs that were highly 
comparable to MSCs derived from long term assays. Using the percentage of 
average differences as opposed to actual differences for generating Bland-
altman plots would have been preferable as the measurements spanned a large 
concentration range (Giavarina, 2015); however, percentage differences were 
not normally distributed and so were unusable. Log transforming the original 
measurement data in this case was preferable, as the differences were then 
normally distributed, and the large disparity between concentration 
measurements was adjusted. 
Growth based assays are simple, quick and cheap. They lend themselves 
to validation according to OECD guidelines (OECD, 2005) to be used in ERA, as 
the lack of time, money and specialist equipment required facilitates inter-
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laboratory testing, and high reproducibility. Growth data can be generated and 
analysed for a minimum of 2 compounds per day, meaning MSC data could be 
rapidly produced for ERA. In time, the assay could be further developed to test 
different bacterial communities, though these would need to be individually 
optimised. This was shown with the pilot effluent experiment, which likely due to 
the reduced bacterial density at the start of the experiment required longer to 
exhibit the strongest dose response relationship (at 9 hours instead of at 6). 
Critically the effect concentrations derived using these two different time points 
were the same, suggesting the assay is likely to be reproducible with a range of 
complex community inocula. Further experiments are required to confirm that this 
approach will always yield the same LOEC. In addition, the dose response 
relationship in the effluent extended over the majority of the duration of the assay, 
indicating effluent could be a better inoculum were this assay standardised to a 
single complex community. However, without further experiments, it is unknown 
whether this is a cell-density or community effect. Also noted was that, in some 
cases, growth of the complex community was higher towards the end of the 
experiment in the presence of the antibiotic than without (for CLA, ERY and TAX 
influent). This suggests adaptive shifts in the community, and or utilisation of 
degraded antibiotics as a carbon source. 
To overcome the issue of the growth phases emerging at different time 
points, the starting density of the assay could be standardised; or pilot assays 
could be used to pinpoint the exponential growth phase and then the most 
significant dose-response relationship determined, to be used as the assay 
‘endpoint’. The latter is recommended, particularly if the assay were to be 
developed to be more environmentally relevant (e.g. through reducing incubation 
temperature, or nutrient content); as slower growing communities would likely be 
favoured by these conditions so the 6 hour time point is unlikely to be 
transferable. Indeed, the simple pilot experiment comparing the growth of influent 
and effluent showed that growth of the effluent based community was better in 
lower temperature and lower nutrient than the influent which may be due to 
adaptation to lower environmental temperatures.   
 Finally, another strength of the growth based assay compared to the long 
term experiments is that it does not limit the MSC estimation to a particular gene, 
or gene class. As it examines phenotypic differences in growth rate, this will 
capture any competition and selection occurring for all the available resistance 
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genes and mutations present in that community. This is in keeping with the 
traditional definition of a MSC – defined as the point at which there is reduction 
in growth rate of susceptible bacteria (Figure 3 chapter two, taken from Gullberg 
et al. (2011)). 
 The growth based LOECs could also be used to inform the concentration 
ranges for future, long term experiments. The MSCs for AZ and ERY are 
predicted to be between 42 and 1000 µg/L and 1053 and 25,000 µg/L, 
respectively – when using ermF as the gene target. The upper boundary is the 
growth based LOEC, and the lower boundary is this value divided by the average 
fold difference (23.75) between the growth LOEC and MSC for all compounds in 
this study (Table 8). Long term experiments should be performed to elucidate the 
accuracy of these estimations.  
 
3.5. Conclusions  
For the first time, different methods for determining antimicrobial MSCs and 
LOECs in the same experimental system have been directly compared. Data was 
generated for a range of antimicrobials spanning different drug classes; through 
assessing both genotypic effects (target gene prevalence) and phenotypic effects 
(growth based assay). Genotypic data was used to derive MSCs and LOECs, 
and phenotypic (growth based) data was also used to derive LOECs. All methods 
were compared using Bland-Altman plots to assess the level of agreement 
between different methods, which was high. 
This study indicates a real risk of in situ selection occurring in the 
environment, (based on RQs calculated from MSCs or PNECRs, and MECs) for 
certain compounds, or in certain environmental hotspots, such as hospital 
effluent. Further work should continue to determine MSCs and RQs for selection 
by different compounds, and the environmental applicability of the tests should 
be assessed. 
Repeatedly, it has been shown there are no rules which can be applied to 
all antimicrobial compounds, which can be used to accurately estimate MSCs - 
they will need to be determined on a case by case basis. Growth based assays 
are shown here to be a rapid, simple and cheap method to reliably estimate MSC 
data, which are currently severely lacking. 
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Chapter four: Using PCR and next-generation sequencing to study class 1 
integron array diversity under selective pressure 
 
4.1. Introduction  
4.1.1. Integrons 
Integrons are genetic backbones which often carry multiple antibiotic resistance 
gene cassettes in ‘arrays’ (Partridge et al., 2009). Most gene cassettes do not 
carry their own promoter, which affects expression of the genes in the array. 
Class 1, 2 and 3 integrons contain a Pc promoter in intI, which promotes 
expression of downstream gene cassettes with decreasing expression the more 
distal the gene (Partridge et al., 2009, Hall, 2012). Infrequently, a gene cassette 
can mobilise into a plasmid or other DNA without the attI site being present, but 
the gene will remain unexpressed unless its cassette also carries a promoter, or 
its new location is downstream of a promoter (Hall, 2012). Integrase expression 
can be induced by antibiotics (Baquero et al., 2013) sometimes under the control 
of the SOS response, which is also induced by low concentrations of antibiotics 
(Guerin et al., 2009, Guerin et al., 2010, Guerin et al., 2008). This means novel 
(to the host) resistance gene cassettes can be acquired or pre-existing resistance 
cassettes can be reshuffled nearer to the promoter, increasing their expression. 
Conversely, reshuffling of resistance cassettes away from the promoter allows 
genes to be silenced (i.e. to reduce fitness cost), which may be another 
mechanism whereby resistance may be maintained in the complete absence of, 
or in presence of only low concentrations, of antibiotics (Guerin et al., 2009). 
Little is known about class 1 integron expression gene cassette array 
dynamics, particularly in a complex microbial community, or when exposed to 
sub-lethal, antimicrobial concentrations. These antimicrobial concentrations are 
becoming more relevant to the study of antimicrobial resistance, owing to an 
increasingly large body of work indicating that selection for antibiotic and 
antimicrobial resistance can occur at very low antimicrobial concentrations at the 
chromosomal and plasmid level (Negri et al., 2000, Negri et al., 2002, Gullberg 
et al., 2014, Gullberg et al., 2011). The lack of understanding of integron diversity 
and gene cassette array plasticity is in part due to a lack of suitable methods, 
discussed further below. The aim of this study was to design a novel method to 
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study gene cassette diversity and their arrangement in class 1 integrons 
harboured by bacteria within a complex bacterial community, and whether these 
are affected by different selective pressures.  
 
4.1.2. Class 1 integrons 
Class 1 integrons comprise of a 5’ conserved sequence (CS) which includes the 
integrase (intI1) gene, attI site and the Pc promoter; and a 3’CS which often 
includes a qacEΔ1 gene, sul1 gene and orf5 (an ORF with unknown function 
(Canal et al., 2016)). Integration of free gene cassettes is performed by intI1 
between the attI site on the integron, and the attC site (sometimes known as the 
59 base element (Mazel, 2006)) present on the gene cassette. The gene cassette 
closest to Pc is most strongly expressed; the gene cassette furthest downstream 
in the array is expressed the least (Partridge et al., 2009). ‘Complex’ class 1 
integrons have also been described, which can harbour additional resistance 
gene cassettes between insertion sequences and partial copies of the 3’ CS 
(Partridge et al., 2009). 
Class 1 integrons are often described as being good indicators of 
anthropogenic impact, pollution and presence of antibiotic resistance genes; and 
can be found both in bacteria in the clinic and in natural environments (Berglund 
et al., 2014, Kotlarska et al., 2014, Gillings et al., 2009, Gaze WH, 2011, Gaze et 
al., 2005, Abella et al., 2015b, Gillings MR, 2008, Gillings et al., 2015, Amos et 
al., 2015, Jechalke et al., 2013). Class 1 integrons are usually more abundant 
than other integron classes (Stalder et al., 2013) and are therefore key vectors 
for the transmission of antimicrobial resistance, both within and between natural 
and man-made environments as they can integrate a number of genes conferring 
resistance to both antibiotics and biocides. The class 1 integrons have therefore 
been chosen for investigation in this study. 
 
4.1.3. Previous methods studying integron gene cassette diversity 
Understanding the impact of different selective pressures on integron prevalence, 
gene cassette diversity and gene cassette location (in relation to Pc), is critical 
for understanding the mobilisation of antimicrobial resistance genes from the 
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clinic to the environment, and vice versa. However, both gene cassette diversity 
and location are still relatively understudied due to several methodological issues.  
Class 1 integrons are at relatively low abundance in the metagenome (so 
study by shotgun metagenomics often does not have enough depth). Primer 
walking (with Sanger sequencing) could be used to determine downstream 
primer sites, but this is slow, laborious and is not high-throughput enough to 
ensure the target is representative of the metagenome. Integrons cannot be fully 
amplified by conventional PCR without bias for two main reasons. Firstly, 
potentially very long gene cassette arrays could be present. These often contain 
many repeats (Partridge et al., 2009) which could compromise amplification. 
Second, using specific primers (based on a priori knowledge of downstream 
sequences) results in amplifying the same type of integron repeatedly introducing 
significant bias, meaning much diversity could remain uncaptured.  
Despite these caveats, integrons and associated cassette diversity have 
generally been investigated with PCR. There have been several studies which 
have used the primers developed by Levesque et al. (1995), which target the 5’ 
and 3’ CS’s in class 1 integrons (Canal et al., 2016, Stalder et al., 2013, Zhang 
et al., 2009a). However, the length of these amplicons was only approximately 
1600 bp, and single colonies were used as the PCR template (Zhang et al., 
2009a, Canal et al., 2016). Therefore only ‘simple’ class 1 integrons were studied, 
and within that group, only a few gene cassettes captured. Further bias arises 
from targeting gene cassettes from a small subsample of bacterial isolates, as 
opposed to the whole community. Indeed, the integron-bearing colony may be 
multidrug-resistant, but the gene cassettes found may only confer resistance to 
a few compounds (Canal et al., 2016). While this could be due to resistance 
genes being harboured elsewhere (e.g. chromosomally, on plasmids or within 
other integron classes), it could also indicate incomplete capture of gene 
cassettes.  
Another primer pair was developed by Stokes et al. (2001) which targets 
the 59 base element (attC site) on gene cassettes. This allowed characterisation 
of gene cassettes within total environmental DNA, a significant improvement on 
PCR performed on individual isolates. However, this is still likely to bias for 
shorter gene cassette arrays due to competition during PCR amplification. This 
approach therefore still does not fully capture all gene cassette diversity (Stokes 
et al., 2001) and no information on integron class or location within the array is 
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generated. Since the original publication, amplicons generated using the 59 base 
element primers have been sequenced with Illumina (similar to a 16S amplicon 
sequencing approach). This newly developed, high-through put method has been 
used to characterise gene cassette function in different environments, and relate 
this to anthropogenic impact (Gatica et al., 2016).  
Another method was developed recently which makes use of the next-
generation sequencing (NGS) platform developed by Pacific Biosciences 
(PacBio) and PCR. Inverse PCR was used to amplify outward from selected 
antibiotic resistance genes, to determine their mobilisation potential by searching 
for mobile genetic elements such as integrons (Pärnänen et al., 2016). While this 
method overcomes the issues arising from lack of depth when using 
metagenomics, this is not a complete picture of gene cassette diversity as 
resistance genes are selected a priori. Additionally, the method is not integron 
specific. 
 
4.2. This study  
This study aimed to develop a novel, unbiased PCR method to amplify gene 
cassette arrays present in class 1 integrons. This method is theoretically 
unbiased due to the use of unspecific, downstream primer sites. Long-range PCR 
was used to generate long amplicons. Amplicons were sequenced using PacBio 
NGS technology, to sequence amplicons in a single read. 
 
4.2.1. A novel PCR approach: FUN-PCR 
FPNI (fusion primer and nested integrated) PCR is a method that was developed 
for rapid chromosome walking, as it can be used to walk from a region with known 
DNA sequence to a region of unknown DNA sequence. The basic premise is the 
use of a forward primer based on a known DNA sequence, and a mixture of 
random, degenerate reverse primers (which also contain a known sequence at 
the 5’ end, the ‘fusion’ sequence). These are used in a PCR reaction with high 
and low stringency cycles to allow amplification of specific product from the 
forward primer; and a mixture of unspecific and specific product from the reverse 
primers. Subsequent rounds of nested PCR based on the known, specific regions 
amplified with the forward primer, and the conserved regions (‘fusion’ regions) in 
151 
 
the reverse primers eliminate non-specific products (Figure 52 (Wang et al., 
2011)): “In the first PCR step, single stranded copies of the target template are 
generated in the high stringency cycles, and double stranded products are 
produced in the low stringency cycle (in total, involving 3-5 repeated PCR cycles); 
in this primary step, amplification of the target products is likely to be 
accompanied with other, nonspecific, products. In the secondary and tertiary 
PCR steps (nested PCR), the target DNA is exponentially amplified by the gene 
specific and adaptor specific primers, while non-target genes are not amplified 
because there is no corresponding gene specific primer (and/or amplification was 
suppressed by the stem-loop structure of the DNA).” In the current study, FPNI 
PCR was modified using reverse primers based on Type II DNA restriction sites. 
This method has been termed FUN (Fusion Unspecific Nested) -PCR.  
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Figure 52. Figure 2 taken from Wang et al. (2011). “A general (theoretical) 
scheme for FPNI-PCR (PCR based method for genomic walking or tagged 
flanking sequence cloning).”  
 
Type II restriction sites have been used for recombinant DNA technology 
in molecular biology since the discovery of the first restriction enzyme HindII in 
1970 (Loenen et al., 2014). Restriction sites are conserved DNA sequences 
ranging from 4 bp to 9 bp in length. The length of the restriction site is linked to 
how frequently the site will appear in any given DNA sequence; therefore the 
longer the restriction site, the less likely and therefore less frequently it will 
 
This image has been removed by the author of this thesis/dissertation for copyright 
reasons 
153 
 
appear. Here, a range of different reverse primers containing different length 
restriction sites (and a conserved ‘fusion’ sequence for subsequent rounds of 
nested PCR) were tested, and compared to the use of a primer used previously 
targeting the qacEΔ1 gene (Gaze et al., 2011). Following subsequent rounds of 
nested PCR, amplicons were sequenced using SMRT (Single Molecule Real-
Time) sequencing developed by PacBio. 
 
4.2.2. Use of PacBio NGS 
PacBio sequencing is a NGS method that offers an average read length of > 
10,000 bp, an N50 of over 20,000 bp and a maximum read length of in excess of 
60,000 bp (Rhoads and Au, 2015). This is useful for investigating integron 
diversity, as longer read length will be unaffected by long stretches of repeats, 
which are often found in integrons (Partridge, 2009). Additionally, larger gene 
cassette arrays maybe be sequenced in a single read. Though PacBio 
sequencing has lower accuracy than other NGS methods (the error rate is 11 – 
15 %), this can be mitigated through increased coverage, by repeatedly 
sequencing smaller length reads (Rhoads and Au, 2015).  
 
4.2.3. Studying the effects of different selective pressures 
In this study, amplicons around 1 – 5 kb in length generated by FUN-PCR 
underwent PacBio sequencing. The DNA template was from an experimental 
evolution experiment where a natural, complex, bacterial community (from 
untreated waste water) was exposed to sub-lethal concentrations of different 
antimicrobials (two antibiotics and one biocide) in daily passage experiments for 
7 days. Selective compounds were the quaternary ammonium compound (QAC) 
benzalkonium chloride (BKC), and two antibiotics trimethroprim (TRMP) and 
ciprofloxacin (CIP) which have been classed as ‘essential’ antibiotics by the WHO 
(WHO, 2017). Further rationale for selecting these compounds in terms of 
environmental and clinical relevance can be found in chapter three. This 
experimental system is based on the previous studies designed for determination 
of minimal selective concentrations (MSCs) for several different antibiotics (see 
chapters two and three).  
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4.2.4. Author contributions 
I applied successfully for the MRC Clinical Infrastructure pilot project, grant 
number: MR/M008924/1 which covered costs for PacBio SMRT cells and staff 
time at Exeter Sequencing Service (ESS) to prepare libraries, sequence and 
perform initial quality analysis of sequence data (equating to ~£2000).  
I designed and performed the evolution experiment and subsequent 
sample preparation. Lihong Zhang selected the restriction enzyme sites and 
advised on primer design. I designed all primers and performed all PCR 
optimisation steps and final PCRs; as well as DNA preparation and quality 
control. Library prep, size fractionation and sequencing was overseen and 
undertaken by Karen Moore and Jeremie Poschman of ESS.  
Demultiplexing of sequences was performed by Paul O’Neill of ESS. I 
designed the sequence analysis pipeline, performed all sequence analysis and 
data analysis. 
  
4.3. Materials and Methods 
4.3.1. Evolution experiment 
Untreated waste water collected from Falmouth sewage treatment plant (serves 
population of 43,000), Cornwall, UK in October 2015 was used as the natural, 
complex bacterial community sewage inoculum. This was washed by spinning 
down and resuspension in equal volume 0.85 % sterile saline twice before use. 
Iso-sensitest broth (Oxoid) was inoculated with a 100x dilution of this suspension 
and split into 3 replicates for each compound, and for the no treatment control.  
Selective compounds used were BKC, CIP and TRMP at half the clinical 
breakpoint concentrations (EUCAST, 2014) or MIC (see chapter five for BKC 
MIC) for Enterobacteriaceae, equating to 8 mg/L, 0.5 mg/L and 2 mg/L 
respectively. The microcosms were then incubated overnight at 37 °C, shaking 
at 180 rpm.  
Each day a 100x dilution of the overnight culture was inoculated into fresh 
media containing the same selective compound. This was repeated for a total of 
6 days. On the 7th day, 500 μl overnight culture was spun down at full speed for 
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2 minutes and resuspended in equal volume of 20 % glycerol, and stored at -80 
°C. 
 
4.3.2. DNA extraction 
Total DNA was extracted from each replicate and 1 ml of the untreated waste 
water inoculum using the MoBio ultraclean kit, according to instructions but with 
the initial spin extended to 3 minutes. All DNA was stored at -20 °C until use. 
 
4.3.3. Primer design and PCR conditions 
All primers were synthesised by IDTDNA. Forward primers were based on the 
intI1 sequence (NCBI reference sequence NG_039604.1), and reverse primers 
comprised of a restriction site plus fusion primer sequence (for round 1 PCR); or 
two fusion sequences for nested PCR (rounds 2 and 3). Primers for barcoding 
comprised of the last nested primer and a unique barcode for PacBio sequencing, 
available online 
(https://github.com/PacificBiosciences/Bioinformatics-
Training/blob/master/barcoding/pacbio_384_barcodes.fasta). 
Table 11 contains a full list of primer sequences. All PCR reactions were 
performed with LA Taq enzyme (ClonTech) and using the cool start method (on 
ice), with optimal conditions based on gradient PCR. The reaction for the first 
PCR was as follows: 0.5 µl LA Taq, 8 µl dNTPs, 5 µl Buffer (MgCl2 plus), 2.5 µl 
IntI14 primer (10 µM), 2.5 µl reverse primer (10 µM), 5 µl template and sterilised 
water to a final volume of 50 µl. The programme was: 94 °C 1 min, two cycles of 
98 °C 10 sec, 62 °C 30 sec, 72 °C 15 min followed by 1 cycle of 98 °C 10 sec, 25 
°C 2 min, 72 °C 15 min for a total of 6 cycles; followed by 98 °C 10 sec, 62 °C 30 
sec, 72 °C 15 min for two cycles and then a final extension at 72 °C 15 min.  
The second PCR reaction was as above, but in a 20 µl reaction with IntI13 
as forward primer (10 µM) and FSP1 as reverse primer (10 µM). 1 µl of PCR 
product from PCR 1 was used as template. The programme was as follows: 94 
°C 1 min, 30x (98 °C 10 sec, 52 °C 30 sec, 72 °C 15min), 72 °C 15 min. 
The final nested PCR reaction used 1 µl of gel purified product sized 1.5 – 
10 kb (NucleoSpin) from PCR 2 diluted 100x, in a 20 µl reaction as above with 
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IntI5 as forward primer (10 µM) and FSP2 as reverse primer (10 µM). The 
programme was as above for round 2, except the annealing temperature was 
increased to 55 °C. 
The final PCR for barcoding ready for library preparation and to allow 
pooling of samples for sequencing was either a 20 or 50 µl reaction as above, but 
with forward and reverse primer volume doubled to 2 µl or 5 µl each, respectively. 
1 µl or 2.5 µl of gel purified product (1.5 – 10 kb in size) from PCR 3 diluted 10x 
or 100x to a final reaction concentration of 1 – 5 ng per 20 µl reaction was used 
as template. 
Following gel electrophoresis verification on a gel stained with ethidium 
bromide, the final PCR product was cleaned up with Zymo Clean and 
Concentrate kit into a final volume of 10 µl, according to instructions but with the 
following amendments: all spins were reduced to 13,000 x g (to reduce shearing), 
an additional wash step and additional drying step of 1 min were introduced (to 
reduce carry over of contaminants, salts etc); and the filter was incubated for 2 
minutes after the addition of elution buffer before the final spin (to increase 
recovery). This then underwent a second clean and concentrate step by repeating 
the previous procedure. All products immediately underwent QC analysis before 
being pooled according to DNA concentration and frozen at -20 °C. Samples 
remained frozen until sequencing. 
 
Table 11. Full list of primers used in this study, their sequence, gene/primer 
target, approximate product size in kb, and reference. 
Primer Sequence Target Approx. 
product  
size (kb) 
Reference 
IntI4 CATCACGAAGCCCGCCACA 
 
intI1 gene - This study 
FP1-BbvC1-1 GTAATACGACTCACTATAGGG
CACGCGTGGTNNNNNNNNCC
TCAGC 
 
BbvC1 site  This study, (Wang et 
al., 2011) 
FP2-Bsu361-1 GTAATACGACTCACTATAGGG
CACGCGTGGT NNNNNNNN 
CCTNAGG 
 
Bsu361 
site 
 This study, (Wang et 
al., 2011) 
FP3-BamH1-1 
 
GTAATACGACTCACTATAGGG
CACGCGTGGTNNNNNNNNGG
ATCC 
BamHI site  This study, (Wang et 
al., 2011) 
FP5-Taq1-1 
 
GTAATACGACTCACTATAGGG
CACGCGTGGTNNNNNNNNNN
TCGA 
 
TaqI site  This study, (Wang et 
al., 2011) 
QacEcom1r CCGACCAGACTGCATAAGCA qacE gene  (Gaze, et al., 2011) 
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IntI3 TTCGCGACGGCCTTGC 
 
intI1 gene,  
nested 
- This study 
FSP1 GTAATACGACTCACTATAGGG
C 
Primer, 
nested 
Variable (Wang et al., 2011) 
IntI5 CAGCGGTTACGACATTCGAA 
 
intI1 gene, 
nested 
- This study 
FSP2  ACTATAGGGCACGCGTGGT Primer, 
nested 
Variable (Wang et al., 2011) 
Barcode 
Forward 
e.g. 
TCAGACGATGCGTCATCAGC
GGTTACGACATTCGAA 
 
Primer, 
nested 
~5 - 10 This study 
Barcode  
Reverse 
e.g. 
GCAGAGTCATGTATAGACTAT
AGGGCACGCGTGGT 
 
Primer, 
nested 
~5 - 10 This study 
 
4.3.4. Quality control and PacBio sequencing 
All final PCR products were quantified using the QuBit fluorometer (2.0, Thermo 
Scientific) and 260/280 and 260/230 ratios determined with Nanodrop (Thermo 
Scientific). Concentrations ranged from 650 ng/μl to 1,630 ng/μl. All 260/280 
ratios were between 1.88 and 1.90 and all 260/230 ratios were between 1.66 and 
2.33. All replicates were pooled into a single sample based on DNA concentration 
to a total weight of 4.55 μg DNA per sample. 
Library preparation and sequencing was carried out by ESS. Sample was 
first size fractionated by SAGE-ELF into a smaller (1 – 5 kb) and larger (5 kb plus) 
fraction. The smaller fraction was sequenced successfully, but the larger fraction 
could not be recovered and therefore there is no data for the larger amplicons. 
 
4.4.4. Sequence analysis pipeline 
All sequences were demultiplexed by Paul O’Neill at ESS. All subsequent 
sequencing analysis was performed in a unix environment (Ubuntu).  
First, the average length of reads for each fastq file was determined: 
 $ awk 'NR%4==2{sum+=length($0)}END{print sum/(NR/4)}'input.fastq 
Then fastq files were converted to fasta files, and the number of reads 
counted: 
 $ sed '/^@/!d;s//>/;N' sample1.fastq > sample1.fasta 
 $ grep –c ‘>’ sample1.fasta 
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ABRicate (Seeman, 2017) (version 0.4) was used to identify reads 
containing intI1 which could then be binned into a new fasta file. ABRicate uses 
BLAST (version 2.2.30) software to BLAST reads against all the main antibiotic 
resistance gene databases individually – Resfinder, ARG-ANNOT, CARD and 
NCBI (as well as PlasmidFinder and VFDB (Virulence Factor Database)). The 
output is a tab delimited file containing the name of the read with the hit, the start 
and end of the hit within that read, the name of the resistance gene, % coverage, 
% identity, and the database the hit is matched to. Personal databases can also 
be created and used with ABRicate. To determine the number of reads within 
each file which contained intI1, I created a database ‘class1’ which contained a 
single fasta sequence of a class 1 integrase, truncated to the be the same size 
as the expected amplicon sequence. The original fasta sequence used for the 
design of the PCR primers was removed from the NCBI site (05/07/17), so 
another sequence was used in its place (M569736.1). This was confirmed with 
MEGA6 (Tamura et al., 2013) to contain the primer sites and have 100 % identity 
to the previous sequence for the amplicon derived following all rounds of nested 
PCR. The fasta file was in the format: “>database~~~~geneID~~~~accession 
gene details” followed by the nucleotide sequence, as specified on the github 
website for ABRicate. The commands for creating a database were as follows: 
 $ cd /path/to/databases 
$ mkdir class1 
 $ cd class1 
 $ cp /path/to/fasta/file/class1.fasta sequences 
$ makeblastdb –in sequences -title tinyamr -dbtype nucl -
parse_seqids -hash_index 
Reads with one or more integrase hits were outputted into a tab delimited file: 
 $ abricate --db class1 example.fasta > example.intI1hits.tab 
This tab delimited file was sorted in excel by the start position of the integrase 
gene hit. The read names containing intI1 hits which started within the first 75 bp 
of the sequence were saved into a new csv file. The 75 bp was selected as it is 
half of the maximum expected, known amplicon sequence (150 bp); and 25 
amino acids (i.e. 75 nucleotides) has been cited as being the minimum coverage 
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required for a hit with > 90 % identity to a known resistance gene (Yang et al., 
2013). Cut offs of > 80 % coverage and > 80 % identity were also applied. The 
lower identity was used to account for the higher error rate of PacBio of 11 – 15 
% (Rhoads and Au, 2015). 
 The reads names were then extracted from the csv file into a text file. This 
was used to bin only those reads containing intI1 from the original fasta file into 
a new fasta file: 
$ grep $'beginning_of_reads_names*' sortedhits.csv > 
readnames.txt 
$ perl -ne 'if(/^>(\S+)/){$c=$i{$1}}$c?print:chomp;$i{$_}=1 if 
@ARGV' readnames.txt original.fasta > intI1filtered.fasta 
For identifying resistance genes, intI1 filtered fasta files underwent BLAST 
against the ARG-ANNOT and CARD databases using ABRicate. CARD was 
chosen as the largest database which included resistance mutations (McArthur 
et al., 2013), and ARG-ANNOT on the basis it has been shown to generate a 
greater numbers of hits, particularly for unknown (previously identified) resistance 
determinants (Gupta et al., 2014).  
 $ abricate --db argannot intI1filtered.fasta > arghits.tab 
 $ abricate --db card intI1filtered.fasta > cardhits.tab 
A secondary database was created (see above) to BLAST for the qac resistance 
genes. Nine qac genes in total were included in the database, including the genes 
listed in the review on integron cassettes by Partridge et al. (2009), and two more 
recent reviews on qac genes (Jaglic and Cervinkova, 2012, Wassenaar et al., 
2015). Only genes with full cds were used. The genes and accession numbers 
were as follows: qacA, qacB, qacC, qacE, qacE2 (also known as qacG or qacG2 
(Partridge et al., 2009)), qacEdelta1, qacF, qacH (also known as qacI (Partridge 
et al., 2009)), and qacJ - corresponding to the accession numbers NG_048037.1,  
AF053772.1:1144-2688, U15783.1:1931-2254, U67194.4:33897-34229, 
KF856624.1:29665-30012, AF034958.3:2039-2371, AF205943.1:1374-1706 
and NG_048046.1:101-424, respectively. Filtered files were searched for qac 
genes using the ABRicate command above, with the database specified as ‘qac’. 
 The tab files were then sorted in excel. Hits were filtered based on length 
(nucleotide sequences ≥ 75, based on the previously published cut off of ≥ 25 
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amino acids (Yang et al., 2013b)) and % identity (≥ 80 % nucleic acid identity, 
reduced slightly from the 90 % amino acid identity cut off published previously 
(Yang et al., 2013b)). This was again lowered to account for the higher error rate 
of PacBio sequencing, of around 11 – 15 % (Rhoads and Au, 2015).  
 
4.4.5. Sequence data analyses 
The percentage of intI1 filtered reads containing resistance genes for each 
database was calculated for each file, and averaged across antimicrobial 
treatments. Percentage of intI1 filtered reads containing each type of resistance 
gene (for each resistance gene database) were also calculated for each file, and 
averaged across antimicrobial treatments. 
Heatmaps were generated using the python packages pandas (McKinney, 
2010), matplotlib (Hunter, 2007) and seaborn (Waskom, 2016). Statistical 
analyses were performed in R studio (RStudio, 2015). 
 
4.5. Results 
4.5.1. PCR optimisation and final primer selection 
Initially, all reverse primers (FP1-BbvC1-1, FP2-Bsu361-1, FP3-BamH1, FP5-
Taq1-1 and QacEcom1r) were tested, with the two 7 bp restriction site primers 
(FP1-BbvC1-1 and FP2-Bsu361-1) mixed 1:1, using the untreated waste water 
DNA as template. The low stringency cycle’s annealing temperature was set to a 
gradient between 25 °C and 50 °C, in increments of 5 °C. Products from these 
reactions then underwent PCR reaction 2, where the annealing temperature was 
tested at 52 °C and 57 °C. Gel electrophoresis showed successful amplification 
for the FP1-BbvC1-1 and FP2-Bsu361-1 combination at 30 °C then 52 °C; and 
FP5-Taq1-1 and QacEcom1r primers at 30 °C and then 52 °C for the first and 
second PCRs, respectively. FP5-Taq1-1 also yielded a product at 30 °C and then 
57 °C for the first and second PCRs, respectively. 
Product from PCR 2 around 7 kb in size (+/- 3 kb) was gel purified then 
diluted 100x and used as template in PCR 3. Here, the brightest band was for the 
FP1-BbvC1-1 and FP2-Bsu361-1 combination so this was selected to be used 
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for amplification of all the evolution experiment replicates (Figures 53 and 54 for 
the round 2 and round 3 PCR products). 
 
 
Figure 53. PCR 2 amplification products using 7 bp cutter primers FP1-BbvC1-1 
and FP2-Bsu361-1 in combination for the evolution experiment replicates (0 = no 
treatment, T = trimethoprim, C = Ciprofloxacin, B = BKC). A 1 % agarose gel 
stained with ethidium bromide run at 120 V for 40 minutes, with GeneRuler 1 kb 
Plus DNA Ladder (ThermoScientific). 5 μl sample with 1 μl DNA loading dye 
(ThermoScientific). 
 
Figure 54. Barcode PCR amplification products using the 7 bp restriction site 
primers FP1-BbvC1-1 and FP2-Bsu361-1 in combination, for the evolution 
experiment replicates (O = no treatment, T = trimethoprim, C = Ciprofloxacin, B 
= BKC). A 1 % agarose gel stained with ethidium bromide run at 120 V for 40 
minutes, with GeneRuler 1 kb Plus DNA Ladder (ThermoScientific). 5 μl sample 
with 1 μl DNA loading dye (ThermoScientific). 
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4.5.2. PacBio sequencing QC  
The first two SMRT Cells bearing the smaller size (~1 – 5 kb) samples were 
successfully sequenced. The majority of reads of insert were around 1 kb in 
length, with a peak of around 7,000 and 15,000 reads at 1 kb for SMRT cells 1 
and 2 respectively. The majority of reads of insert were also of high quality (Figure 
55). 
 
 
Figure 55. The average read length (left charts) for numbers of reads of insert 
and read quality (right charts) for SMRT cells 1 (top) and 2 (bottom). 
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4.5.3. IntI1 detection 
The average length of the reads for all treatments was 1,189 bp, with a maximum 
length of 2,449 bp and a minimum length of 940 bp. The breakdown of the 
numbers of reads at each stage of filtering can be seen in Table 12. 
 
Table 12. Table showing the numbers of reads at each stage of intI1 filtering. 
INT HITS             
 Treatment  Replicate No. reads Int hits Start < 75 
> 80 % 
coverage > 80 % ID 
BKC 1 25025 21598 9101 8828 7992 
  2 480301 361978 162515 144808 140775 
  3 18000 13980 5871 5075 4930 
TRMP 1 276583 238979 108309 100714 97879 
  2 25882 22548 10120 9400 9127 
  3 213261 192223 93150 88066 85755 
CIP 1 58554 48305 22128 20411 19874 
  2 288586 210441 93044 81653 79182 
  3 15599 11981 5767 5293 5150 
Control 1 5348 2230 746 626 605 
  2 188369 122288 57068 50716 49631 
  3 12982 12179 3077 2826 2738 
Raw 1 17402 14615 5713 5308 5173 
 
The average (n=3, except for the ‘Raw’ treatment, which was a single replicate 
only) number of reads containing an intI1 hit within the first 75 bp of the start of 
the sequence, with greater than 80 % coverage and over 80 % identity to the 
expected amplicon sequence are shown in Figure 56. The CIP and TRMP 
treatment resulted in a significantly greater percent of reads containing intI1 
(Figure 56) compared to the no treatment control (p = 0.007 and p = 0.052, 
respectively, ANOVA with Tukey test). 
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Figure 56. Average (n=3, except ‘Raw’ n=1) percent of total reads bearing hits for 
intI1 within the first 75 bp of the read, with a minimum of 80 % coverage and 
identity. Shown with standard error bars. 
 
4.5.4. Antibiotic resistance gene detection with ARG-ANNOT and CARD 
Resistance genes in the intI1 filtered reads were identified by using ABRicate to 
BLAST against the ARG-ANNOT and CARD databases. Percentage of intI1 
filtered reads containing each gene hit were averaged within treatments. If the 
same gene was detected in both databases, these percentages were also 
averaged within treatments. Genes present in only one database are also 
discussed below. 
The resistance genes detected by searching both ARG-ANNOT and 
CARD were blaTEM, mphA, and aad (Figures 57 and 58). The β-lactamase gene 
blaTEM (Canton and Coque, 2006) had a relatively high prevalence compared to 
other detected resistance genes (though there were a greater number of hits with 
ARG-ANNOT than with CARD). The TRMP treatment had the highest 
prevalence, followed by the CIP and BKC treatments. All antimicrobial treatments 
had a significantly increased average percentage of blaTEM hits compared to the 
no treatment control (p < 0.005 for both CIP and TRMP, p = 0.055 for BKC, 
ANOVA with posthoc Tukey test). For mphA, exposure to BKC or CIP decreased 
mphA hits, whereas TRMP increased mphA hits (compared to the no treatment 
control – Figures 57 and 58). However, none of these differences were significant 
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(Wilcoxon Rank Sum tests). The aminoglycoside resistance gene aad (Partridge 
et al., 2009) was only detected following CIP exposure, and the percentage of 
intI1 hits bearing aad was significantly different compared to the control (p = 
0.028, Wilcoxon Rank Sum test).  
The most common cassette gene in intI1 filtered reads was catB (found in 
the ARG-ANNOT search only), which encodes chloramphenicol resistance 
(Partridge et al., 2009). The no treatment control had the highest average 
percentage of catB hits, followed by the TRMP, CIP and BKC treatments (Figure 
57). The differences between treatments were not significant (Kruskal Wallis).  
The strB gene (detected only with the ARG-ANNOT search) encodes 
streptomycin resistance (Partridge et al., 2009). The number of strB hits 
decreased following culturing but increased persistence was observed following 
CIP exposure (Figure 58).  Differences in the percentage of intI1 hits bearing strB 
compared to the control were not significant for any of antimicrobial treatments 
(Kruskal Wallis test).  
The aph genes encode aminoglycoside resistance (Partridge et al., 2009) 
and were only detected with the CARD search. Aph hits were greatest in the 
original inoculum but were almost completely lost following culturing (Figure 58). 
However, aph was enriched by antimicrobial exposure compared to the control, 
with the CIP exposure resulting in the highest percentage of aph hits (Figure 58). 
However, none of these differences were significant (ANOVA or Kruskal Wallis, 
as appropriate). 
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Figure 57. Average (n=6 for blaTEM, mphA and aad, n=3 for strB, aph and catB) 
percent of intI1 filtered reads containing different resistance genes hits of a 
minimum of 75 bp and 80 % identity, using both the ARG-ANNOT and CARD 
databases. Shown with standard deviation bars. 
 
 
Figure 58. Average (n=6 for blaTEM, mphA and aad, n=3 for strB, aph and catB) 
percent of intI1 filtered reads containing different resistance genes hits of a 
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minimum of 75 bp and 80 % identity, using both the ARG-ANNOT and CARD 
databases. Average percentages are normalised within each resistance gene 
type (for each column, the minimum is subtracted from each value and then 
divided by maximum value). 
 
Table 13. Average percentage (n=6 for blaTEM, mphA and aad, n=3 for catB, strB 
and aph) of intI1 filtered reads with different resistance gene hits.  
 
Gene 
Treatment blaTEM mphA aad catB strB aph 
Raw 1.797796 0 0 16.60545 0.019331 0.019331 
Control 5.412487 0.207635 0 31.62422 0 0 
 
 
4.5.5. Qac gene detection 
Surprisingly, there were no hits for any qac genes, for any of the replicates, for 
any treatment. 
 
4.6. Discussion 
4.6.1. FUN-PCR – fit for purpose? 
The percentage of total reads with an intI1 hit passing the acceptance criteria 
was, on average, around 30 %. As the coverage and identity cut offs were 
lowered to account for the higher error rate of PacBio sequencing (Rhoads and 
Au, 2015), the location of hit (i.e. within the first 75 bp of the read) resulted in the 
greatest reduction of hits. This approach was adopted due to the uncertainty and 
novelty of the FUN-PCR method, and to highlight resistance genes which would 
be closest to the intI1 gene (and therefore Pc). However, this approach would 
have excluded the multiple integron hits which were detected within the same 
read. These could be PCR artefacts, but could also have been amplified from 
integrons within plasmids, where more than 1 integron may be present (Tosini et 
al., 1998). Further analysis could investigate associated resistance genes (if any) 
with other integrase hits further downstream. 
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The low diversity of resistance genes identified suggests FUN-PCR may 
be subject to some bias. Only five different resistance genes were detected with 
ARG-ANNOT, and four with CARD. While catB, aph and aad genes were 
amongst the genes identified which are also well known resistance gene 
cassettes (Partridge et al., 2009); compared to all known integron-associated 
resistance genes, very few were detected. It may be that the same integrons were 
repeatedly amplified during PCR, or that the original inoculum had a very low 
integron carriage and / or diversity. Based on the intI1 qPCRs for the CIP and 
TRMP experiments in chapter three, there were on average around 250 intI1 
copies at day 0. As the same inoculum was used in this study, it could be the lack 
of resistance gene diversity is a reflection of the low class 1 integron number in 
the original inoculum. Though free gene cassettes (i.e. those not integron-
associated) may have also existed in the original inoculum and could have been 
captured, the diversity and number of non-integron associated resistance gene 
cassettes in natural communities has not been studied; and so the likelihood of 
their integration into integrons cannot be predicted. Alternatively, greater gene 
cassette diversity may also have been carried within the larger size fraction of 
amplicons, which was unfortunately lost before sequencing.  
 The blaTEM and mphA genes are not listed in the 2009 review by Patridge 
et al., (2009) as common resistance cassettes, but these have been identified 
previously in a range of different integron backbones in different hosts 
(INTEGRALL (Moura et al., 2009) search, 12th July 2017). However in the 
INTEGRALL database, mphA is only reported twice, once in an Aeromonas 
species and once in a Shigella species. BlaTEM has five reports in the INTEGRALL 
database, with all of these hits also from Enterobacteriaceae hosts. The relatively 
high numbers of hits for these genes is explained by the inoculum used in this 
study – untreated waste water, which would include abundant 
Enterobacteriaceae spp. This could be confirmed with 16S sequencing of the 
communities. 
Class 1 integrons contain a qacEΔ1 and sul1 gene in the 3’ CS. As there 
were no hits for either of these genes, particularly under BKC exposure, it 
suggests the sequences were too short to include the 3’ CS. Indeed, the average 
length of all the reads across all treatments was just over 1 kb. This could also 
explain the lack of observed resistance genes diversity, which again may have 
been more apparent in the lost, larger sized fraction of amplicons.  
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4.6.2. Sequence analysis pipeline 
Integron_Finder (Cury et al., 2015) was used initially to search for integrase 
genes on each read within each multifasta library, using the options for linear 
sequences and ‘local-max’ searches (to increase the chances of a hit for an 
integrase gene). However, very few integrases were defined due to the amplified 
gene being truncated (as a result of the nested PCR) – so truncated, it would not 
be detected (pers. comm. Jean Cury).  
The ABRicate tool successfully identified intI1 hits and resistance gene 
hits. Were this method to be used again, the pipeline would benefit from 
development of additional commands to manipulate and filter hits within the tab 
file. Additionally, it would be advantageous to group multiple intI1 hits within the 
same read, to determine the distance between those hits, and the distance to 
associated resistance genes. This could be useful for determining if resistance 
gene cassettes ‘reshuffled’ under selective pressure (antimicrobial exposure) to 
be closer to the promoter, where the genes would be more strongly expressed 
(Partridge et al., 2009). It appears the method did capture some gene cassette 
rearrangements, as the aad genes were undetected in both the raw inoculum and 
control treatment; but were detected following CIP exposure. The additional steps 
in the analysis pipeline would be most crucial for larger amplicons. However, as 
the average length of the reads was just over 1 kb, it can be assumed that on 
average, any resistance genes detected in this study are close to the promoter, 
and are therefore being highly expressed. 
 
4.6.3. Selective effects of antimicrobial treatment 
Both TRMP and CIP exposure resulted in significant increases in one or more 
resistance genes. TRMP and CIP significantly enriched for β-lactam resistance, 
while CIP also significantly enriched for aminoglycoside resistance (via aad 
genes, and a non-significant increase in aph was observed). Interestingly, neither 
TRMP nor CIP resistance gene cassettes were detected following TRMP or CIP 
exposure. These findings could suggest, as with the multiple intI1 hits, that these 
integrons were located on multidrug resistance plasmids which may have also 
harboured genes conferring resistance to the exposure antibiotic; or that 
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resistance genes to the selecting antibiotics were positioned further downstream 
in the integron array (though these would still be less highly expressed than the 
co-selected resistance genes). Full metagenomic sequencing of the samples 
should be carried out to determine if any other resistance determinants were co-
selected by the antimicrobial treatments; and if TRMP, CIP or BKC resistance 
determinants were directly selected for. If TRMP, CIP or BKC resistance genes 
were detected, it may be that integrons are not the key mobile genetic elements 
carrying these resistance determinants in this community. Unfortunately, this 
could not be completely confirmed without the larger sized amplicon fraction.  
 
4.7. Conclusions 
FUN-PCR is a novel method which can be used to amplify integrons and 
associated resistance gene cassettes in a complex bacterial community. Coupled 
with PacBio sequencing, it has the potential to identify resistance genes 
previously unrecognised as class 1 integron-associated gene cassettes, and to 
track gene cassette integration following exposure to different selective 
pressures.  
This novel approach has shown TRMP and CIP are important co-selectors 
for antibiotic resistance, and may induce gene cassette ‘reshuffling’ (most likely 
via excision). Combined with the findings in chapters two and three, these results 
indicate the co-selective potential of a compound should always be considered in 
complex communities, and therefore when risk assessing antibiotics and 
identifying environmental protection goals in terms of antimicrobial resistance 
selection potential. 
Though the concentrations used here were much greater than those found 
in the environment, findings from chapter one indicate that the strength of 
selection does not necessarily increase proportionally with antibiotic 
concentration. Therefore, there may be little difference in terms of intI1 and 
associated, antimicrobial resistance gene cassettes selection at lower 
antimicrobial concentrations.  
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Chapter five: Investigating co-selection for antibiotic and quaternary 
ammonium compound resistance in the environment – a functional 
metagenomics study 
 
5.1. Introduction 
Co-selection is the term used to describe indirect selection for one or more 
resistance mechanisms. There are two main mechanisms by which this can 
occur: co-resistance, and cross-resistance. Co-resistance is when two or more 
resistance genes are genetically linked, for example on a plasmid; and therefore 
only one compound needs to be present in order to select for the plasmid (and 
consequently both resistance mechanisms). Cross-resistance is when a single 
resistance gene can confer resistance to multiple compounds, for example a 
multi-drug efflux pump; and therefore a single selective compound can select for 
the gene (Baker-Austin et al., 2006, Larsson, 2014).  
The Scientific Committee on Emerging and Newly Identified Health Risks 
(SCENIHR) confirmed that that co-selection for antibiotic resistance is likely to 
occur in the environment (SCENIHR, 2009). The most well studied compounds 
that co-select for antibiotic resistance are biocides and metals, and to a lesser 
extent, other antibiotics. Co-selection via co-resistance has been shown to occur 
under laboratory conditions (Tandukar et al., 2013, Gullberg et al., 2014) and 
there is evidence for co-selection of antibiotic resistance genes in the 
environment (Gaze et al., 2005, Gaze et al., 2011, Drudge et al., 2012, Berg et 
al., 2010, Berg et al., 2005). More recently, all genomes in the NCBI database 
were analysed for co-occurrence of antimicrobial resistance genes. 86 % of all 
genomes which harboured a metal or biocide resistance gene also contained an 
antibiotic resistance gene. Similarly, plasmids bearing metal or biocide resistance 
determinants were also significantly more likely to harbour antibiotic resistance 
genes, showing many of these are excellent candidates for co-selection to act 
upon (via co-resistance) (Pal et al., 2015). However, still more work is required to 
understand the role of co-selection in the maintenance and spread of mobile 
antibiotic resistance determinants (Andersson and Hughes, 2014). 
So far in this thesis, research has focused on direct selection for antibiotic 
resistance in vitro in natural bacterial communities rather than in single “model” 
organisms. However, a holistic approach to tackle the global issue of antibiotic 
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resistance requires improved understanding of co-selection for antibiotic 
resistance by other micropollutants such as biocides as well as direct selection 
for antibiotic resistance as a result of exposure to antibiotics. Additionally, it is 
important to understand how selection for AMR occurs in the environment, and 
to study natural communities in an unbiased way. Functional metagenomics 
removes some causes of sampling or sequence analysis biases, as it allows 
functional screening to determine both novel and previously characterised genes 
alike; without subjecting the community to culture bias, and without requiring a 
priori knowledge of resistance genes (dos Santos et al., 2017). This chapter 
describes an un-replicated, functional metagenomics field study which 
investigated co-selection for antibiotic resistance in quaternary ammonium 
compound (QAC) impacted environments. 
 
5.1.2. Quaternary ammonium compounds (QACs) and resistance genes 
There is a vast range and chemical diversity of QACs which will not be discussed 
here. The QACs discussed further and which formed part of this study are the 
first generation QACs, benzalkonium chlorides (‘BKC’, such as BAC-12, BAC-14 
etc.), and cetyltrimethylammonium bromide (CTAB), a third generation QAC 
(Gerba, 2015). 
QACs are biocides, antimicrobial compounds used not as therapeutic 
agents, but as surfactants, detergents and disinfectants (Oh et al., 2013) and as 
preservatives in personal care products (Buffet-Bataillon et al., 2012). Their use 
precedes that of antibiotics (Gillings et al., 2009) and they are also estimated to 
be produced in quantities several orders of magnitude greater than antibiotics 
(Calero-Caceres et al., 2014), with annual estimates for surfactant production at 
greater than 18 million tons (Cirelli et al., 2010).  
QACs’ mode of action is to first interact with, then penetrate, the bacterial 
cell wall; then to disrupt the cytoplasmic membrane which causes leakage of 
intracellular constituents, including autolytic enzymes. These enzymes then 
degrade the cell wall, resulting in cell lysis (Zhang et al., 2015, Gerba, 2015). 
Biocides are used at concentrations up to 1000x greater than MIC (in order 
to reduce the likelihood of resistance emerging at sub-inhibitory concentrations), 
due to the fact toxicity in humans is not a problem as with antibiotic chemotherapy 
(Chapman, 2003). However, though QACs are bactericidal at around 10 mg/L 
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and bacteriostatic at around 0.5 mg/L (Gerba, 2015), toxicity to the common 
ecoxtoxicological model species is quite high, with EC50’s of benzalkonium for 
fish and invertebrates around 280 µg/L and 5 µg/L respectively. The toxicity to 
model bacterial species is an EC50 of benzalkonium for Vibrio fischeri determined 
as 0.5 mg/L, and for Pseudomonas putida as 6 mg/L (Zhang et al., 2015). These 
high effect concentrations for the target organism are again alarming (as 
discussed in chapters one and three), as it suggests the current ecotoxicological 
tests may be unsuitable for determining the selective potential of a compound (as 
opposed to toxic effect). However, for QACs it appears that non-bacterial 
ecotoxicological model species are more protective of the environment and 
natural ecosystems, which not the case for antibiotics (see chapter one and 
chapter three).  
Measured Environmental Concentrations (MECs) of QACs tend to be very 
high. For example in Sweden, average concentrations across several different 
WWTPs of a BKC homologue was 89 µg/g in activated sludge (dry weight), 30 
µg/L in WWTP influent and 0.3 µg/L in treated effluent. Another QAC, CTAB, was 
measured at 370 µg/L in sludge, 54 µg/L in influent and 0.3 µg/L in effluent 
(Östman et al.). In previous studies, a BKC (BAC-12) was measured at 170 µg/L 
in influent (Martinez-Carballo et al., 2007). Finally, QAC concentrations in surface 
water tend to be in the µg/L range (Zhang et al., 2015), though have also been 
detected up to 5 mg/L in hospital effluent (Kummerer, 2009b).  
The majority of MECs should not be toxic according to the effect 
concentrations, but this is not due to WWTP degradation. Rather, due to the 
cationic charge of QACs, the majority bind to sludge, (Zhang et al., 2015), which 
explains the very high sludge MECs. However, this sludge would then be applied 
to agricultural land as fertiliser, and though there would be some sorption to soil, 
it is likely there would still be an effect on the soil biota (Cirelli et al., 2010). 
Due to their wide use at very high concentrations and poor biodegradability 
(Buffet-Bataillon et al., 2012, Oh et al., 2013, Chapman, 2003, Zhang et al., 
2015), QACs could confer a stronger selective pressure than low, environmental 
concentrations of antibiotics. For example, QAC concentrations in surface water 
tend to be in the µg/L range (Zhang et al., 2015), whereas antibiotics are typically 
in the low ng/L range (Homem and Santos, 2011). Though some argue novel 
resistance to QACs is unlikely to develop due to the nature of its antimicrobial 
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activity (Gerba, 2015), this does not mean pre-existing QAC or antibiotic 
resistance mechanisms would not be co-selected for by QACs. 
In fact, the nature of and genetic context of QAC and antibiotic resistance 
genes lend themselves to be ideal co-selection candidates. For example, the co-
selective potential of QAC’s was shown to be the highest of all biocides and 
metals studied (alongside mercury (Pal et al., 2015)). The qac efflux genes (e.g. 
qacE, qacEΔ1 and qacH) are excellent examples of genes which facilitate co-
selection through both cross-resistance (as it encodes a multi-drug efflux pump) 
and co-resistance (as it is often located on integrons, which in turn carry a vast 
diversity of antibiotic resistance genes). These qac efflux genes have been shown 
to have a relatively high prevalence in polluted environments (Gaze et al., 2005, 
Gaze et al., 2011, Gillings et al., 2009). In fact, most resistance to QACs is via 
efflux pumps such as the qac genes, which tend to belong to either the small 
multi-drug proteins, or the major facilitator family. These can all be found on a 
range of multi-drug resistant plasmids (Chapman, 2003), which again make co-
selection likely. 
 
5.1.3. This study 
This study aimed to investigate co-selection of antibiotic resistance in QAC-
exposed environments. Functional metagenomic libraries generated previously 
by Lihong Zhang from: reed bed (RB) soil used to remediate the effluent of a 
textile factory; sewage cake (SC); and ‘pristine’ grassland (GL) from the 
Rothamsted site, England (protected from anthropogenic impact); were screened 
for BKC and CTAB resistance. BKC and CTAB are both common QACs with 
applications as preservatives in pharmaceuticals, personal care products and in 
household cleaning products, detergents and fabric softeners (Buffet-Bataillon et 
al., 2012, Östman et al., 2017), and so both the RB and SC environments were 
expected to have much higher QAC exposure compared to the GL environment.  
Initially, all libraries were screened on CTAB and BKC to determine levels 
of QAC resistance. Then occurrence of co-selection was investigated, by 
determining the proportion of CTAB resistant clones from both exposed libraries 
that were also resistant to two antibiotics: ampicillin (AMP) and trimethoprim 
(TRMP). The MICs for unique BKC resistant clones were determined and these 
clones then underwent full sequencing to search for co-resistance and cross-
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resistance candidates; and transposon mutagenesis to functionally identify the 
genes conferring BKC resistance. A subset of these ORFs which were common 
to virtually all knock outs was sub-cloned to screen for cross-resistance to a range 
of antibiotics.  
 
5.1.3.1. Choice of antibiotics for investigating co-selection 
TRMP was chosen as its target is dihydrofolate reductase, and resistance arises 
due to acquisition of alternative enzymes encoded by the dfr genes. 30 dfr genes 
have been recorded, and they are frequently associated with class 1 and class 2 
integrons, which have been found extensively in environmental bacteria (Abella 
et al., 2015a, Abella et al., 2015b, Berglund et al., 2014, Gatica et al., 2016, Gaze 
et al., 2005, Gaze et al., 2011, Gillings et al., 2015), and which often harbour QAC 
resistance genes such as qacE (Gillings et al., 2009, Partridge et al., 2009). Due 
to the increased in resistance in recent years TRMP use has reduced. Despite 
this, dfr gene prevalence has not decreased suggesting the genes confer a low 
fitness cost (Brolund et al., 2010). Low fitness cost and well-defined integron 
association makes TRMP co-selection likely.  
Additionally, TRMP is commonly used to treat urinary tract infections 
(UTIs), but is not metabolised fully within the body (Brolund et al., 2010), nor is it 
biodegradable (Sirtori et al., 2010). Concentrations of TRMP in WWTP effluent 
range from 20 – 1340 ng/L (Le-Minh et al., 2010), which though greatly below the 
MIC of the host with an empty vector, may still be high enough to select for 
resistance (Gullberg et al., 2011).  
AMP is a β-lactam antibiotic and prevents cell wall synthesis. Resistance 
is commonly mediated by β-lactamases which cleave the β-lactam ring such as 
ampC, blaTEM, blaSHV and others, which have been isolated in natural 
environments and shown in some cases to be integron associated (Henriques et 
al., 2006). As well as resistance via target modification and reduced permeability, 
β-lactam resistance can also be conferred by efflux pumps (Reygaert, 2011), and 
qacEΔ1 has been shown to confer ampicillin resistance (Kücken et al., 2000). For 
this reason, AMP was chosen alongside TRMP as it is a likely co-selection 
candidate based on environmental detection of resistance determinants and 
integron association. 
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For the disc diffusion assay, a range of antibiotics were chosen based on 
resistance profiling conducted in previous work for commonly identified 
resistance genes (Kazimierczak et al., 2009, Nakao et al., 2006). These were a 
range of tetracyclines, and imipenem. Cefotaxime (TAX) and sulfamethoxazole 
(SMX) resistance was also evaluated due to association of ESBLs and SMX 
resistance genes such as sul1 with integrons (Henriques et al., 2006, Partridge 
et al., 2009), and due to the fact SMX is commonly used with TRMP to treat UTIs 
(Sirtori et al., 2010). 
 
5.1.3.2. Primary aims of the study 
 Determine if the studied QAC-exposed environments have higher levels 
of QAC and antibiotic resistance compared to the ‘pristine’ study 
environment. 
 Determine the genes responsible for these resistance(s). 
 
5.1.3.3. Secondary aim of the study 
 Sub-clone the most common ORFs conferring QAC resistance and 
perform disc diffusion assays to generate antibiotic susceptibility profiles, 
to determine level of cross-resistance. 
 
5.1.4. Author contributions 
Lihong Zhang generated the metagenomic libraries. I received input from both 
Lihong Zhang and William Gaze on the initial experimental design for QAC and 
co-selection screening, and transposon mutagenesis. I selected compounds for 
subsequent experiments to screen for co-selection. I designed and performed all 
experiments, and analysed all the numerical and sequence data. I wrote this 
chapter and a manuscript for publication. 
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5.2. Materials and methods 
5.2.1 Sampling sites and metagenomics library construction 
SC (fully digested, dehydrated and limed sewage) was collected from a West 
Midlands WWTP. The RB soil was amended with effluent from a textile mill with 
high usage of quaternary ammonium compounds (QACs). The grass land soils 
were taken from the Rothamsted Park Grass experimental plots.  
 
5.2.2. Culturing and identifying unique inserts 
All culture media (liquid and in agar) contained tetracycline (‘TET’ 12.5 mg/L) for 
vector maintenance. Incubation was stationary or shaking (150 - 180 rpm) at 35 
– 37 °C overnight.  
Libraries were screened by plating on five LB agar plates containing MIC 
(of host with empty vector) concentrations of BKC and CTAB (16 mg/L and 32 
mg/L respectively) with 100 μl of RB cells, GL cells or SC cells diluted to 10-1, 
which equates to at least one coverage per library across the five plates. 
Plasmid DNA extraction was performed on a random selection of 24 BKC 
resistant clones from both the RB and SC library alongside the single BKC 
resistant clone isolated from GL with the GeneJet MiniPrep Kit 
(ThermoScientific), according to instructions for low plasmid copy number. 
Restriction digest with EcoRI and BamHI FastDigest Green (Fermentas, 
now ThermoScientific) identified unique inserts. Total reaction volumes for each 
sample were 1 μl Buffer, 0.3 μl enzyme, 4.7 μl sterile dH20 and 4 μl of plasmid 
DNA (due to low DNA concentration). Reactions were incubated in a heat block 
at 37 °C for 20 minutes. Reactions were loaded to a 0.8 % agarose gel stained 
with EtBr for gel electrophoresis at 110 Volts for 45 minutes to identify unique 
inserts. 
 
5.2.3. Gene knock out and sequencing 
Unique vector inserts underwent transposon mutagenesis using the EpiCentre 
Kan-25 EZ Kit, according to manufacturer’s instructions. Unique vector inserts 
were combined in equal proportions and were also mutagenised individually (for 
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quick screening and complete recovery, respectively). Mutagenised vectors were 
electroporated into electrocompetent EC100 cells (Epicentre) by mixing 1 μl 
mutagenised DNA with 50 μl cells in 2 mm cuvettes and shocking at 2200 - 2500 
V. Successfully shocked cells (pulse time > 4.0 ms) were recovered in 500 μl 
SOC media and incubated for 60 – 90 minutes. 100 μl of cells were diluted to 10-
3 in LB broth and spread on plates containing TET only, to assess transformation 
success. The remainder of cells were spread in 100 μl aliquots onto LB agar 
plates containing kanamycin (‘KAN’) 50 mg/L (to select for clones with successful 
transposon insertion) and TET.  
ClonTech chemically competent (Stellar™) cells were also used for 
transformation according to manufacturer’s conditions. 1 µl plasmid DNA was 
combined with 40 µl chemically competent cells, and incubated on ice for 5 
minutes. Cells were then shocked at 45 °C for 45 seconds, and recovered 
immediately in 500 µl SOC media. After 60 minutes shaking at 180 rpm at 37 °C, 
100 µl cells were spread per selective plate. 
Following incubation overnight, clones were randomly selected to be 
functionally screened for resistance gene knockouts. Mutants were spotted onto 
LB agar plates containing kanamycin (50 mg/L) and TET and also onto LB agar 
plates containing KAN (50 mg/L), TET and BKC at 16 mg/L, 24 mg/L or 32 mg/L 
(to assess the extent to which resistance was lost). Over 120 mutants were 
screened per mutagenesis reaction. Clones unable to grow on one or more of the 
BKC plates were picked from the plates without BKC, and grown overnight in 10 
ml (due to low plasmid copy number) LB broth for plasmid extraction as described 
previously.  
Restriction digest (as above) determined unique mutants for the 
transposon reactions with mixed vector, and these along with the single 
transposon knock outs were sent for sequencing (GATC) using the forward and 
reverse primers provided in the EpiCentre Kan-25-EZ Kit at a 1:9 ratio of primer 
to DNA (10 μl total), due to low DNA concentration (~30 ng/µl, nanodrop). 
For sequence analysis, ab1 files were first examined for sequence quality, 
and the ends were trimmed of bases with low or indistinct peaks. For the mutants, 
the transposon sequence was first removed and then forward and reverse 
sequences were combined to give the knock out gene sequence using MEGA5.2 
(Tamura et al., 2011). GenBank ORF finder was used to identify potential ORFs 
which then underwent BLASTp.  
179 
 
Entire inserts were also sequenced to search for co-resistance, by primer 
(IDTDNA) walking using plasmid DNA extracted as above (sequencing 
performed by Macrogen Europe). Read quality was assessed as above and 
alignment performed in MEGA 6.0 (Tamura et al., 2013). 
 
5.2.4. Phylogenetic analysis 
Phylogenetic analyses were performed in MEGA 6.0 (Tamura et al., 2013). UDP-
like proteins identified in this study were aligned, trimmed and used to generate 
a maximum likelihood tree (with default settings) with 500 bootstrap replicates 
using a UDP-galactose-4-epimerase sequence from GenBank (Accession 
NC004663.1). Maximum likelihood was chosen as the most robust analysis 
available for the small selection of sequences, and sequence length. 500 
bootstrap replicates were used as the uppermost value to yield reliable results 
(Pattengale et al., 2010).  
 
5.2.5. Cloning UDP-galactose-4-epimerase -like ORFs and expression 
Two ORFs (R11 and S78) and the positive control (included in the Champion 
pET101 expression kit) were successfully amplified using Q5 enzyme (New 
England Biolabs) in the following reaction: 10 μl buffer, 1 μl dNTPs, 5 μl primer 
pair, 0.5 μl Q5 and 43.5 μl sterile water. Cycling conditions were as follows: 98 
°C for 30 seconds, followed by 30 cycles of 98 °C for 10 seconds, 62 °C for 30 
seconds, 72 °C for 1minute and a final extension of 72 °C for 10 minutes. The 
other ORF (R161) was amplified using HotStart OneTaq (New England Biolabs) 
in a 20 μl reaction comprising of 10 μl HotStart OneTaq Master Mix, 2 μl forward 
and reverse primer combined (10 μM each), 7 μl sterile water and 1 μl template. 
Cycling conditions were as follows: 95 °C for 1 minute, followed by 30 cycles of 
95 °C for 1 minute, 53 °C for 30 seconds and 68 °C for 1 minute, and a final 
extension of 5 minutes at 68 °C. Primer sequences for PCR reactions are shown 
in Table 16 (Appendix). 
Products were run on a 0.8 % agarose gel to verify successful amplification 
of a single, specific band. All reactions were cleaned up using the NucleoSpin 
Clean and Concentrate kit (Mackery-Nagel), according to manufacturer’s 
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instructions. PCR products were also sequenced before cloning (Macrogen 
Europe) using the same primers in ratios described previously to verify high 
fidelity amplification. 
R11 and the positive control vector were successfully cloned into the 
pET101 vector using the Champion pET Directional Expression kit (InVitrogen) 
according to the manufacturer’s instructions, and were electroporated as above. 
The other two ORFs (R161 and S78) could not be successfully cloned using the 
pET101 kit, so they were cloned in a Hot-Phusion reaction (Fu et al., 2014), which 
required additional bases to be added to the primers with homology to the 
pET101 vector (Table 16, Appendix). Briefly, 1.5 μl of PCR product was combined 
with 0.5 μl linearised pET101, 5 μl 2x HotFusion Master Mix (Fu et al., 2014) and 
water to a final volume of 10 μl. Reactions were incubated at 50 °C for 1 hr, then 
45 seconds at 5 °C decreasing temperatures (e.g. 45 °C, 40 °C etc). 1 μl was 
transformed into electrocompetent cells (EpiCentre) as described above.  
Colony PCR (conditions as previously described, but water volume 
adjusted) with T7 forward and reverse primers from the cloning kit confirmed the 
ORF had been successfully cloned into the vector. The vector was also 
sequenced (Macrogen Europe) using primers provided in the Champion 
Directional Expression kit (T7 forward and reverse) to confirm the insert was in 
the correct orientation. 
All UDP-like ORFs and the positive control expression vector were 
chemically transformed into the OneShot (InVitrogen) expression cells according 
to instructions. Briefly, 2 μl UDP DNA or 1 μl control vector DNA was gently mixed 
with competent cells (25 μl cells and 25 μl cold 10 % glycerol) and incubated on 
ice for 30 mins. Cells were shocked at 42 °C for 30 seconds, then held briefly on 
ice before being transferred to 250 μl room temperature SOC media. Cells were 
incubated for 30 minutes at 37 °C at 180 rpm, then added to 10 ml LB broth with 
AMP (50 mg/L) and incubated overnight. This culture was used for the initial disc 
diffusion assays. Freezer stocks were made as described above, and cultured 
from two consecutive single colony and overnight cultures before being used for 
E test assays. 
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5.2.6. MIC/Co-selection testing 
MIC testing of the resistant clones was performed using Iso-sensitest agar, using 
the two 5 μl spot method of overnight culture diluted to OD 600nm 0.25 (Andrews, 
2001). EC100 pcf430 (host with empty vector) was used as a negative control. 
This was performed to determine BKC MIC for all the fully sequenced BKC 
resistant original inserts and the cloned UDP-like ORFs. 
For assessing significance between the numbers of clones resistant to 
BKC or CTAB, first the total numbers across all plates were corrected for library 
coverage. Coverage for RB, SC and GL are 302 μl, 7.42 μl and 306 μl, 
respectively. Library coverage was determined by dividing the amount of library 
plated across the 5 plates (500 μl for RB and GL, and 50 μl for SC) by the volume 
of a single coverage. Total numbers of resistant clones for each library and each 
treatment (BKC or CTAB) were divided by this library coverage and rounded to 
the nearest whole value.  
The entire RB and SC libraries were also screened on AMP and TRMP to 
investigate possible co-resistance of CTAB and antibiotic resistance genes in the 
insert DNA. Approximately similar numbers of clones (~ 200) were isolated by 
plating on one plate containing only TET, and another containing BKC (16 mg/L) 
and TET. These were replica plated onto agar containing AMP or TRMP at the 
MIC of the host with empty vector (4 and 1.5 mg/L, respectively), approximately 
1.5x this MIC (7 mg/L and 2.25 mg/L, respectively) and at clinical breakpoint 
concentrations for Enterobacteriaceae (8 and 4 mg/L, respectively (EUCAST, 
2014)), as the host was E. coli.  
Original BKC resistant inserts and cloned UDP-like ORFs were tested for 
increased antibiotic resistance compared to the empty vector control (pcf430 for 
original inserts, or pET101 for UDP-like ORFs) with disc diffusion assays (Fisher-
Scientific). Antibiotic susceptibility disc diffusion assays were performed for 
Doxycycline hydrochloride (30 μg) and Minocyline (30 μg) for the UDP-like ORFs 
only (as all other vectors contained TET resistance); and AMP (10 μg) for the 
original inserts only (as UDP-like ORF containing vectors contained an AMP 
resistance gene). Both UDP-like ORFs and original inserts were also screened 
on TRMP (2.5 μg), Cefotaxime (‘TAX’ 5 μg), Imipenem (‘IMP’ 10 μg), Colistin 
(‘COL’ 10 µg) and Sulfamethoxazole (‘SMX’ 25 μg). Testing was performed 
according to EUCAST standards (Matuschek et al., 2014), with Mueller Hinton 
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(MH) agar amended with TET for vector maintenance for the original inserts; or 
AMP (50 mg/L) for vector maintenance and IPTG (0.025 µM final concentration) 
to induce expression for the UDP-like ORFs. It is noted there may be some 
problems with the reliability of colistin disc diffusion assays (EUCAST, 2016). 
Negative control expression plates without IPTG were included, as well as 
the positive control expression vector plated as above on plates also containing 
X-Gal (to allow for visual confirmation of expression through blue/white 
screening). Disc diffusion assays were performed in triplicate for all three 
expression vectors and for the expression vector control. Inhibition zone sizes 
were averaged, and inhibition zone sizes were compared using an ANOVA and 
Tukey post-hoc test for significance. 
E tests (Biomerieux) for SMX, TRMP and SMX / TRMP were also 
performed on UDP-like ORFs with appropriate controls following EUCAST 
standards, using MH agar supplemented as above.  
 
5.2.7. Statistics 
Statistical analyses were performed in R Studio (RStudio, 2015). 
 
5.3. Results 
5.3.1. QAC exposed libraries had higher QAC, TRMP and AMP resistance 
Contaminated libraries (RB, SC) had significantly higher numbers of resistant 
clones compared to the ‘pristine’ environment (GL, all p < 0.001, ChiSq Test). 
Numbers of clones resistant to BKC or CTAB were significantly different in the 
RB library (p < 0.001, Chi-Sq Test) but there were no significant differences 
between treatments (BKC or CTAB) in the SC or GL libraries (Table 14). 
 
Table 14. Numbers of BKC or CTAB resistant colonies from each of the three 
metagenomics libraries from the initial screen, and corrected for per Gb of library, 
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rounded to the nearest whole number. The library coverages are 0.63, 1.59 and 
1.53 Gb for RB, SC and GL, respectively. 
 
An initial screen for co-selection for antibiotic resistance found greater than 
80 % of all CTAB resistant clones in the RB and SC libraries also had reduced 
susceptibility to both TRMP and AMP (compared to the empty vector control MIC, 
Figure 59). Clinical resistance was extremely rare (1 CTAB resistant clone was 
also clinically resistant to TRMP). 
 
Figure 59. Percentage of the entire sewage cake (‘SC’) and reed bed (‘RB’) 
libraries resistant to CTAB, or with reduced susceptibility to Ampicillin, and 
Trimethoprim compared to the empty vector control (MIC 32 mg/L, 4 mg/L and 
1.5 mg/L respectively). 
 
5.3.2. Full insert sequencing discovered many co-resistance and cross-
resistance genes 
To identify the genes responsible for BKC resistance, 8, 6, and 1 unique BKC 
resistant clones were identified for the RB, SC and GL libraries respectively, via 
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restriction digestion. Following transposon mutagenesis, 20 and 10 potentially 
unique knock out clones of interest were sequenced for the RB and SC libraries, 
respectively; however, only three of each of the original 8 (RB) and 6 (SC) 
plasmids were recovered in this initial mutagenesis. Subsequent mutagenesis 
with individual plasmids was performed, but this was still unable to identify a 
knock out mutant for all unique inserts. Therefore, all inserts were fully sequenced 
by primer walking to account for the possibility there could be multiple resistance 
genes within the insert. 
Full sequencing of the ‘unique’ inserts identified some of the inserts as 
identical (based on ~ 2,000 bp in forward and reverse having 100 % homology), 
so sequencing of these was discontinued. The full sequences for the remaining 
unique inserts were examined for genes that could potentially confer antimicrobial 
resistance, through ORF Finder and BLASTp searches. 
The full list of ORFs, their predicted function and identity is shown in Table 
18 (Appendix). Three inserts contained ORFs with varying similarity to known 
antibiotic genes. Insert S4 contained a tetracycline resistance MFS efflux pump 
(100 % ID) and multidrug resistance protein mdtB (42 % ID); R17 contained a 
HTH MrM multiple antibiotic resistance protein (52 % ID); and R3 contained a 
penicillin binding protein (30 % ID). Intriguingly, S4 also contained part of a 
transposase (100 % ID but only 42 % coverage), suggesting recent mobilisation 
of the tetracycline MFS efflux pump and the potential for further transfer. Insert 
R10 also contained a transposase, suggesting co-localised genes such as the 
ABC transporter protein and UDP-galactose-4-epimerase also within this insert 
would be potentially mobilisable. In terms of biocide resistance, the only notable 
ORF was found in insert R24, which contained a sulfatase, (up to 96 % ID) 
capable of degrading anionic surfactants (Jovcic et al., 2010). 
Other key ORFs identified could be loosely grouped into 3 types based on 
predicted resistance mechanism strategy. For membrane / transporter / efflux 
pumps, there were hits for ABC transporters, MFS transporters, a FIST-domain 
containing protein (involved in transport and binding of small ligands) and other 
membrane proteins. For preventing cell lysis / penetration there were hits for a 
predicted capsular polysaccharide biosynthesis protein and cell wall / membrane 
synthesis proteins, including the UDP-like ORFs and a UDP-galactopyranose-
mutase. To combat cell damage, there were hits for an oxidoreductase and a 
divalent ion tolerance protein. In one of the inserts, there was high sequence 
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identity and coverage for 16S rRNA and several other genes (including an ABC 
transporter) from Pseudomonas veronii, which has been shown to have potential 
bioremediation capabilities (Nam et al., 2003, Onaca et al., 2007).  
 
5.3.3. Transposon mutagenesis revealed QAC resistance was mediated by 
a diverse set of previously uncharacterised genes 
For the transposon mutagenesis knock outs, the ORF name, sequence similarity 
and number of mutant clones containing knocked out ORFs for both RB and SC 
libraries are shown in Table 19 (Appendix). UDP-galactose-4-epimerase-like 
genes were present in the majority of knock outs; these have been found in 
previous functional metagenomic studies, referred to as galE genes which confer 
increased resistance to tetracyclines (Kazimierczak et al., 2009) and increased 
salt tolerance (Culligan et al., 2012). GalE mutants have also been shown to 
exhibit increased susceptibility to clinically important antibiotics such as TAX, 
IMP, and vancomycin (Nakao et al., 2006, Nayak et al., 2006).   
Alignment of these UDP-galactose-4-epimerase like ORFs with the ORFs 
published in the paper by (Kazimierczak et al., 2009) found limited sequence 
similarity (Table 20, Appendix). A brief phylogenetic analysis (Figure 60) was 
conducted to visualise the similarity of UDP-galactose-4-epimerase like ORFs 
between knock outs from this study. This identified 7 distinct groups of UDP-like 
proteins. One UDP-like ORF from 3 of the identified subgroups which grouped 
closely with the reference gene were selected to be sub-cloned to screen for 
cross-resistance; namely R11, R161 and S78. These were sub-cloned into the 
pET101 expression vector and screened for reduced susceptibility to a range of 
antibiotics, alongside the original BKC resistant clones. 
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Figure 60. Maximum likelihood tree of the UDP-galactose 4-epimerases identified 
in this study, with a reference strain from GenBank (Accession NC 004663.1). 
Bootstrap values based on 500 bootstrap replicates. Sequences beginning with 
R are from the RB library, and with S from the SC library. 
 
Antibiotic disc diffusion assays were conducted to determine the antibiotic 
susceptibility profiles of the original BKC resistant clones and the three sub-
cloned UDP-like ORFs. For all the original BKC resistant clones, there was a 
slight decrease in susceptibility to SMX, which was marginally significant for insert 
S2 (p = 0.066, ANOVA with Tukey post-hoc test), and insignificant for all other 
inserts. Insert S2 also showed a decrease in susceptibility to TAX and a slight 
decrease in susceptibility to TRMP, both of which were insignificant. R10 showed 
a minimal decrease in susceptibility to COL but this was not significant. For all 
other compounds, susceptibility increased for the inserts compared to the empty 
vector control, which was significant for all inserts to IMP and for S4 to AMP (p < 
0.05, ANOVA with Tukey post-hoc test, Figure 61).  
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Figure 61. A reduction in the average inhibition zone indicates decreased 
susceptibility compared to the empty vector control. Values are calculated by 
averaging (n=3) the inhibition zone sizes, and subtracting the control zone size 
from the zone size of the inserts (S# = from the SC library; R# = from the RB 
library). TRMP = Trimethoprim, IMP = Imipenem, COL = Colistin, TAX = 
Cefotaxime, AMP = Ampicillin, SMX = Sulfamethoxazole. * indicates significant 
difference in size compared to control (p < 0.05, ANOVA and Tukey post-hoc test. 
Red * = (p < 0.1). 
 
For the UDP-like ORFs, Figure 62 shows the difference in size of inhibition 
zone compared to the empty vector control, with significance determined by One-
way ANOVA with Tukey post-hoc test. UDP-like ORF R11 and S78 showed 
significant increases in susceptibility to TAX (p < 0.01 and p < 0.05, respectively), 
whereas R161 showed a significant decrease (p < 0.05). All three showed 
significant decreased susceptibility to SMX (all p < 0.01), and S78 also showed a 
significant decrease in susceptibility to IMP (p < 0.05) and TRMP (p < 0.05). 
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Figure 62. Values are calculated by averaging the inhibition zone sizes (n=3), and 
subtracting the control zone size from the zone size of the inserts. COL = Colistin, 
DOX = Doxycycline, MIN = Minocycline, TAX = cefotaxime, SMX = 
sulfamethoxazole, TRMP = trimethoprim, IMP = imipenem. Average difference = 
average size of inhibition zone (mm) for ‘UDP-like’ ORF (11, 161 or 78) – average 
size of inhibition zone (mm) for the empty vector control. Biological replicates n=3. 
Significance according to ANOVA and Tukey test, p value < 0.05 = *. (Unable to 
screen on AMP as used for vector maintenance).  
 
To verify these results and determine the difference in MIC, MIC strip (E 
test) assays were performed (Table 15). Only UDP R11 showed an increase in 
TRMP MIC compared to the control; meanwhile the MIC for UDP R161 was the 
same and for UDP S78 there was a slight decrease. For SMX, the increase in 
MIC was more pronounced, with the MIC of UDP R11 and UDP S78 tripling that 
of the control. As TRMP and SMX are commonly administered in combination 
therapeutically (Sirotori et al., 2010), MICs using the TRMP / SMX E test 
combination strip were also determined. The average MICs (n=2) were slightly 
higher for all cloned UDP inserts than the control. 
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Table 15. E test MIC results for cloned UDP-like ORFs. TRMP = Trimethoprim, 
SMX = Sulfamethoxazole, TRMP / SMX = Trimethoprim / Sulfamethoxazole 
combination strip. ' '^ represents increase in MIC, '-' represents no difference in 
MIC, '˅' = decrease in MIC (all compared to empty vector control pET101).  
Antibiotic Empty vector 
control pET101 
MIC (µg/ml) 
R11 MIC (µg/ml) R161 MIC 
(µg/ml) 
S78 MIC (µg/ml) 
TRMP 0.19  0.25 ^ 0.19 -  0.125 ˅ 
SMX 2 6 ^ 2 - 6 ^ 
TRMP / SMX 0.019 0.0255 ^ 0.0275 ^ 0.032 ^ 
 
Cloned UDP like ORFs also had their BKC MIC’s determined again in the 
expression vector to confirm BKC resistance. BKC MIC for the expression control 
was > 2 and < 4 mg/L. For UDP R11 and UDP R161 the BKC MIC was > 4 and 
< 6mg/L; and for UDP S78 it was > 6 and < 8 mg/L. 
 
5.4. Discussion 
Several studies have utilised a functional metagenomic approach to investigate 
the environmental resistome (Allen et al., 2009, Amos et al., 2014b, Wichmann 
et al., 2014, Su et al., 2014), as it allows definitive identification of the gene 
responsible for resistance whilst not being subject to culture bias (Garcia-Armisen 
et al., 2013). However, as an un-replicated field study, the findings may only be 
applicable to the environments studied. Additionally, this method is not without 
difficulty. In this study, to ensure biocide resistance genes for all unique inserts 
were knocked out, transposon mutagenesis was performed on unique vectors 
individually. With an insert size of 15 kb and allowing for gene sizes of around 
500 bp, one in 30 mutagenised clones were expected to be a BKC knock out. 
However, after screening over 300 clones generated from some unique clones, 
no knock out mutants could not be obtained. It is possible that these inserts 
contained more than one gene conferring resistance to BKC and as the EpiCentre 
Kan-25 kit is optimised for single insertion events only, complete loss of 
phenotypic resistance was observed. Therefore, these inserts were sequenced 
fully by primer walking.  
This simultaneously allowed for screening for co-resistance candidates; 
i.e. QAC and antibiotic resistance genes clustering within the same insert. There 
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was some evidence of this, including a mobilised tetracycline resistance MFS 
efflux pump (100 % ID) co-located with a transposase, and a sulfatase. This is 
particularly significant given the small insert size and the limited number of inserts 
sequenced. Other known resistance genes were identified but these had low 
sequence similarity to the database entries. However, a recent study found 
predicted ORFs with sequence similarity as low as 55 % (unpublished data, 
Lihong Zhang) can still produce the same function.  
Many ORFs had varying levels of similarity to proteins in the database, 
including a variety of possible efflux pumps (MFS / ABC transporter), genes 
involved in cell wall / polysaccharide capsule synthesis; or involved in reducing 
reactive oxygen species (oxidoreductase, nitrilase). These genes would need 
further characterisation to confirm a definite functional role in either biocide or 
antibiotic resistance. Some proteins had very low sequence similarity to any 
entries in the GenBank database (< 40 %), and these could have been captured 
from unculturable bacteria, which would be largely underrepresented in the 
database. Research should continue to focus on isolating these proteins and 
functionally verifying their resistance mechanism(s), and ideally their host 
background and genetic context, in order to better understand co-selection of 
antibiotic resistance in the environment and potential for HGT into pathogens. 
Together, these results show there is a large environmental resistome in these 
anthropogenically impacted sites, consisting of a diverse range of resistance 
mechanisms, most of which have not been fully characterised as in previous 
studies (Su et al., 2014, Amos et al., 2014b). 
On a phenotypic level, reduced susceptibility to AMP and TRMP was both 
observed and common to CTAB resistant clones in both ‘contaminated’ libraries. 
Reduced susceptibility to either antibiotic was greater in the RB library, which is 
likely to have a higher QAC exposure than the SC library. There were no WWTP 
or agricultural farms near the RB site which may have resulted in exposure to 
antibiotics, antibiotic resistant bacteria or antibiotic genes. This suggests that 
more co-selection for antibiotic resistance occurred in the RB environment (as 
opposed to direct selection, which is more likely in SC as it will be exposed directly 
to antibiotics). Though clinical resistance was extremely rare, this does not render 
the findings of this study clinically insignificant as it is possible the resistance 
mechanisms in their current genetic context are under low level expression, and 
form part of the proto-resistome (Perry et al., 2014). Genetic context has been 
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shown to greatly influence MIC previously (Amos et al., 2014a), so with 
mobilisation into a new genetic context allowing higher levels of expression 
(which with some of the inserts would be possible, due to the presence of a 
transposase); or with higher gene copy numbers MIC could increase via the gene 
dosing effect (Martinez and Baquero, 2000). 
In fact, most of the ORFs identified in the study have not been reported 
previously as conferring resistance; only genes encoding a hydrolase (Su et al., 
2014) and UDP-galactose-4-epimerases (Nayak et al., 2006, Nakao et al., 2006, 
Kazimierczak et al., 2009) have been reported previously as conferring antibiotic 
resistance. To investigate their cross-resistance potential, a subgroup of UDP-
like ORFs were sub-cloned into a new vector to allow for definitive assignment 
as resistance determinants.  
MIC assays were performed for TRMP, SMX and TRMP / SMX in 
combination on the cloned UDP-like ORFs. TRMP and SMX are often used in 
combination to treat urinary tract infections (UTIs); but TRMP is not metabolised 
fully within the body (Brolund et al., 2010), nor is it biodegradable (Sirtori et al., 
2010). Therefore, concentrations of TRMP in waste water treatment plant effluent 
range from 20 – 1340 ng/L (Le-Minh et al., 2010), and could be selective 
(Gullberg et al., 2014). Therefore, though it is possible TRMP may have co-
selected for QAC resistance rather than vice versa, the presence of the UDP-like 
ORFs in the RB library (presumed to have no direct exposure to antibiotics) 
suggests it is again QACs co-selecting for TRMP resistance, at least in the RB 
library. 
Two of three tested UDP-like ORFs conferred significantly decreased 
susceptibility to SMX, equating to a 50 % increase in MIC compared to the empty 
vector control according to E test assays. Slight increases in TRMP / SMX were 
also observed for all three tested UDP-like ORFs, but only UDP R11 showed an 
increase in TRMP MIC. None of these MICs were clinically significant; but as 
discussed above, genetic context, gene copy number and so on could all 
influence MIC. There was also a decrease in BKC MIC when the UDP-like ORFs 
were cloned into the expression vector (a decrease from > 64 mg/L to 4 – 6 mg/L). 
However, the BKC MIC was still increased compared to the empty vector control, 
demonstrating these ORFs do indeed confer low level resistance to BKC. It also 
suggests the genetic context within the insert; or other genes present in the 
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inserts were contributing to the elevated BKC MICs in the original metagenomic 
libraries. 
UDP-galactose-4-epimerases were present in all sequenced inserts, 
including the single BKC resistant clone from the GL library. While this indicates 
this gene is likely to be located in an intrinsically resistant organism, in one case 
a UDP-like protein was co-localised with a transposase suggesting it had recently 
been, or could potentially be, mobilised. If mobilised into a human pathogen, 
these findings indicate certain UDP-like gene variants have the potential to confer 
multidrug resistance / reduced susceptibility to BKC, SMX and TRMP (and 
potentially other antimicrobials not screened in this study). It is likely UDP-like 
proteins confer this resistance through modifying the bacterial 
exopolysaccharide, thereby interfering with antimicrobial interaction and 
penetration (Santander et al., 2013, Wu et al., 2014).  
If any selection for QAC resistance is observed, it is likely that other 
resistance genes are selected for which may confer cross-resistance. This could 
promote co-resistance by selecting (for example) qacE on integrons, which are 
known to often carry antibiotic resistance genes such as sul1 and be found at 
relatively high abundance in the environment including the environments used to 
generate these libraries (Gaze et al., 2005, Gaze et al., 2011). Intriguingly, no 
qacE genes or its variants were identified in this study, which is unusual as they 
are common in natural, contaminated environments. Lack of qac gene detection 
may also be a result of the small library insert size, but also suggests the 
resistance determinants are also more common in these environments than the 
qac genes. However, this also demonstrates the necessity of functional 
metagenomic studies to identify novel resistance determinants, shown in this 
study to be diverse and conferring higher levels of resistance than known genes. 
For example, the BKC MIC of clones in this study was more than double (≥ 64 
mg/L) of that conferred by the qacE gene (32 mg/L, unpublished data). 
 
5.5. Conclusions 
This study suggests that anthropogenic activities are directly impacting microbial 
resistance to biocides and some clinically important antibiotics. The resistance 
determinants identified were diverse, largely uncharacterised and conferred a 
higher level of QAC resistance than the well-known qacE gene, justifying the 
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continued used of functional metagenomic studies. In the case of the common 
ORFs (“UDP-like proteins”), this is the first time these have been shown to 
functionally confer cross-resistance to QACs and reduced susceptibility to 
clinically important antibiotics. 
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6.1. Environmental implications 
This thesis comprises four novel research studies which together, indicate that 
selection and co-selection for antibiotic resistance is likely to occur in the 
environment.  
Selection endpoints for several different antibiotics spanning different drug 
classes have been determined, forming the most comprehensive dataset of 
MSCs to date. Critically, these endpoints were determined in complex bacterial 
communities which are more environmentally representative and so provide more 
realistic endpoints for ERA than MSCs determined in single species systems 
(Berendonk et al., 2015, Brandt et al., 2015). Previous work using single species, 
isogenic host competition experiments (Gullberg et al., 2014, Gullberg et al., 
2011) showed that MSCs determined for the same antibiotic in the same 
experimental system can be highly different, depending on the resistance 
determinant present. For example, the tetracycline MSC for the chromosomal 
insertion mutation Tn10dTet was 15 µg/L (Gullberg et al., 2011) but for the 
plasmid-borne tetRA resistance gene the tetracycline MSC was 45 µg/L. In this 
study, single species and community assays were directly compared for the first 
time. This revealed that single species MSCs, at least for cefotaxime, are poor 
predictors of MSCs in complex communities, with a huge disparity (a four order 
of magnitude difference) between MSCs in a complex community compared to 
single species experiments. Further research should focus on community-derived 
endpoints, and to validate these experimental systems as being representative 
of natural environments (e.g. by exploring lower nutrient and temperature 
conditions).  
Co-selection for antibiotic resistance by both antibiotics and QACs was 
observed in chapters two, four and five. In chapter two, metagenome analyses 
showed cefotaxime co-selected for genes conferring resistance to many different 
antibiotic classes. The FUN-PCR method coupled with PacBio sequencing in 
chapter four showed antibiotics and the QAC BKC selected for increased 
numbers of resistance genes to unrelated antibiotic classes in the first position in 
class 1 integron arrays. The co-selected genes would therefore be more highly 
expressed due to proximity to the Pc promoter (Partridge et al., 2009). 
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Additionally, in chapter five, co-resistance (or reduced susceptibility) to 
antibiotics, CTAB and BKC was observed in functional metagenomic libraries 
generated from QAC-impacted environments in an unreplicated field experiment. 
This is a cause for concern particularly in the SC library, as QACs are commonly 
present at high concentrations in WWTPs (Buffet-Bataillon et al., 2012). If the SC 
was spread directly onto agricultural land as fertiliser, these resistance 
mechanisms would have direct contact with the environmental resistome, 
potentially allowing HGT. Additionally as WWTPs are a HGT hotspot (Rizzo et 
al., 2013), hospital sterilisation and human health may be compromised if QAC 
resistance is transferred into opportunistic human pathogens (Gillings et al., 
2009). A clade of novel genes (UDP-galactose-4-epimerases) was identified as 
conferring cross-resistance to BKC and reduced susceptibility to antibiotics. 
Similar genes, UDP-4 glucose-epimerases, have been reported to confer biocide 
resistance once before (Tansirichaiya et al., 2017) but cross-resistance to 
antibiotics was not assessed. These UDP-4 glucose-epimerases were cloned 
from the human oral metagenome rather than the environment, where selection 
for biocide resistance may be less expected. Together, these findings necessitate 
further study that should also consider the co-selective potential of a wide range 
of compounds to fully protect the environment. Selection experiments such as 
those performed in chapters two, three and four can be used for this purpose. 
These can be combined with metagenome analyses as in chapter two; or even 
undergo massively parallel qPCR quantification of diverse resistance 
determinants, as the studies in chapters two and three confirm qPCR as being 
the more sensitive method for MSC determination (Lundstrom et al., 2016). 
Understanding persistence of integrons in microbial populations is crucial 
for determining the potential for fixation or maintenance of antimicrobial 
resistance within the environment, and potential for future capture of antimicrobial 
resistance gene cassettes. Class 1 integrons can persist in soil, albeit at low 
levels, even 24 months after application of sludge (Gaze et al., 2011). Following 
on from the work in chapter four, it would be interesting to track integron 
prevalence and diversity during antimicrobial exposure, but also integron 
persistence after the exposure has ended. FUN-PCR coupled with PacBio 
sequencing could also be used to investigate more communities exposed to other 
antimicrobials at more environmentally relevant concentrations, to elucidate the 
selective and co-selective potential of different antimicrobials. These results 
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should be compared to the MSCs determined using the assay in chapter two, to 
reveal if these MSCs are still protective in an integron / gene cassette selection 
context.  While chapter four studied class 1 integron arrays directly, chapter three 
showed antibiotics can select for increased class 1 integron prevalence. 
Enrichment of integrons provides not only a platform for the selection of 
resistance genes within a host, but also mobilisation to different hosts; some of 
which could be pathogenic, having significant impacts on human and animal 
health.  
 
6.2. Towards improved ERA 
A range of different community-based endpoints were determined for the first time 
(MSCs, LOECs, and empirical PNECRs) in chapters two and three for antibiotics 
all deemed as ‘critical’ or ‘highly important’ to human medicine, based on WHO 
recommendations (WHO, 2015). Therefore, improved stewardship of these 
antibiotics is essential. Long term experiment LOECs gave the highest selection 
endpoint values, followed by growth based LOECs and then MSCs (in all but one 
case, where the clarithromycin growth based LOEC was higher than the long 
term LOEC). The standard ecotoxicological risk assessment approach of 
applying a safety factor of 1000 to emulate acute exposure (Straub, 2013) was 
applied to LOECs to generate empirical PNECRs. These endpoints were 
compared to previously derived ecotoxicological PNECs (see chapter three) and 
estimated PNECRs (Bengtsson-Palme and Larsson, 2016). In some cases the 
empirical PNECRs were more protective; in others, the estimated PNECRs were 
more protective. However, for all antibiotics tested, with the exception of 
trimethoprim, the ecotoxicological PNECs were protective of both estimated and 
empirical PNECRs. It is reassuring that ecotoxicological PNECs are also 
protective of resistance selection, but the case of trimethoprim indicates work 
should continue to determine empirical PNECRs to ensure complete protection. 
Estimated PNECRs could be used to guide these experiments, as recommended 
previously (Bengtsson-Palme and Larsson, 2016). 
The unadjusted endpoints (i.e. MSC and LOECs based on long term or 
growth experiments) for all the antibiotics studied were highly comparable, but 
further data generation is required to determine firstly, which endpoint should be 
used for ERA to afford greatest protection against selection for resistance; and 
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secondly, simply more data on the selective potential of more antimicrobials is 
necessary (i.e. including, but not limited to, antibiotics). There are 22 different 
classes of antibiotics approved for clinical use (Coates et al., 2011), and to date 
only six classes have an MSC or selective endpoint determined (including four 
which were generated as part of this thesis (Gullberg et al., 2014, Gullberg et al., 
2011)). Based on the findings in chapter three, these MSCs or LOECs will need 
to be determined on a case by case basis. There is still the possibility that there 
may be some similarity in MSCs or LOECs within the same antibiotic class or the 
same type of resistance mechanism, which should be explored as it could 
facilitate more rapid risk assessment.  
The highest available MECs in aquatic systems for antibiotics investigated 
in this study were used to calculate RQs, and in the majority of cases the RQs 
were unacceptably high suggesting selection for resistance may occur (in many 
cases, irrespective of the selective endpoint used). However, these are ‘worst 
case’ scenarios, and many environmental compartments with lower MECs will 
not be under risk for resistance selection based on the endpoints determined in 
this thesis. More thorough, coordinated monitoring of MECs is necessary for 
adequate ERA and environmental protection.  
Chapters three and four described novel tools that can generate further 
data to quantify the risk posed by different selective compounds. The next step 
will be to determine the selective effect of mixtures of different antimicrobials in 
complex bacterial communities, or additive effects of mixtures of antibiotics within 
the same class. The growth rate assay described in chapter three provides real 
potential to test these effects, as well as further, rapid data generation and the 
ability to test environmental applicability. Ultimately this growth rate assay can be 
used to test the selective potential of effluent and surface water samples. Whilst 
this is still an in vitro assay, it may be preferable to in situ experiments as 
experimental conditions can be closely controlled to discern individual biological 
effects (Jansen et al., 2014). Though in situ experiments will provide the most 
realism, they will be subject to sampling bias and a potentially vast number of 
confounding interactions that may be difficult to disentangle. For example, the 
research conducted previously in biofilms (Lundstrom et al., 2016) is subject to 
such issues, as uncharacterised communities were being constantly introduced 
into the experimental system. Therefore, the observed effects could be due to the 
composition of the community, and not the controlled experimental conditions 
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(i.e. antibiotic concentration). Replication would no doubt be another issue for in 
situ experiments, and may mask biological effects due to large variation between 
replicates as observed in chapters two and three; indeed, increases in prevalence 
were observable at concentrations below the LOEC for all compounds tested but 
these were not statistically significant. MSCs and PNECRs were determined as 
an attempt to mitigate this potential underestimation of risk. Higher replication 
and / or an estimated endpoint (i.e. MSC) could mitigate these issues for in situ 
experiments. Finally, in situ experiments may be subject to other biases (such as 
sampling biases), and will inevitably take much longer to gather results due to the 
lower nutrient levels and lower temperatures there will be in the environment, 
which will increase bacterial generation times. This in turn will greatly inflate 
experimental costs. Particularly if selection or resistance is cumulative over time 
in situ, as shown in chapter two, the time required for an effect to be observed in 
situ could exceed experimental feasibility. The growth rate assay can be used to 
explore environmental conditions much more simply, and at lower cost. Time 
taken to observe biological effects (i.e. selection) could be determined under 
environmental conditions using the growth rate assay, and used to inform in situ 
experiments, if required.  
 
6.3. Clinical implications 
Novel research presented in this thesis has direct relevance to evolution of 
antibiotic resistance in the clinic, as well as the environment. It has been 
suggested that longer courses of antibiotics may select for antibiotic resistance 
(Day et al., 2015). In chapter two, increase in blaCTX-M prevalence was shown to 
be cumulative over time, both within 24 hours and over several days. Also in 
chapter two, indirect selection was shown to occur at very high antibiotic 
concentrations (32 mg/L, much higher than the clinical breakpoint concentration 
of 2 mg/L). This means indirect selection is likely to occur during antibiotic 
chemotherapy. Further work should investigate these implications. Particular 
resistance genes could be identified which confer ‘high risk’ of indirect selection, 
and patients could be screened for presence / absence of these genes in order 
to personalise treatment. Efforts should be made to determine if such individually 
tailored treatment plans improve patient outcome and reduce selection for (or 
enrichment of pre-existing) resistance in vivo. 
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There has been considerable research investigating the optimal dosage of 
antibiotics in the body, although recent data suggest that the current, standard 
(intermittent) dosing regimens do, at times, allow for antibiotic concentrations to 
become suboptimal (i.e. sub-inhibitory). This is expressed in pharmacokinetic / 
pharmacodynamics terms as a percentage of the amount of time (‘T’) serum 
concentrations are below or above the MIC of the target organism (e.g. T > MIC 
40 % is serum concentrations exceed the target organism MIC only 40 % of the 
time (Van Herendael et al., 2012)). In chapter two, selection for resistance 
plateaued at sub-inhibitory concentrations, meaning that blaCTX-M genes were 
selected just as strongly at sub-inhibitory concentrations as those exceeding the 
clinical breakpoint. Therefore T < MIC of antibiotics during chemotherapy may be 
even more crucial than previously described. If a similar situation occurs for β-
lactamase inhibitor (βLI) concentrations, this could result in increased selection 
for β-lactamases as a result of preferential binding to extracellular β-lactamases, 
as hypothesised in chapter two. Furthermore, no work has investigated the MECs 
of βLIs, and the potential role these could play in selecting for β-lactamase 
mediated resistance in the environment, despite previous work showing 
increased selection for resistance at sub-inhibitory antibiotic concentrations and 
very low βLI concentrations (Yurtsev et al., 2013).  
Antibiotic resistance has been described as the ‘quintessential’ One 
Health issue (Robinson et al., 2016). The One Health approach is described by 
the American Veterinary Medicine Association (AVMA) as “...the collaborative 
effort of multiple disciplines – working locally, nationally, and globally – to attain 
optimal health for people, animals and our environment…” (AVMA, 2008). 
Therefore, it is crucial to consider the role of the environment in human and 
animal health.  
It has been shown that clinically important, highly mobile resistance genes, 
such as the blaCTX-M genes, originated in environmental bacterial species 
(Humeniuk et al., 2002, Cantón et al., 2012, Olson et al., 2005). Therefore, 
isolated mobilisation events in the environment do occur, with clinical 
implications. There have been limited studies which have investigated 
transmission between the natural environment, humans and animals. For 
example, the risk of MRSA colonisation in pig farm workers increases by 760x 
compared to the general population (Voss et al., 2005), and recreational use of 
different, natural environments can result in exposure to resistant pathogens 
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(Leonard et al., 2015, Jones et al., 2017). This thesis has shown that MECs of 
some antibiotics have the potential to select for resistance. Increased prevalence 
of resistance in the environment results in increased probability of ‘isolated’ 
mobilisation events; and / or contact between people or animals and the 
environmental resistome. It seems reasonable then, to consider environmental 
protection against resistance selection synonymous to protection of human and 
animal health against resistant infections. 
Much work is still required to determine the conditions under which 
transmission of antibiotic resistance from the natural environment to humans and 
animals occurs. Risk of colonisation and infection following environmental 
exposure should also be determined. Knowledge of this interplay between the 
environment and human and animal health will greatly impact investment by 
stake holders towards any mitigation strategies that are required, once the 
selective risk of antibiotics in the environment has been fully and appropriately 
assessed. 
 
6.4. Concluding remarks  
This research suggests there is a risk of selection and co-selection for antibiotic 
resistance occurring in the environment, for particular compounds and in certain 
environmental hotspots. A method to rapidly generate further data has been 
described. The direct implications of this in terms of animal and human health 
were not investigated in this thesis, but will be essential for convincing stake 
holders to design and undertake the necessary mitigation strategies. The 
purpose of this research is a vital one – to prolong the utility of current antibiotics 
and safeguard novel compounds by delaying resistance emergence for as long 
as possible. Only time will show if our response has been swift enough, but 
currently, time is ticking towards the eventuality of a post-antibiotic era.  
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Appendix 
 
 
Figure 63. Pilot experiment for determining the dilution of untreated waste water 
to use for the complex community experiments. Average (n=2) growth of blaCTX-
M bearing E. coli in cefotaxime (µg/L) over 24 hours, shown with standard 
deviation. 
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Figure 64. Pilot experiment for determining the dilution of untreated waste water 
to use for the complex community experiments. Average (n=2) growth of 
untreated waste water inoculated at a 10x dilution in cefotaxime (µg/L) over 24 
hours, shown with standard deviation. 
 
 
Figure 65. Pilot experiment for determining the dilution of untreated waste water 
to use for the complex community experiments. Average (n=2) growth of 
untreated waste water inoculated at a 100x dilution in cefotaxime (µg/L) over 24 
hours, shown with standard deviation. 
 
Table 16. Table showing primer sequences used for amplifying UDP-galactose-
4-epimerase-like ORFs to be cloned into the pET101 vector. 
Reaction/name Primer sequence Product 
size 
(bp) 
Cloning/R11F CACCATGCGTGTGCTCGTC 1,025 
Cloning/R11R TTACACATACCCTTGCGG 1,025 
Cloning/R161F CACCATGCGCGTTTTAGTAACAGG 1,020 
Cloning R161R TTACAAGCCAGCAGCGCCCC 1,020 
HotPhusion/R161F2 TCAGGAGCCCTTCACCATGCGCGTTTTAGTAACAGG 1,040 
HotPhusion/R161R2 AATTGAGCTCGCCCTTACAAGCCAGCAGCGCCCC 1,040 
Cloning/S78F CACCATGAACGGGAAGGTAATAG 1,043 
Cloning/S78R TCATGATTTCTTGTTTTTCAGTTTGTTTTCCC 1,043 
HotPhusion/S78F2 TCAGGAGCCCTTCACCATGAACGGGAAGGTAATAG 1,053 
HotPhusion/S78R2 AATTGAGCTCGCCCTCATGATTTCTTGTTTTTCAGTTTGTTTTCCC 1,053 
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Table 17. Co-resistance experiment. CTAB resistant clones and a random 
selection of unscreened clones from RB and SC libraries were replica plated onto 
ampicillin (‘AMP’) and trimethoprim (‘TRMP’) at different concentrations. Percent 
resistance (n = 200). Increased resistance at 1.5x MIC compared to at MIC could 
be explained by stress-induced expression of resistance determinants or 
spontaneous mutation in the host. 
 
 
Table 18. All the ORFs identified by primer walking all unique BKC resistant 
inserts.  Shown is the name of the predicted protein, the % identity to the entry in 
the GenBank database, and the accession number for this highest hit. For some 
ORFs, multiple predicted proteins are shown with coverage in brackets. ORFs of 
particular interest (antimicrobial resistance genes or genes that logically could 
have roles in conferring resistance) are marked by ‘***’.  
Insert ORF % ID Accession 
GBKC 
*** 
UDP-glucose 4-epimerase [Chlorogloeopsis fritschii] 61 WP_016875182.1 
*** UDP galactose 4-epimerase (EC 1.7.7.12) 
[Streptomyces lividans] 
52 AAA26747.1 
*** pyridoxal-dependent decarboxylase [Candidatus 
Koribacter versatilis] 
54 WP_011522086.1 
*** pyridoxal-dependent decarboxylase [Candidatus 
Koribacter versatilis]  
70 WP_011522086.1 
 permease [Acetobacterium dehalogenans] 38 WP_035356200.1 
 sulfur reduction protein DsrE [Dehalococcoidia 
bacterium SCGC AB-539-J10] 
28  
WP_029475985.1 
 hypothetical protein [Burkholderia gladioli] 32 WP_046578597.1 
 hypothetical protein [Kitasatospora phosalacinea] 41 WP_033256445.1 
 hypothetical protein [Streptomyces sp. MspMP-M5] 39 WP_018536861.1 
    
R2 *** peptide ABC transporter substrate-binding protein 
[Pseudomonas veronii] 
96 WP_046488955.1 
 probable polyvinylalcohol dehydrogenase [Gimesia 
maris] 
48 WP_002649604.1 
 nitrilase [Candidatus Solibacter usitatus] 77 WP_011684136.1 
 hypothetical protein [Phyllobacterium sp. 
UNC302MFCol5.2] with Domiain of Unknown Function 
(DUF) 
42 WP_027231546.1 
 transcriptional regulator [Pseudomonas veronii] 100 WP_046381648.1 
 
Percentage resistance 
 
AMP TRMP 
 
MIC (4 
mg/L) 
1.5x MIC (7 
mg/L) 
Clinical (8 
mg/L) 
MIC (1.25 
mg/L) 
1.5x MIC (2.25 
mg/L) 
Clinical (4 
mg/L) 
RB 82.3 94 0 76.8 94.6 0 
RB-
CTABR 
41.9 94 0 61.7 94.5 0 
SC 92.9 71.6 0 90.5 89.1 0 
SC-
CTABR 
61.7 82.6 0 37.6 94.8 <1 
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*** peptide ABC transporter substrate-binding protein 
[Pseudomonas veronii] 
84 WP_046381647.1 
*** peptide ABC transporter substrate-binding protein 
[Pseudomonas veronii] 
88 WP_017846050.1 
*** UDP-glucose 4-epimerase [Planctopirus limnophila] 57 WP_013109608.1 
 aldehyde dehydrogenase [Pseudomonas veronii] 100 WP_046381649.1 
 MULTISPECIES: 50S ribosomal protein L28 
[Pseudomonas] 
100 WP_003176907.1 
*** UDP-glucose 4-epimerase [Planctopirus limnophila] 68 WP_013109608.1 
    
R3  divalent ion tolerance protein CutA [Azoarcus sp. 
BH72] 
73 WP_011764057.1 
*** UDP-galactose 4-epimerase [uncultured prokaryote] 72 BAL57187.1 
 2-hydroxyhepta-2,4-diene-1,7-dioate isomerase 
[Anaerolinea thermophila] 
61 WP_013559783.1 
 glutamyl-tRNA(Gln) amidotransferase [Anaerolinea 
thermophila] 
75 WP_013558748.1 
 2-hydroxyhepta-2,4-diene-1,7-dioate isomerase 
[Anaerolinea thermophila] 
60 WP_013559783.1 
 thiol-disulfide interchange protein [Sulfuritalea 
hydrogenivorans sk43H] 
72 BAO31229.1 
 riboflavin synthase subunit alpha [Sulfuritalea 
hydrogenivorans] 
85 WP_041101012.1 
 chemotaxis protein [Massilia sp. LC238] 44 WP_036215602.1 
***FIST 
DOMAIN 
hypothetical protein AZKH_2025 [Azoarcus sp. 
KH32C]   
52 BAL24338.1 
 Uncharacterised protein [Bordetella pertussis] 56 CFD85428.1 
 PREDICTED: probable ribonuclease ZC3H12D 
isoform X3 [Macaca nemestrina] 
43 XP_011751866.1 
 
 
 
 
*** 
hypothetical protein AW09_003777 [Candidatus 
Accumulibacter sp. BA-91] 
 
penicillin-binding protein [Rhodococcus sp. ARP2] 
62 
 
30 
KFB71096.1 
 
 
WP_047889119.1 
 DUF1745 domain-containing protein [Methylobacter 
tundripaludum] 
65 WP_006893638.1 
    
R10 glycerol kinase [Perlucidibaca piscinae] 77 WP_022956698.1 
 hypothetical protein [Citromicrobium bathyomarinum] 47 WP_040378562.1 
*** UDP-galactose-4-epimerase [Bacillus 
selenatarsenatis] 
72 WP_041963976.1 
 UDP-glucose 6-dehydrogenase [Acidovorax 
delafieldii] 
28 WP_005794330.1 
 
 
*** 
 
 
hypothetical protein [Bacillus thuringiensis] 
 
transposase [Escherichia coli] 
 
 
beta galactosidase alpha [Cloning vector pNOT218] 
62 
 
68 
 
67 
WP_013555072.1 
 
WP_012766388.1 
 
AAL79196.1 
*** UDP-galactose-4-epimerase [Rhodopirellula 
sallentina] 
68 WP_044303185.1 
 hypothetical protein [Balneatrix alpica] 52 WP_027312693.1 
 glucose-6-phosphate isomerase [Psychrobacter 
cryohalolentis] 
60 WP_011512493.1 
*** ABC transporter permease [Streptomyces galbus] 63 WP_033524975.1 
    
R14 
 
 
*** 
hypothetical protein [Firmicutes bacterium CAG:646] 
 
UDP-galactose-4-epimerase [Dasania marina] 
70 
 
71 
WP_022010496.1 
 
WP_019530321.1 
 putative polysaccharide transport system component 
signal peptide protein (ragA) [Ralstonia solanacearum 
PSI07] 
42 CBJ50510.1 
    
R17 hypothetical protein [Nocardioides insulae] 57 WP_028660028.1 
 hypothetical protein [Burkholderiales bacterium GJ-
E10] 
60 WP_045469855.1 
 hypothetical protein [Rubrivivax gelatinosus] 40 WP_050985547.1 
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 hypothetical protein [Aquincola tertiaricarbonis] 47 WP_046115559.1 
*** conserved hypothetical protein [Novosphingobium sp. 
KN65.2]  
52 CDO35116.1 
 Ankyrin repeat and death domain-containing protein 
1A [Pteropus alecto] 
51 ELK05332.1 
 
 
 
 
*** 
hypothetical protein [Aphanizomenon flos-aquae] 
 
UDP-galactopyranose mutase [Haliscomenobacter 
hydrossis]   
64/65 
 
51/62 
WP_027402397.1 
 
WP_013765800.1/ 
WP_013765800.1 
*** MULTISPECIES: membrane protein [Streptomyces]  55 WP_037659172.1 
    
R24 *** UDP-glucose 4-epimerase [Pseudomonas sp. 11/12A] 69 WP_047530443.1 
 aminoglycoside phosphotransferase [Streptomyces 
aureofaciens] 
33 WP_052838580.1 
 protein tyrosine kinase [Pseudomonas sp. 11/12A] 92 WP_047530445.1 
 hypothetical protein [Pseudomonas sp. 11/12A] 98 WP_047530451.1 
*** sulfatase [Pseudomonas sp. 11/12A]   88 WP_047530441.1 
 protein tyrosine kinase [Pseudomonas sp. 11/12A] 91 WP_047530445.1 
*** lipopolysaccharide biosynthesis protein 
[Pseudomonas sp. 11/12A] 
99 lipopolysaccharide 
biosynthesis protein 
[Pseudomonas sp. 
11/12A] 
*** sugar ABC transporter substrate-binding protein 
[Pseudomonas sp. 11/12A] 
97 WP_047530453.1 
*** sulfatase [Pseudomonas sp. 11/12A] 96 WP_047530441.1 
    
S2 *** MFS transporter family protein [Candidatus 
Cloacimonas acidaminovorans] 
36 WP_015425243.1 
*** UDP-glucose 4-epimerase [Anaerolinea thermophila] 74 WP_013561327.1 
 
 
 
hypothetical protein [bacterium JGI-5] 
 
protease [Peptococcaceae bacterium BICA1-7]  
58 
 
56 
WP_047133258.1 
 
WP_034123852.1 
    
S3 *** oxidoreductase [Hassallia byssoidea] 67 WP_039746039.1 
*** UDP-galactose-4-epimerase [Draconibacterium 
orientale] 
66 WP_038558124.1 
 dTDP-glucose 4,6-dehydratase [Thermophagus 
xiamenensis] 
70 WP_010526628.1 
 UDP-N-acetyl-D-galactosamine dehydrogenase 
[Adhaeribacter aquaticus] 
68 WP_026462223.1 
    
S4 hypothetical protein [Escherichia coli] 87 WP_052913615.1 
 
 
 
*** 
 
 
*** 
hypothetical protein UUU_05190 [Klebsiella 
pneumoniae subsp. pneumoniae DSM 30104] 
 
Multidrug resistance protein mdtB [Erwinia amylovora 
MR1] 
 
membrane protein [Thiorhodococcus sp. AK35] 
58 
 
42 
 
49 
EJK92533.1 
 
CCP06064.1 
 
WP_043755805.1 
 FIG00732864: hypothetical protein [Klebsiella 
pneumoniae IS10] 
55 CDK62066.1 
 hypothetical protein WRSd5_03586 [Shigella 
dysenteriae WRSd5] 
95 ESU79657.1 
*** tetracycline resistance protein, class A [Escherichia 
coli BWH 24] 
93 ERO93707.1 
 hypothetical protein [Salmonella enterica] 100 WP_001372230.1 
 hypothetical protein HMPREF9551_04418 
[Escherichia coli MS 196-1] 
100 EFI86627.1 
*** UDP-glucose 4-epimerase [Anaerolinea thermophila] 68 WP_013561327.1 
*** MULTISPECIES: MFS transporter [unclassified 
Cloacimonetes] 
42 WP_029949877.1 
*** UDP-galactose 4-epimerase [Leptolinea tardivitalis] 76 GAP20355.1 
 lactose operon repressor domain protein 
[Staphylococcus aureus Lyso 2 2010] 
93 KEK30836.1 
*** tetracycline resistance MFS efflux pump [Escherichia 
coli] 
100 WP_011178609.1 
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*** 
 
putative transposase [Escherichia coli 3-020-
07_S4_C1] 
100 
(42% 
cover) 
KEJ62634.1 
 transcriptional regulator AraC [Broad host range vector 
pMLBAD] 
99 AAM63382.1 
 MULTISPECIES: hypothetical protein 
[Enterobacteriaceae] 
100 
(86% 
cover) 
WP_000028208.1 
 hypothetical protein [Escherichia coli] 
 
96 
(44% 
cover) 
WP_012644004.1 
 
 
*** 
Transcriptional regulator AraC [Shigella sonnei] 
 
zinc ABC transporter ATPase [Salmonella enterica 
subsp. enterica serovar Enteritidis str. EC20121178] 
96 
 
67 
CSP96607.1| 
 
 
AHO12049.1 
*** uncharacterized membrane protein [Longilinea 
arvoryzae] 
66 GAP15674.1 
*** tetracycline repressor protein class A transposon 1721 
[Klebsiella pneumoniae] 
95 KMH64585.1 
 hypothetical protein HPMG_01967 [Helicobacter 
pullorum MIT 98-5489] 
60 EEQ64510.1 
 fumarate hydratase [delta proteobacterium MLMS-1] 
 
50 WP_007295173.1| 
 
*** tetracycline repressor protein class A [uncultured 
bacterium] 
96 
(80% 
cover) 
AFR44371.1 
 conserved hypothetical protein [Escherichia coli 042] 
 
100 CBG36934.1| 
 LacOPZ-alpha peptide from pUC9; putative 
[unidentified cloning vector] 
93 
(84% 
cover) 
AAA75561.1 
 hypothetical protein [Methanosarcina mazei] 
 
 
 
 
pyruvate formate lyase-activating enzyme 1 
[Escherichia coli KO11FL] 
72 (96 
cover) 
 
74 (62 
cover) 
WP_048049241.1 
 
 
 
AFH18616.1 
 hypothetical protein [Achromobacter arsenitoxydans] 
 
putative acetyltransferase YhhY [Salmonella enterica 
subsp. enterica serovar Typhimurium str. DT104] 
100 
(40% 
cover) 
WP_008166363.1 
 
CQA99509.1 
*** UDP-glucose 4-epimerase [Anaerolinea thermophila] 68 WP_013561327.1 
 PREDICTED: E3 ubiquitin-protein ligase synoviolin-
like [Nicotiana sylvestris] 
34 |XP_009786500.1| 
*** MFS transporter family protein [Candidatus 
Cloacimonas acidaminovorans] 
36  WP_015425243.1 
*** UDP-galactose 4-epimerase [Leptolinea tardivitalis] 76 GAP20355.1 
*** uncharacterized membrane protein [Longilinea 
arvoryzae] 
66 GAP15674.1 
 titin2 [Bombyx mori] 36 NP_001091843.1| 
    
S21 ferrochelatase [Photobacterium damselae] 48 WP_036764187.1 
 UDP pyrophosphate phosphatase [Thalassolituus 
oleivorans] 
63 WP_025266051.1 
 tyrosine protein kinase [Pseudomonas sp. GM49] 51 WP_007999450.1 
 phosphotyrosine protein phosphatase [Pseudomonas 
pelagia] 
52 WP_022964347.1 
*** MULTISPECIES: UDP-galactose-4-epimerase 
[Alcanivorax] 
70 WP_035458552.1 
 hypothetical protein [Pseudomonas nitroreducens] 55 WP_017521157.1 
*** capsular polysaccharide biosynthesis protein 
[Pseudomonas fluorescens] 
53 (97 
cover) 
WP_003211361.1 
*** capsular polysaccharide biosynthesis protein 
[Pseudomonas sp. M1] 
44 (67) ETM67913.1 
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Table 19. Predicted ORFs' function and amino acid identity, and the numbers of 
knock outs containing this ORF. 
No. knock 
outs  
ORF name % amino acid 
identity 
10 UDP-galactose-4-epimerase 66 - 99 
4 ‘Hypothetical protein’ 33 - 98 
2 Drug/metabolite transporter permease/PecM-like protein  96 - 99 
2 KAP family P-loop domain protein 87 - 98 
2 Putative MFS transporter protein 36 - 40 
1  Multidrug transporter/transporter permease/PecM-like protein/integral membrane 
protein 
96 - 98 
1 Putatative membrane-associated metal-dependent hydrolase 78 
1 Phage T7 exclusion protein 78 
1  Oxidoreductase 69 
1 Putative polysaccharide transport system component signal protein 46 
1 Quinone/putative oxidoreductase 34 
 
 
Table 20. Table showing sequence similarity between UDP-galactose-4-
epimerases identified in this study and in the study by Kazimierczak et al. (2009) 
(‘Clone 9’ and ‘Clone 15’). M = Megablast, n = blastn. The first number is the 
sequence identity, the second number following the / is the percentage coverage. 
Alignment was performed with NCBI blastn for alignment of two sequences.  
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